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RÉSUMÉ 
La prééclampsie est responsable du quart des mortalités maternelles et est la 
deuxième cause de décès maternels associés à la grossesse au Canada et dans le 
monde. L’identification d’une stratégie efficace pour la prévention de la 
prééclampsie est une priorité et un défi primordial dans les milieux de recherche 
en obstétrique. Le rôle des éléments nutritifs dans le développement de la 
prééclampsie a récemment reçu davantage d’attention. Plusieurs études cliniques 
et épidémiologiques ont été menées pour déterminer les facteurs de risque 
alimentaires potentiels et examiner les effets d’une supplémentation nutritive 
dans le développement de troubles hypertensifs de la grossesse.  
Pour déterminer les effets de suppléments antioxydants pris pendant la 
grossesse sur le risque d’hypertension gestationnelle (HG) et de prééclampsie, un 
essai multicentrique contrôlé à double insu a été mené au Canada et au Mexique 
(An International Trial of Antioxidants in the Prevention of Preeclampsia – 
INTAPP). Les femmes, stratifiées par risque, étaient assignées au traitement 
expérimental quotidien (1 gramme de vitamine C et 400 UI de vitamine E) ou au 
placebo. En raison des effets secondaires potentiels, le recrutement pour l’essai a 
été arrêté avant que l’échantillon complet ait été constitué. Au total, 2640 
femmes éligibles ont accepté d’être recrutées, dont 2363 (89.5%) furent incluses 
dans les analyses finales. Nous n’avons retrouvé aucune évidence qu’une 
supplémentation prénatale de vitamines C et E réduisait le risque d’HG et de ses 
effets secondaires (RR 0,99; IC 95% 0,78-1,26), HG (RR 1,04; IC 95% 0,89-
1,22) et prééclampsie (RR 1,04; IC 95% 0,75-1,44). Toutefois, une analyse 
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secondaire a révélé que les vitamines C et E augmentaient le risque de 
« perte fœtale ou de décès périnatal » (une mesure non spécifiée au préalable) 
ainsi qu’une rupture prématurée des membranes avant terme. 
Nous avons mené une étude de cohorte prospective chez les femmes 
enceintes recrutées dans l’INTAPP afin d’évaluer les relations entre le régime 
alimentaire maternel en début et fin de grossesse et le risque de prééclampsie et 
d’HG. Un questionnaire de fréquence alimentaire validé était administré deux 
fois pendant la grossesse (12-18 semaines, 32-34 semaines). Les analyses furent 
faites séparément pour les 1537 Canadiennes et les 799 Mexicaines en raison de 
l’hétérogénéité des régimes alimentaires des deux pays. Parmi les canadiennes, 
après ajustement pour l’indice de masse corporelle (IMC) précédant la grossesse, 
le groupe de traitement, le niveau de risque (élevé versus faible) et les autres 
facteurs de base, nous avons constaté une association significative entre un faible 
apport alimentaire (quartile inférieur) de potassium (OR 1,79; IC 95% 1,03-3,11) 
et de zinc (OR 1,90; IC 95% 1,07-3,39) et un risque augmenté de prééclampsie. 
Toujours chez les Canadiennes, le quartile inférieur de consommation d’acides 
gras polyinsaturés était associé à un risque augmenté d’HG (OR 1,49; IC 95% 
1,09-2,02). Aucun des nutriments analysés n’affectait les risques d’HG ou de 
prééclampsie chez les Mexicaines. 
Nous avons entrepris une étude cas-témoins à l’intérieur de la cohorte de 
l’INTAPP pour établir le lien entre la concentration sérique de vitamines 
antioxydantes et le risque de prééclampsie. Un total de 115 cas de prééclampsie 
et 229 témoins ont été inclus. Les concentrations de vitamine E ont été mesurées 
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de façon longitudinale à 12-18 semaines (avant la prise de suppléments), à 24-26 
semaines et à 32-34 semaines de grossesse en utilisant la chromatographie 
liquide de haute performance. Lorsqu’examinée en tant que variable continue et 
après ajustement multivarié, une concentration de base élevée de γ-tocophérol 
était associée à un risque augmenté de prééclampsie (quartile supérieur vs 
quartile inférieur à 24-26 semaines : OR 2,99, IC 95% 1,13-7,89; à 32-34 
semaines : OR 4,37, IC 95% 1,35-14,15). Nous n’avons pas trouvé de lien entre 
les concentrations de α-tocophérol et le risque de prééclampsie.  
En résumé, nous n’avons pas trouvé d’effets de la supplémentation en 
vitamines C et E sur le risque de prééclampsie dans l’INTAPP. Nous avons 
toutefois trouvé, dans la cohorte canadienne, qu’une faible prise de potassium et 
de zinc, tel qu’estimée par les questionnaires de fréquence alimentaire, était 
associée à un risque augmenté de prééclampsie. Aussi, une plus grande 
concentration sérique de γ-tocophérol pendant la grossesse était associée à un 
risque augmenté de prééclampsie. 
 
Mots-clés: Prééclampsie, Hypertension gestationnelle, Vitamines C et E, 
Alimentation maternelle, Tocophérol, Étude clinique, Étude de cohorte, Étude 
cas-témoins  
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ABSTRACT  
Preeclampsia (PE) accounts for about one-quarter of cases of maternal 
mortality, and ranks second among the causes of pregnancy-associated maternal 
deaths in Canada and worldwide. The identification of an effective strategy to 
prevent PE is a priority and fundamental challenge in obstetrics research. The 
role of nutritional factors in the etiology of PE has recently received increased 
attention. Many clinical and epidemiological studies have been conducted to 
investigate potential dietary risk factors for PE and to examine the effects of 
nutritional supplementation on the development of hypertensive disorders of 
pregnancy.  
To investigate the effects of prenatal antioxidant supplementation on the risk 
of gestational hypertension (GH) and PE, a double blind, multicenter trial (The 
International Trial of Antioxidants for the Prevention of Preeclampsia – the 
INTAPP trial) was conducted in Canada and in Mexico. Women were stratified 
by their risk status and assigned to daily experimental treatment (1 gram vitamin 
C and 400 IU vitamin E) or to placebo. Due to concerns about potential adverse 
effects, recruitment for the trial was stopped before the full sample had been 
achieved. A total of 2640 consenting eligible women had been recruited at that 
point with 2363 women (89.5%) included in the final analysis. We found no 
evidence that prenatal supplementation of vitamins C and E reduced the risk of 
GH and its adverse conditions (RR: 0.99, 95% CI 0.78-1.26), GH (RR 1.04, 95% 
CI 0.89-1.22), and PE (RR 1.04, 95% CI 0.75-1.44). However, in a secondary 
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analysis, we found that vitamins C and E increased the risk of ‘fetal loss or 
perinatal death’ (a non-pre-specified outcome) as well as preterm premature 
rupture of membranes (PPROM). 
We conducted a prospective cohort study on pregnant women enrolled in the 
INTAPP trial to investigate the associations between maternal diet in early and 
late pregnancy and the risk of PE and GH. A validated food frequency 
questionnaire (FFQ) was administered twice during pregnancy (12-18 weeks, 32-
34 weeks). Analyses were conducted separately for 1537 Canadian and 799 
Mexican women as there were significant heterogeneities in various nutrient 
intakes between the two countries. Among Canadian women, after adjusting for 
pre-pregnancy body mass index (BMI), treatment group, risk stratum (high 
versus low) and other baseline risk factors, we found that the lowest quartiles of 
potassium (OR 1.79, 95% CI 1.03-3.11) and zinc (OR 1.90, 95% CI 1.07-3.39) 
intake were significantly associated with an increased risk of PE. Also in 
Canadian women, the lowest quartile of polyunsaturated fatty acids was 
associated with an increased risk of GH (OR 1.49, 95% CI 1.09-2.02). None of 
the nutrients analyzed were found to be associated with PE and GH risk among 
Mexican women.  
We further conducted a case control study ancillary to the INTAPP trial to 
assess the relationship between plasma concentration of antioxidant vitamins and 
the risk of PE. A total of 115 PE cases and 229 matched controls were included. 
Vitamin E concentrations were measured longitudinally at 12-18 weeks (prior to 
supplementation), 24-26 weeks, and 32-34 weeks of gestation using high-
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performance liquid chromatography (HPLC). When examined as a continuous 
variable, and after multivariate adjustment, elevated baseline γ-tocopherol 
concentrations were associated with an increased risk of PE (OR 1.35, 95% CI 
1.02-1.78). Analyses of repeated measurements indicated that elevated γ-
tocopherol levels were associated with an increased risk of PE (highest vs. 
lowest quartile at 24-26 weeks: OR 2.99, 95% CI 1.13-7.89; at 32-34 weeks: OR 
4.37, 95% CI 1.35-14.15). We found no associations between α-tocopherol 
concentrations and the risk of PE.  
In summary, we found no effects of vitamins C and E supplementation on the 
risk of PE in the INTAPP trial. However, in the Canadian cohort we found that 
lower intakes of potassium and zinc as estimated by the FFQ were associated 
with an increased risk of PE. Moreover, higher plasma concentration of γ-
tocopherol during pregnancy was associated with an increased risk of PE.  
 
Key words: Preeclampsia, Gestational Hypertension, Vitamins C and E, 
Maternal Nutrition, Tocopherol, Clinical Trial, Cohort study, Case Control study 
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INTRODUCTION 
Preeclampsia (PE), defined as pregnancy-induced hypertension and 
proteinuria, is a syndrome that is unique to human pregnancy, affecting between 
2% and 8% of pregnancies.(1-3) It accounts for 10%-15% of direct maternal 
deaths in low- and middle income countries as well as in high income 
countries.(4, 5) Gestational hypertension (GH), especially PE, is a frequent cause 
of low birth weight (<2500g) in infants and thereby perinatal deaths through both 
preterm delivery and intrauterine growth restriction (IUGR).(6-10) Since 
delivery is the only known cure, PE is a leading cause of indicated premature 
delivery(11) and accounts for about 15% of infants with growth restriction.(12) 
As many as 60% of extremely low birth weight (< 800g) infants suffer learning 
disabilities and low IQ(13), increasing the hidden costs of the disease. The study 
of the etiology, prevention and outcomes of PE and other hypertensive disorders 
of pregnancy remains a research priority. Effective prevention of PE would have 
major health benefits and result in considerable savings to health care budgets.  
It has long been suggested that diet may play a role in PE. Much of the 
clinical and basic research into the nutritional causes of the hypertensive 
disorders of pregnancy has paralleled research on the etiology of hypertension, 
focusing on individual nutrients such as calcium, sodium, magnesium, and fatty 
acids. Until now, the effects of diet and specific nutrients on the hypertensive 
disorders of pregnancy have rarely been studied in a prospective cohort. Dietary 
assessment methods have not often been validated for use among pregnant 
women. The present research represents one of the very few studies to date that 
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have comparatively assessed the role of diet in the etiology of PE among women 
living in different geographic settings– in this case, in Canada and in Mexico - 
both in early pregnancy and in late pregnancy. In addition, our goal was to assess 
the role of diet on the development of PE at different stages of gestation. We 
believe that this study makes a novel contribution to understanding of the role of 
maternal nutrient intakes and supplementation in early and late pregnancy on the 
risk of PE.  
 
STUDENT’S CONTRIBUTION  
The studies described in this thesis were conducted in the context of a 
research program that involved a number of researchers.  As a PhD student in 
this program, I played a key role in all of the studies described. With respect to 
the INTAPP trial, I played a leading role in preparation and modification of Case 
Report Forms and Standard Operation Procedures, the data management and 
adjudication of the primary outcomes (Gestational hypertension and 
Preeclampsia), and the planning and execution of data analysis. I played a key 
role in the Data Safety and Monitoring Committee, making significant 
contributions to the work of  that committee including: 1) preparation of the 
report of potential adverse events associated with vitamins C and E in the 
literature; and 2) conducting the interim analysis regarding the adverse events 
observed in the INTAPP trial. With respect to the preparation of the tools for the 
nutritional surveys, I worked closely with nutritional experts in the INTAPP 
team and made significant contributions to FFQ validations study in Canada 
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including preparing of the statistical analysis plan and conducting data analysis. 
Regarding the ancillary study of nutrient intakes during pregnancy and risk of 
hypertensive disorders, I played a leading role in the conceptualization of the 
study, data management and quality assessment of the FFQ data, preparation of 
study analysis plan and conduct of  the study analysis.  
I worked closely with our colleagues at Québec Lipid Research Center and 
played a leading role in the conceptualization and implementation of the case 
control study of plasma tocopherol concentrations in relation to PE risk. The 
main specific responsibilities for this study were: 1) study design and preparation 
of study protocol; 2) implementation of the study including identifying cases and 
controls for laboratory measurements; and 3) preparing the statistical analysis 
plan and conducting data analysis using appropriate statistical models.    
I drafted all manuscripts listed in the present dissertation and was the primary 
author for each of the manuscripts.  
  CHAPTER 1   LITERATURE REVIEW 
1.1 Causal mechanisms of PE 
PE is a multisystem disorder that is specific to human pregnancy and only 
can be resolved by delivery. Generally, the etiology of PE can be conceptualized 
in two broad categories: PE of placental origin and PE of maternal origin.(14)  
PE of placental origin arises from a hypoxic placenta and progresses in two 
stages described as pre-clinical (poor placentation) and clinical features.(14) PE 
of maternal origin arises from the interaction between a normal placenta and 
maternal constitutional factors such as microvascular disease, chronic 
hypertension, obesity, inflammation or diabete that predispose the woman to the 
condition. Thus pregnancy may represent a metabolic and vascular ‘stress test’ 
that unmasks latent cardiovascular risk.(15) However, involvement of both 
placental and maternal constitutional factors is very common in the development 
of PE and these broad categories are likely not mutually exclusive. Most patients 
are somewhere on a continuum between these two etiologic pathways.  
Several etiologic theories of PE have been proposed and extensively 
investigated. (14), (16-21) During normal pregnancy, cytotrophoblasts invade 
the maternal decidua and spiral arteries and completely remodel the maternal 
spiral arteries into large capacitance vessels with low resistance. In 
preeclampatic pregnancies, shallow endovascular cytotrophoblast invasion of the 
spiral arteries results in a hypoxic and dysfunctional placenta, and the release of 
factors such as cytokines, growth factors and certain chemicals into the maternal 
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circulation.(14-26)  These maternal circulating factors mediate endothelial 
dysfunction, leading to the clinical signs of PE. Increased levels of factor VIII-
related antigen, total and cellular fibronectin, thrombomodulin, endothelin, and 
disturbances of the prostacyclin to thromboxane A2 ratio all support the 
hypothesis that systemic endothelial dysfunction plays a central role in the 
pathogenesis of PE.(27-36) Several lines of evidence support the hypothesis that 
the abnormal placentation may play a role in inducing an alteration in the 
balance of circulating levels of angiogenic/antiangiogenic factors such as 
vascular endothelial growth factor (VEGF), free placental growth factor (PlGF), 
soluble fms-like tyrosine kinase (sFlt1) and soluble endoglin (sEng), which 
contributes to endothelial cell dysfunction in the maternal vasculature.(19, 37-40) 
Recent studies suggest that women with clinically established PE have 
significantly lower levels of PlGF and VEGF compared with gestational age-
matched normotensive controls.(16, 41-46) Circulating sFlt1, a receptor binding 
VEGF and PlGF, is significantly increased before the onset of PE.(46-48) 
However, it remains unclear whether impaired placental perfusion initiates 
symptoms such as hypertension, endothelial dysfunction, and increased sFlt1 
expression, or whether inadequate placental development occurs initially and is 
followed by a pathological rise in sFlt1 expression and secretion.(49)  
The role of oxidative stress in the pathogenesis of PE is also increasingly 
recognized.(21, 50, 51) Oxidative stress is an imbalance between pro-oxidant 
and antioxidant forces, resulting in an accumulation of free radicals or reactive 
oxygen or reactive nitrogen species. Deleterious effects of free radicals include 
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lipid peroxidation, oxidative damage to bimolecules, and cellular dysfunction. It 
has been hypothesized that hypoxia stimulates the activity of xanthine or 
nicotinamide adenine dinucleotide phosphate-oxidase (NAD (P)H) in placenta, 
which leads to superoxide generation. Oxidative stress likely contributes to 
maternal endothelial cell activation, enhanced apoptosis of trophoblast, and is 
believed to underlie the intense vasoconstriction and procoagulant state of 
PE.(14) (16-21) Markers of oxidative stress, such as isoprostanes and 
malondialdehyde, are increased in plasma,(52, 53) small arteries(54) and decidua 
basalis(55) of women with PE.  
Experimental and epidemiological data support the role of maternal-fetal 
immune maladaptation in the etiology of PE.(56-59) There are reports of altered 
immune status in PE.(60-62) A significantly lower proportion of T-helper cells 
was demonstrated in women who later developed PE.(60) Deposition of 
immunoglobulin (IgM), complement (C3), and fibrin has been observed in the 
walls of spiral arteries in women who develop PE.(61, 63) Studies have shown 
that mothers lacking most or all activated killer cell immunoglobulin-like 
receptors (KIRs, AA genotype) when the fetus had HLA-C (human leukocyte 
antigens) were at a substantial risk of PE.(63) These findings are supported by 
epidemiological studies investigating the relationship between parity, paternity 
and the risk of PE.(64, 65) It has been demonstrated that multiparity is associated 
with a reduced risk of PE, which suggests an immune tolerance phenomenon. 
Interestingly, some studies suggest that the protective role of primiparity is lost 
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with the change of partner, suggesting that primpaternity, rather than primparity, 
is related to the risk of PE. (64, 65)    
PE is associated with an increase in systematic inflammatory responses. The 
causes of these responses remain unknown. One attractive concept is that 
placental ischemia and reperfusion with oxidative stress may induce the higher 
proliferation of cytotrophoblasts and increase the deportation of 
syncytiotrophoblasts.(14, 20) Thus, the altered balance between proliferation and 
apoptosis of trophoblasts may cause aponecrotic or even necrotic release of 
trophoblasts, accentuating maternal inflammatory burdens. It has been reported 
that there are increased amounts of trophoblast debris, comprised of 
syncytiotrophoblast membrane microparticles, cytokeratin fragments, and 
soluble fetal proteins in maternal circulation in women with PE. (14), (16-21) 
Enhanced activation of cytokine mediators of apoptosis (especially interferon, 
tumour necrosis factor) have been found in PE. (14), (16-21) It is well known 
that severe PE and eclampsia have a familial tendency. Nilsson and colleagues 
reported a heritability of 31% for PE and 20% for GH.(66) Chesley et al. 
reported a 26% incidence of PE in daughters of women with PE compared to 
only an 8% incidence in the daughters-in-law.(67) It seems that a number of 
maternal susceptibility genes or perhaps fetal genes may contribute to the 
pathogenesis of PE by interacting with the maternal cardiovascular or hemostatic 
systems, or by regulating endothelial activation and inflammatory responses.(68-
71)   
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In summary, there are numerous theories of the pathogenesis of PE. 
(Appendix: Figure1) These different underlying mechanisms are not mutually 
exclusive, but rather likely interactive. A vast array of initiating agents and 
multiple pathogenic mechanisms have been implicated in the development of PE, 
including increased systematic vascular resistance, enhanced platelet aggregation, 
activation of coagulation systems and endothelial dysfunction.  
1.2 Involvement of nutritional factors in the pathogenesis of PE 
The role of maternal diet in the etiology of PE has recently received 
increased attention. Information largely derived from studies external to 
pregnancy indicates that certain nutrients may be involved in several important 
steps in the current proposed concepts of the pathogenesis of PE.(71-74) Several 
nutrients, in particular, omega-3 (n-3) fatty acids, antioxidants, folic acid, and L-
arginine have important roles in modulating endothelial function.(71, 72)  Higher 
intake or supplementation of these nutrients is associated with the decreased 
expression of endothelium adhesion molecules (VCAM-1), but increased levels 
of endothelium dependent vasodilation and nitric-oxide production.(75-80) The 
influence of these nutrients on endothelial function is multiple and complex, 
including inhibition of monocyte adhesion and platelet activation, and 
improvement of vasodilation and blockage of lipid oxidation.(71, 72, 74) 
Nutrients can affect oxidative stress by increasing or decreasing free radicals 
or antioxidants, by providing substrates for the formation of free radicals, or by 
modulating functions of antioxidant enzymes. For instance, lipids are extensively 
involved in the generation of free radicals.(81) Antioxidants (vitamin C, E, alpha 
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or beta-carotene, copper, selenium, zinc, etc.) can directly or indirectly scavenge 
free radicals or function as essential substrates or cofactors for the adequate 
functioning of antioxidant enzymes. Therefore, adequate dietary antioxidant 
intake is crucial for maintaining pro-oxidant and antioxidant balance as some 
nutrients are not synthesized in humans.  
Compelling evidence suggests that nutrients may modify certain 
inflammatory responses.(82-85) For example, nutrients can affect the production 
of monocyte tumor necrosis factor-α (e.g. antioxidants and fatty acids), modulate 
pro-inflammatory cytokine production and actions (e.g. iron, fatty acids), or 
activate genes involved in the inflammatory responses (e.g. polyunsaturated fatty 
acids). (82-85)These mediators are essentially implicated in the pathogenesis of 
PE such as trophoblast apoptosis, inflammatory response and endothelial 
activation.  
It has also been suggested that nutrients such as trace elements, fatty acids 
and folic acid can contribute to insulin resistance, a risk factor for PE.(86-89)   
Both experimental and epidemiological studies have indicated that n-3 fatty 
acids can improve glucose tolerance and prevent insulin resistance.(90, 91)  
1.3 Macronutrients and risk of PE  
1.3.1 Energy and diet composition  
It is proposed that high-energy diets can affect endothelial function and 
inflammatory responses by activating oxidative stress-responsive transcription 
factors, inflammatory cytokine production and the expression of adhesion 
molecules.(92, 93) Abnormal lipid metabolism can be present in women with 
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mild or severe PE: these anomalies are characterized by increased levels of 
triglycerides, low-density lipoprotein cholesterol (LDL-C), LDL-III (small dense 
lipoprotein) and apolipoprotein A-I.(94, 95)  
A large case-control study was conducted in Jerusalem, involving 180 
women with PE and 360 healthy controls who were matched for country of 
origin, parity, month of delivery, age, year of immigration and years of schooling. 
A dietary history was obtained at the time of delivery. Results indicated that 
preeclamptic women had significantly lower intakes of protein, fat and energy. 
However, further investigations suggested that these differences might be 
secondary to the disease rather than causal.(96) Atkinson et al. carried out a case-
control study in Zimbabwe using a crude (simple/qualitative/non-quantitative) 
food frequency questionnaire (FFQ) and found no significant differences 
between 180 women with PE and 194 normtensive controls.(97) Only a few 
prospective population-based studies have examined the relationship between 
energy intake and the risk of PE, and they have yielded inconsistent findings.(98, 
99) A US study evaluated diet using a 24-hour dietary recall at 13-21 weeks 
gestation in 4157 women who had been enrolled in a randomized controlled trial 
of calcium supplementation in the prevention of PE.(99) There was no evidence 
of an increased risk of PE in women with a higher intake of energy. Moreover, 
there was no difference between cases and controls in the intake of any of the 28 
nutrients that were studied.(99) A Norwegian team administered a semi-
quantitative FFQ to 3771 women at 17-19 weeks of gestation.(98) The risk of PE 
was increased among women with a high energy intake (adjusted OR: 5.4, 95% 
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CI: 2.3 –12.4, for the 4th quartile) and a high intake of polyunsaturated fatty 
acids (adjusted OR: 2.3, 95% CI: 1.1-4.6). Differences persisted even after 
adjusting for age, smoking and body mass index (BMI). Moreover, the authors 
observed a stronger association for early onset PE. The discrepancy between 
these studies may be partially explained by the methods used to estimate dietary 
intake, the time in pregnancy at which diet is assessed, different definitions of 
PE and GH, or population differences (i.e. lifestyle, heterogeneity in nutrient 
intake, socio-demographic factors). It is worth pointing out that in both the 
Norwegian(98) and American Studies, (99) women who later developed PE had 
a higher pre-pregnancy body weight, suggesting the potential role of energy 
balance before pregnancy in the development of PE.  
1.3.2 Fiber 
Evidence derived from randomized controlled trials indicates that dietary 
fiber may have beneficial effects on plasma lipid and lipoprotein profiles, 
postprandial glucose metabolism, insulin sensitivity and blood pressure.(100, 
101)The clinical data on the role of fiber in pregnancy are however quite limited.  
In 1991, Skajaa et al. found no differences in mean daily fiber intake during 
the third trimester between PE cases and controls.(102) Frederick et al. 
conducted a case-control study of 172 preeclamptic women and 339 
normotensive controls to explore the relation between PE risk and maternal 
intake of dietary fiber, potassium, magnesium and calcium. They reported that 
fiber intake was inversely associated with the risk of PE. (103) They found that 
women with fiber intake in the highest quartile (>24.3g/day) had a reduction in 
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the risk of  PE (OR 0.46, 95% CI 0.23-0.92) compared to the lowest quartile 
(<13.1g/day). In this study, the FFQs were administered at the end of pregnancy, 
therefore the possibility of recall bias can be not excluded.(103) More recently, 
Qiu et al. carried out a prospective cohort study of 1,538 pregnant women in 
Washington State, in which a 121-item FFQ was administered at a mean 
gestational age of 13.1 weeks. The adjusted relative risk of PE for women in the 
highest (>21.2 g/day) vs. the lowest quartile (<11.9 g/day) was 0.28 (95% CI 
0.11-0.75). (104) The authors observed similar magnitudes of associations for 
the highest vs. the lowest quartiles of water-soluble fiber (RR 0.30; 95% CI 0.11-
0.86) and insoluble fiber (RR 0.35; 95% CI 0.14-0.87).(104) Furthermore, mean 
triglyceride concentrations were significantly lower and high-density lipoprotein 
cholesterol concentrations were nonsignificantly higher for women in the highest 
quartile compared to those in the lowest quartile.(104) Additional well designed 
cohort studies and clinical trials are needed to further explore the role of fiber as 
well as of obesity, insulin resistance, and dyslipidemia in the development of PE.  
1.3.3 Protein intake  
It has been suggested that certain amino acids such as arginine, citrulline, 
glycine, taurine, and histidine, as well as small peptides that directly scavenge 
oxygen free radicals are essential for normal endothelial vasomotion.(71, 72) 
However, epidemiological studies have not yielded compelling evidence to 
support an association between protein deficiency and the increased risk of 
PE.(96-99) Furthermore, trials of protein supplementation have failed to 
demonstrate a reduction in the risk of PE.(105, 106) The effects of high protein 
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supplementation (protein/energy supplementation in which the protein content of 
the supplement provided >25% of its total energy content) on pregnancy 
outcome were assessed in a Cochrane systematic review. No significant benefits 
of protein supplementation were observed.(107) Another systematic review to 
assess the effects of the balanced protein-energy supplementation on pregnancy 
outcomes (protein content less than 25% of total energy content) showed no 
effects on pregnancy outcomes including the risk of PE.(108) It should be noted 
that the trials included in these systematic reviews had methodological flaws. 
Alternate treatment allocation rather than a solid randomization method was used, 
and a large proportion of women were lost to follow up for the primary outcome. 
On the other hand, it has been hypothesized that high protein diets may 
increase the risk of PE by contributing to oxidative stress via increased 
homocysteine production and increased whole-body nitric oxide (NO) 
production from nitric oxide synthase (NOS) induction.(109) However, a 
published meta analysis showed that, in three trials involving 384 women, 
energy/protein restriction had no effect on pregnancy-induced hypertension or 
PE, despite the fact that women who were overweight or who exhibited high 
weight gain significantly reduced weekly maternal weight gain and mean birth 
weight.(110) 
1.3.4 Lipid intake  
Several studies have documented dyslipidemia in women with PE. Reduced 
HDL (111, 112) and increased triacylglycerols (113), LDL cholesterol (114, 115) 
and small dense LDL (116) were demonstrated in women with PE. Increases in 
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serum triglycerides and free fatty acids among women who later developed PE 
were evident before 20 weeks of gestation.(117)   
Increased levels of polyunsaturated and total free fatty acids, and other lipids 
and reduced (n-3) fatty acids have been observed in women with PE.(118, 119) 
One study prospectively assessed dietary fatty acid intake and fatty acid 
composition in maternal, fetal and umbilical blood.(120) Maternal blood was 
sampled in a large cohort of women at less than 16 and at 22-32 weeks of 
gestation, and within 24 hours of delivery. A subset of women underwent dietary 
assessment in each trimester. The results showed that there were no differences 
between groups (GH with or without proteinuria vs normotensive women) in 
maternal fatty acid and nutrient intake at 16 and 32 weeks of gestation. After 
delivery, levels of essential fatty acids, including 18:2 (n-6) Linoleic acid and 
18:3 (n-3) α-Linoleic acid were significantly lower, whereas the sum of (n-6) 
long-chain polyenes (polyunsaturated fatty acids with 20 or more carbon atoms 
and three or more double bonds) were significantly higher in hypertensive 
women compared to controls.(120) In another prospective study, an increased 
intake of polyunsaturated fatty acids was demonstrated in women who later 
developed PE.(98) 
Omega-3 (n-3) fatty acids have been suggested to have a preventive effect on 
early delivery and hypertensive disorders of pregnancy.(121, 122) Omega-3 (n-3) 
fatty acids are known to reduce fasting and postprandial triglycerides and to 
decrease platelet and leukocyte reactivity. It has been suggested that high-dose 
n–3 fatty acid intake could reduce maternal thromboxane A2 synthesis and 
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enhance maternal refractoriness to angiotensin II, which may reduce the risk of 
PE.(123) Low erythrocyte levels of omega-3 fatty acids and high levels of 
omega-6 fatty acids, particularly arachidonic acid, appear to be associated with 
an increased risk of PE.(124) Wang et al. observed a significantly lower level of 
total n–3 and n–6 polyunsaturated fatty acids in women with PE.(125) However, 
recent clinical trials failed to detect any significant effect of fish oil 
supplementation on PE risk in women at high risk of GH.(126-129) Interestingly, 
a recent study reported that dietary intake in polyunsaturated fatty acids (PUFAs: 
n-3 and n-6) was positively correlated with glutathione peroxidise (GSH-Px) 
activity in healthy pregnant women. (130) The author suggested that increased 
GPx activity may be a response to the increased oxidative stress generated by the 
relatively higher concentrations of PUFAs.(130) Moreover, a recent prospective 
study indicated that the odds ratio for hypertensive disorders presented a U-
shaped curve across different intake levels of n-3 long-chain polyunsaturated 
fatty acids (n-3 LCPUFA). (131) The authors concluded that excessive 
consumption in early pregnancy of n-3 LCPUFA or other nutrients (e.g. vitamin 
A, D, E) found in liquid cod-liver oil may increase the risk of developing 
hypertensive disorders in pregnancy.(131) However, Horvath et al. carried out a 
meta analysis of randomized controlled trials to evaluate the LCPUFAs on 
pregnancy outcomes.(132) There was no evidence of an effect of LCPUFAs on 
the rate of pregnancy-induced hypertension or PE. 
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1.4 Micronutrient and risk of PE 
1.4.1 Calcium  
Calcium is the micronutrient that has been most extensively studied in 
relation to PE. Numerous studies have demonstrated reduced levels of serum or 
urinary calcium in PE.(133-136) Several epidemiological studies indicate an 
association between low dietary intake of calcium and increased risk of PE.(103, 
137)  
Encouraged by the results of observational studies, a number of controlled 
trials have been conducted to confirm the beneficial effects of calcium 
supplementation, but with conflicting results.(138-140) A recent large trial 
investigated whether calcium supplementation of pregnant women with low 
calcium intake reduced PE and preterm delivery.(141) Calcium supplementation 
was associated with a small reduction in the incidence of PE and/or eclampsia 
(4.1% versus 4.5%; RR 0.91, 95% CI 0.69-1.19), early onset PE and/or 
eclampsia (RR 0.77; 95% CI 0.54-1.11) and GH (RR 0.96, 95% CI 0.86-1.06), 
however, null effects were not excluded. A life table analysis indicated that 
effects on PE and/or eclampsia were evident by 35 weeks of gestation (1.2% in 
calcium group versus 2.8% in placebo group, P = .04). Furthermore, calcium 
supplementation was associated with a reduced risk of eclampsia (RR 0.68, 95% 
CI, 0.48-0.97) and severe GH (RR 0.71, 95% CI 0.61-0.82).(141) Overall, there 
was a statistically significant reduction in the severe preeclamptic complications 
index including any of the following: severe PE, early onset PE, eclampsia, 
placental abruption, HELLP syndrome (hemolysis, elevated liver enzymes, and 
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low platelet count), or severe GH (RR 0.76, 95% CI 0.66-0.89, life-table analysis, 
log rank test P =.04).(141) Hofmeyr et al. recently conducted a meta analysis of 
12 randomized controlled trials, including 15,528 women, in which 66% women 
had a low dietary calcium intake and 96% women were at low risk for GH or 
PE.(142) The dose of calcium administered varied from 1.5 to 2.0 grams per day. 
Calcium supplementation significantly reduced the risk of high blood pressure 
(11 trials, 14,946 women: relative risk 0.70, 95% CI 0.57-0.86), PE (12 trials, 
15,206 women: RR 0.48, 95% CI 0.33-0.69), and maternal death or serious 
morbidity was reduced (four trials, 9732 women: RR 0.80, 95% CI 0.65-0.97). 
The effect was greatest for women at high risk for hypertensive disorders of 
pregnancy (five trials, 587 women: RR 0.22, 95% CI 0.12-0.42) and for those 
with low baseline calcium intake (seven trials, 10,154 women: RR 0.36, 95% CI 
0.18-0.70).(142) However, HELLP syndrome was increased in the calcium 
supplementation group compared to the placebo group (two trials, 12,901 
women: RR 2.67; 95% CI 1.05-6.82). There were no differences in neonatal 
outcomes such as preterm birth or stillbirth or death before discharge from 
hospital.(142) 
1.4.2 Sodium  
A Cochrane review indicated that manipulating sodium intake does not affect 
the frequency of PE.(143) In addition, a study in Japan indicated that a low-salt 
diet is not only ineffective for the prevention of PE, but also accelerates volume 
depletion in PE.(144) A reduction in sodium intake may cause a significant 
reduction in the intake of energy, protein, carbohydrates, fat, calcium and other 
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nutrients.(145) Therefore, based on recent evidence, salt restriction is not 
recommended in pregnancy.  
1.4.3 Vitamins C and E  
Vitamins C and E are two essential nutrients that can scavenge free radicals 
and constitute a strong line of defence in delaying or preventing ROS-induced 
cellular damage. Vitamin C (ascorbic acid) is an essential water-soluble vitamin, 
and serves as a non-enzymatic antioxidant by delivering a hydrogen atom with a 
single electron to a reactive oxygen molecule. Adequate dietary intake is 
required to prevent oxidative stress. Vitamin E is the major peroxyl radical 
scavenger in biological lipid phases, such as membranes or LDL. Its antioxidant 
action has been ascribed to its ability to chemically act as a lipid-based free 
radical chain-breaking molecule, thereby inhibiting lipid peroxidation and 
oxLDL formation.(146) Vitamins C and E also play a key role in the modulation 
of enzymes involved in the vascular endothelial damage known to contribute to 
the pathophysiological mechanisms of the clinical expression of PE.(147) In 
vitro and in vivo studies demonstrate a synergistic effect between the two 
vitamins.(148) 
Numerous studies have reported low levels of vitamin C in women with 
PE.(149-151) A case- control study (99 women with PE compared with 99 
controls) found that women with both elevated oxidized LDL and low vitamin C 
concentration had a 9.8 fold risk of PE (95% CI 3.0-32.2).(151) Sagols et al. 
reported that plasma levels of ascorbic acid and serum antioxidant activities were 
significantly decreased in mild and severe PE compared to normtensive 
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controls.(152) Serum alpha-tocopherol levels were significantly decreased only 
in severe PE.(152) Furthermore, a case control study using a semi-quantitative 
FFQ found that women who consumed <85mg of vitamin C daily, as compared 
with others, experienced a two-fold risk of PE. Women with plasma ascorbic 
acid less than 34.6 micromol/liter had a 3.8-fold increased risk of PE, compared 
with those in the highest quartile. Analyses were adjusted for maternal age, 
parity, pre-pregnancy BMI, and energy intake.(153)  
A reduced level of vitamin E in association with PE has been reported in 
some,(154-156) but not in all studies.(149, 150, 157-160) Reduced levels of 
vitamin E have been most consistently demonstrated in severe cases of PE.(152, 
154, 161, 162) The variation across studies may be explained by the fact that 
concentrations of lipid soluble vitamin E had not been adjusted for lipid 
concentrations although the elevation of total cholesterol and triglycerides is one 
of characteristics of PE.(163) Moreover, the measurement of plasma vitamin E is 
a far from satisfactory estimate of the focal site of vitamin E activity, namely the 
cell membrane. To date, no study has measured vitamin E concentrations in red 
cell membrane or those in any other tissue in women with PE. It is striking that 
the diversion from normal values correlated with severity of disease in the 
reports describing either lowered or elevated plasma vitamin E concentration in 
women with PE.(152, 154, 156, 164) 
The first clinical trial to investigate the effects of vitamin C and E on the risk 
of PE was conducted by a UK research group.(165) Patients were included in the 
study if they were at increased risk of PE, as defined by abnormal uterine artery 
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Doppler waveform or by past history of the disease. Among women who were at 
risk,  the investigators reported a  reduction in PE in the group with 
supplementation of vitamin C (1000 mg/day) and vitamin E (400 IU alpha-
tocopherol/day) for (RR 0.39; 95% CI 0.17-0.90). The ratio of PAI-1 
(plasminogen activator inhibitor-1, a marker of endothelial cell activation) to 
PAI-2 (a marker of placental function) was significantly decreased in the 
vitamin-treated group. High-risk women who developed PE in the placebo group 
had lower plasma vitamin C concentrations (p<0.002) compared with normal 
pregnant controls and these returned to normal levels on supplementation.(166) 
Plasma concentrations of the isoprostane, 8-epi-prostaglandin F2alpha, a marker 
of lipid peroxidation were raised in the high-risk placebo group but fell to 
concentrations comparable to low risk subjects after vitamin C and E 
supplementation.(166) Another small trial of women who were considered as 
being at high risk on the basis of their clinical history found no evidence of 
benefits with the same antioxidants.(167)  
1.4.4 Vitamin A 
The role of vitamin A and β-carotene (pro-vitamin A) in pregnancy induced 
hypertension and PE is also a subject of controversy. Many clinical studies have 
found significantly lower levels of vitamin A and β-carotene in preeclamptic 
women than in healthy women.(168-172) However, the decreased levels of 
retinol and β-carotene might be secondary to disease as a part of an acute phase 
reaction rather than the results of a causal relationship. Further studies are 
needed to determine the temporal relationship between carotenoids and the risk 
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of adverse pregnancy outcomes. High dose of vitamin A could be toxic and there 
is concern about its teratogenicity. (173-177) Given the fact that it is unlikely 
that a safety threshold of vitamin A consumption in early pregnancy will be 
established over the next few years, it will therefore be ethically difficult to 
conduct human trials to assess the effects of vitamin A supplementation in early 
pregnancy on the risk of PE.   
1.4.5 Folate (Folic acid) 
Folate is the generic term for this water-soluble B-complex vitamin. It 
functions as a coenzyme in single-carbon transfers in the metabolism of amino 
acids and nucleic acids, and is therefore required by all cells for growth. Folic 
acid (pteroylmonoglutamic acid, or PGA), which is the common form used in 
vitamin supplements and fortified food products, is the most oxidized and stable 
form of folate. Most naturally occurring folates, called food folate, are 
pteroylmonoglutates, which contain one to six additional glutamate molecules 
joined in a peptide linkage to the γ-carboxyl of glutamate. 
The importance of adequate folate supply during pregnancy and lactation is 
increasingly recognized. It has been suggested that folic acid from food intake 
and routine supplementation may be sufficient during the periconception period, 
but larger doses may be required in early gestation, in particular for women with 
higher risk of adverse pregnancy outcomes (e.g. PE).  Folate may reduce the risk 
of developing PE by improving endothelial function at both the placental and 
systemic levels,(178) or by lowering homocysteine, a risk factor for PE.(179)   
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Epidemiologic studies have found that supplementation of multivitamins 
containing folic acid was associated with reduced risk of PE.(180),194) Bodnar 
et al. examined the association between regular use of multivitamins containing 
folic acid at <16 weeks' gestation and the risk of PE in 1,835 women in 
Pittsburgh, Pennsylvania between 1997 and 2001.(180) They found that regular 
use of multivitamins containing folic acid was associated with a 45% reduction 
in PE risk compared with nonusers (OR 0.55; 95% CI 0.32-0.95). Hernandez-
Diaz et al. also observed a significant reduction of risk for GH after 
supplementation of multivitamins containing folic acid (adjusted OR 0.55; 95% 
CI 0.39- 0.79).(181) Wen et al. carried out a prospective cohort study of 2951 
women in Ottawa and Kingston, Canada. They found that supplementation with 
multivitamins containing folic acid in the early second trimester was associated 
with increased serum folate, lowered plasma homocysteine, and reduced risk of 
PE (adjusted odds ratio 0.37; 95% CI 0.18-0.75).(182) Catov et al. examined the 
associations between supplementation of multivitamin containing folate or folate 
only during a 12-week periconceptional period, using data from the Danish 
National Birth Cohort.(183) They found that regular use of periconceptional 
multivitamin containing folate use was associated with a 20% reduction of the 
risk of PE among normal-weight women. However, such a reduction was not 
observed for folate only supplements.(183) Furthermore, Ray and Mamdani 
found that there is a small reduction in the rates of PE in Canada after folic acid 
food fortification in 1998 (prevalence ratio 0.96; 95% CI 0.94- 0.98).(184)  
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Evidence from trials assessing the effects of folate supplements on the risk of 
PE, is very limited. Taylor et al. conducted a randomized trial to assess the 
effects of supplementation of elemental iron (65 mg/day) and folic acid (350 
µg/day) on adverse pregnancy outcomes in 48 healthy pregnant women. They 
found no effect of iron-folic acid supplementation on the risk of PE.(185) 
Charles et al. re-analysed data from a large randomised controlled trial 
performed between 1966 and 1967 and found that the risk of PE was lower in 
groups receiving the supplementation of folic acid 200µg/day and 5mg/day 
compared to the placebo group.(186)  
1.4.6 Vitamin D 
The immunomodulatory properties of the hormonal vitamin D system could 
potentially have beneficial effects for successful maintenance of pregnancy.(187) 
Impaired vitamin D metabolism is demonstrated in preeclamptic pregnancy.(187, 
188) Therefore, ensuring adequate vitamin D status/intake could potentially 
contribute to the prevention of PE.(189)  
Studies exploring the role of maternal vitamin D status in adverse pregnancy 
outcomes are scarce. Bodnar et al. conducted a nested case-control study of 
pregnant women followed from less than 16 wk gestation to delivery (1997-2001) 
to assess the association of maternal serum 25(OH) D levels with the risk of 
PE.(190) Their results indicated that serum 25(OH) D concentrations in early 
pregnancy were lower in women who subsequently developed PE compared with 
controls. There was a monotonic dose-response relationship between serum 
25(OH) D concentration at <22 week of gestation and the risk of developing PE. 
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A 50-nmol/liter decline in 25(OH)D concentration doubled the risk of 
developing PE (adjusted OR 2.4, 95% CI 1.1-5.4). Newborns of preeclamptic 
women were twice as likely as control newborns to have 25(OH)D less than 37.5 
nmol/liter (adjusted OR 2.2, 95% CI 1.2-4.1).(190) A recently published study 
by Haugen et al. examined the association between vitamin D intake during 
pregnancy and the risk of PE in 23,423 nulliparous pregnant women taking part 
in the Norwegian Mother and Child Cohort Study.(191) They found that the 
odds ratio of PE for women with a total vitamin D intake of 15-20 [mu]g/d was 
0.76 (95% CI 0.60-0.95) compared those with less than 5 [mu]g/d. Moreover, 
they reported a 27% reduction in the risk of PE (OR 0.73; 95% CI 0.58-0.92) for 
women taking 10-15 [mu]g/d vitamin D supplements as compared with no 
supplements. However, no association was found between vitamin intake from 
the diet alone and the risk of PE. (191) There may be a correlation between 
vitamin D supplementation and intake of other nutrients (e.g. calcium, Omega-3 
fatty acid).(191) Further studies with data on other nutrients intake and vitamin 
D status will be necessary to further disentangle the effect of each on PE risk.   
1.4.7 Magnesium 
Magnesium is an essential mineral needed by humans in relatively large 
amounts. It is crucial for regulating temperature and protein synthesis and 
maintaining electrical potential in nerves and muscle membranes. A prospective 
observational study used a FFQ to assess diet at 30 weeks of gestational age and 
found no difference in magnesium intake in Danish women who developed PE 
compared to controls.(102) Observational studies suggest that supplementation 
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with magnesium is associated with a reduced risk of PE.(192) However, a 
Cochrane systematic review of randomized trials found no evidence of a benefit 
of magnesium supplementation on the risk of PE.(193) The methodological 
quality of trials included in the review was poor.  
1.4.8 Other micronutrients  
Certain trace elements are essential co-factors for adequate activation of 
antioxidant enzymes. These trace elements (e.g., copper, iron and selenium) are 
directly implicated in oxidative/anti-oxidative balance - a key pathogenic process 
in PE, and are highly dependent on dietary habits and supplements.(194-196) 
Serum concentrations of magnesium, copper and zinc have been reported to be 
significantly lower in PE compared with controls.(136, 197) 
Epidemiological studies have suggested that deficiencies of zinc, iron, and 
selenium are associated with an increased risk of PE. However, randomized 
trials have failed to demonstrate a beneficial effect of trace elements 
supplementation in the prevention or management of PE.(198-200) Little 
information is available with respect to the specific roles of these trace elements 
in early pregnancy for PE susceptibility.  
1.5 Obesity, weight gain and risk of PE 
Obesity is an independent risk factor for PE.(17) The link between obesity 
and PE is complex. The metabolic changes in obese women, such as increased 
lipid availability, higher cholesterol and triglyceride levels, or insulin resistance 
may lead to a derangement of the VLDL/toxicity-preventing activity balance and 
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enhance cytokine-mediated oxidative stress, subsequently leading to endothelial 
cell dysfunction.(201-203) Moreover, elevated cardiac output with compensatory 
vasodilation in women with obesity may also lead to endothelial cell dysfunction. 
Most observational studies consistently demonstrate that maternal obesity or a 
higher prepregnancy BMI is associated with an increased risk of PE or GH.(204-
207)  
Bodnar et al. reported that pre-pregnancy adiposity is a strong independent 
risk factor for PE.(204) The authors further explored the dose-dependent 
relationship between pre-pregnancy BMI and the risk of PE. The results 
indicated that PE risk rises through most of the BMI distribution. Compared with 
women with a BMI of 21, the risk of PE doubled for women at BMI of 26, and 
nearly tripled risk for those at a BMI of 30.(204) A systematic review, 
identifying three cohort studies in 1.4 million women (from US, Sweden, the 
Netherlands, Latin America, the Caribbean, Taiwan, and the UK), demonstrated 
that the risk of PE typically doubled with each 5-7 kg/m2 increase in pre-
pregnancy body mass index.(205)  
The prevalence of obesity is rapidly increasing worldwide and the epidemic 
is especially pronounced in women of child bearing age.(208, 209) It has been 
reported that the prevalence of pre-pregnancy obesity increased by 69% over a 
10-year period, from 13% in 1993–1994 to 22% in 2002–2003.(209) As obesity 
confers a significant risk for PE, the epidemic of obesity therefore will 
undoubtedly increase the incidence of PE. Wallis et al. analyzed public-use data 
from the National Hospital Discharge Survey and reported that rates of PE and 
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GH had increased by 25% and 184% respectively from 1987 to 2004.(210) Thus, 
public health programs to promote the reduction of overweight or obesity as well 
as  further research to evaluate their effectiveness are needed to suppress  the 
epidemic of obesity and thereby the significant rise in PE.  
Over the past 25 years, several authors have demonstrated a significant 
association between excessive weight gain and hypertensive disorders of 
pregnancy.(206, 207, 211-213) Brennand et al. showed that obese women with 
excessive weight gain had a higher prevalence of PE (14.9%) than obese women 
with low (3.7%) or acceptable (6.3%) weight gain.(214, 215) Saftlas et al. did 
not find an association between excessive weight gain and the risk of PE 
although the risk of transient hypertension was increased more than twofold 
among women in the highest quartile of the weight gain index (OR 2.55; 95% CI 
1.66-3.92).(215)  A prospective population-based cohort study by Cedergren of 
245,526 singleton term pregnancies showed that obese women with low 
gestational weight gain had a decreased risk for PE (OR 0.52; 95% CI 0.42-0.62) 
compared to those with excessive weight gain. There was a 2-fold increased risk 
for PE among average and overweight women with excessive weight gain.(216) 
Kiel et al. carried out a population-based cohort study of 120,251 pregnant obese 
women to examine the associations between gestational weight change and 
adverse outcomes.(217) The authors reported that, among overweight or obese 
pregnant women, gestational weight gain of less than the currently recommended 
15 lb was associated with a significantly lower risk of PE. The authors concluded 
that limited or no weight gain in obese pregnant women has favourable 
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pregnancy outcomes. Langford et al. conducted a population-based cohort study 
to examine the association between gestational weight gain and adverse 
outcomes among overweight women (BMI 26.0-29.0 kg/m2).(218) Compared to 
women who gained 15-25 lbs, women who gained <15 lbs were 0.8 (95% CI 
0.6-1.0) times as likely to have PE, but women who gained >25 lbs were 1.7 
(95% CI 1.5-1.9) times as likely to have PE.(218) The Institute of Medicine 
(IOM) has recently revised guidelines for healthy ranges of weight gain in 
pregnancy for overweight or obese women: 15-25 lb of weight gain for 
overweight (BMI 25-29.9 kg/m2), and 11-20 lb of weight gain for obese women 
(>30kg/m2).(219)  Continued research and changes in health policy should 
promote the implementation of the new guidelines and determine its impact on 
health care.   
1.6 Other risk factors of PE 
Other risk factors including life style factors, environmental factors, genetic 
factors, psychosocial factors, and pregnancy related factors were reviewed in the 
following sections.  
1.6.1 Genetic and epigenetic factors and risk of PE  
Studies have suggested that a family history of PE nearly tripled the risk of 
PE. (220) Some ethnic groups, like African-American and Hispanic women in 
the US, have a higher incidence of hypertensive disorders of pregnancy 
compared to white women.(221) Various candidate genes implicated in 
thrombophilia, haemodynamics, cytokines, oxidative stress, lipid metabolism, 
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angiogenesis, and invasion were identified. (222) Epigenetic features are also 
implicated in the pathogenesis of PE. It has been described that medically 
assisted procreation increased the risk of PE. (58) For non-imprinted genes, 
epigenetic alterations are also possible in PE. For instance, methylation 
alterations of the SER-PINB5 and SERPINA3 promoters have been 
demonstrated recently in PE.(222)  
1.6.2 Life style factors and risk of PE  
1.6.2.1 Smoking, alcohol use and PE 
Smoking is associated with a variety of adverse pregnancy outcomes, but 
paradoxically it has a protective role against hypertensive disorders of pregnancy. 
Previous studies suggest that women who smoke during pregnancy have a 
reduced risk of PE compared to non-smokers, even when confounders are 
carefully controlled.(99),(223-225) Ioka et al. conducted a retrospective cohort 
study and did not find evidence of a protective effect of cigarette smoking on the 
risk of PE.(226) Lain et al. found that smoking during pregnancy is associated 
with reduced cellular fibronectin and increased intracellular adhesion molecule-
1.(227) The authors further suggested that the negative association of smoking 
and PE may be mediated, in part, by the interaction of changes in endothelial 
activation that are the results of pregnancy and changes that are the result of 
smoking. Smoking may result in a decrease in basal endothelial activation and a 
stronger perturbation may be required among smokers to achieve the endothelial 
activation that is present in preeclamptic women. Results from previous studies 
on whether or not smoking before pregnancy may also reduce the risk of PE are 
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conflicting.(228-230) A secondary data analysis from a large trial of Calcium for 
Preeclampsia Prevention (CPEP) indicated that women who smoked at 
enrolment had a reduced risk of GH (RR 0.8, 95% CI 0.6-0.9). Women who quit 
smoking before their LMP did not demonstrate a reduced risk (RR 1.1, 95% CI 
0.9-1.3). The author adjusted for maternal age, race, BMI, type of health 
insurance, and clinical centre. Results were similar when GH and PE were 
considered separately.(230)  
The prevalence of smoking during pregnancy in developed countries ranges 
from 15% to 50%.(231, 232) It has been reported that smoking or alcohol use 
during pregnancy may increase maternal micronutrient requirements. Numerous 
studies indicated that serum concentrations of certain micronutrients (e.g. 
vitamin C, vitamin B12, ß-carotene, folate, iron, etc.) appear to be lower in 
smokers than in non smokers.(233, 234) Current evidence suggest that smoking 
or alcohol use could interact with micronutrient deficiencies to affect pregnancy 
outcome.(234) It is possible that smoking or alcohol use may decrease appetite 
and therefore may decrease the amount of nutrients consumed by pregnant 
women. Smoking or alcohol use may decrease the absorption of nutrients and 
affect their metabolism. It is also possible, however, that micronutrient 
deficiency or excess may increase the risk of adverse pregnancy outcomes in 
women who smoke or drink alcohol. Smoking or alcohol use may also be 
associated with drug use and other unhealthy lifestyle. 
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Therefore, studies evaluating the associations between maternal nutrient 
intake during pregnancy and PE and other adverse pregnancy outcomes should 
consider the joint effects of smoking or alcohol use and nutrient intakes.  
1.6.2.2 Physical activity and PE 
The results of epidemiological studies of the association between physical 
activity and risk of PE have been conflicting.(235-238) In a prospective cohort 
of 1,043 predominantly Puerto Rican prenatal care patients conducted from 
2000-2004 in Western Massachusetts, there was a statistically significant trend 
of decreasing risk of hypertensive disorders with increasing sports/exercise in 
early pregnancy (ptrend=0.04). High levels of early pregnancy active living 
activity (OR: 0.4, 95% CI: 0.1-1.1, ptrend=0.07) and household/caregiving 
activity (OR: 0.4, 95% CI: 0.1-1.3, ptrend=0.07) were associated with a 60% 
reduction in risk of hypertensive disorders relative to low levels. However, these 
associations were of marginal statistical significance.(235) In another hospital-
based and longitudinal study conducted in Congo, physical activity during 
pregnancy (RR=0.63 CI 95% 0.33 to 0.94) was found to be significantly 
associated with the reduced risk of PE.(236) Østerdal et al. conducted a 
prospective cohort of 85,139 pregnant Danish women to assess the associations 
between leisure time physical activity in first trimester and the risk of PE.(237) 
The authors reported that the two highest physical activity levels were associated 
with increased risk of severe PE compared with the nonexercising group, with 
adjusted ORs of 1.65 (95% CI: 1.11-2.43) and 1.78 (95% CI: 1.07-2.95) 
respectively. They found no statistically significant association between more 
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moderate levels of physical activity (1-270 minutes/week) and the risk of 
PE.(237) Tyldum et al. conducted a population based prospective cohort study of 
3,656 pregnant women and found no link between pre-pregnancy physical 
activity and PE. Only among the women physically active for 120 min/week or 
more, a tendency for reduced risk was found (adjusted OR: 0.6, 95% CI 0.3-
1.2).(238) 
1.6.3 Pregnancy related factors and risk of PE 
Research indicated that nulliparity triples the risk for PE. (239, 240) Case 
control studies suggested that women with PE are twice as likely to be 
nulliparous as women without PE.(241, 242)   
Duckitt and Harrington conducted a systematic review of controlled studies 
published between 1966 and 2002 to determine the risk of PE associated with 
factors that may be present at antenatal booking.(220) Five cohort studies show 
that women who have PE in a first pregnancy have seven times the risk of PE in 
a second pregnancy relative to those with uncomplicated first pregncies (RR 7.19, 
95%CI 5.85 - 8.83).(220) Six case control studies indicate that women with PE 
in their second pregnancy are also more than seven times more likely to have a 
history of PE in their first pregnancy than women who did not develop PE in 
their second pregnancy (OR 2.35, 95%CI 1.80-3.06).(220)  
Numerous epidemiological studies indicate that twin pregnancy nearly triples 
the risk for PE.(220) Neither the chorionicity nor zygosity of the pregnancies 
alters this increased risk.(243, 244) Moreover, compared with twin pregnancy, a 
triplet pregnancy nearly triples the risk of PE.(245)  
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In a Norwegian population based study, the time interval between 
pregnancies significantly increased the risk of PE. (246) The association was 
more significant compared to the association between change of partner and the 
risk of PE. The risk of PE was increased by 1.12 for each year increase in 
interval after adjusting for change of partner, maternal age, and year of delivery 
(OR 1.12, 95%CI 1.11-1.13). After an interval of at least 10 years following the 
1st pregnancy, the absolute risk of PE was about the same as that in nulliparous 
women. (246) Another Danish cohort study found that a long interval between 
pregnancies was significantly associated with the increased risk of PE in a 
second pregnancy when PE had not been present in the first pregnancy and 
paternity had not changed.(247) A cross sectional study reported that time 
intervals of more than 59 months had significantly increased risks of PE 
compared to 18-23 months between pregnancies (OR 1.83, 95%CI 1.72-
1.94).(248)  
1.6.4 Psychosocial factors and risk of PE 
Several epidemiological studies have demonstrated that maternal stress 
played a role in the development of PE. In a cohort study of 2,601 pregnant 
women by Qiu et al., a positive history of maternal mood or anxiety disorder was 
associated with a 2.12-fold increased risk of PE (95%CI 1.02-4.45). The risk of 
PE appeared to be more strongly related with maternal mood or anxiety disorders 
first diagnosed during the index pregnancy (adjusted RR = 3.64; 95% CI 1.13-
11.68). The corresponding RR for maternal mood and anxiety disorders 
diagnosed before pregnancy was 1.73 (95% CI 0.71-4.20).(249) In another 
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prospective population-based study, depression and anxiety were significantly 
associated with the risk of PE with the reported ORs of 2.5 (95%CI 1.1-5.4) and 
3.2 (95% CI 1.4-7.4) respectively. (250)    
1.6.5 Pre-existing medical conditions  
A population based case control study found that the frequency of chronic 
hypertension was higher in women who developed PE than women who did not. 
(251) Studies indicated that a diastolic blood pressure before 20 weeks of either 
>110 mmHg or >100 mmHg was most predictive of the development of 
superimposed PE. (252) 
Women with hypertensive disorders in pregnancy were more likely to have 
gestational diabetes and pre-existing diabetes compared with normotensive 
women (2.3% and 0.3%, respectively). (220) 
Davies et al. also reported the higher prevalence of renal disease in women 
who developed PE compared to those that did not (5.3% vs 1.8%).(251) 
Martinell et al. compared women with renal disease due to a history of urinary 
tract infection with a prospective control population matched for age, parity, 
smoking and date of delivery. A total of 6.7% of women with renal disease 
(scarred kidneys) developed PE compared with 2.6% of women in the control 
group. (253) 
A recently reported systematic review of 49 published observational studies 
found that the risk of PE was significantly increased in pregnant women in the 
presence of urinary tract infection (pooled OR 1.57, 95%CI 1.45-1.70) and 
periodontal disease (pooled OR 1.76, 95%CI 1.43-2.18). However, no 
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associations between PE and presence of antibodies to Chlamydia pneumonia, 
Helicobacter pylori, and cytomegalovirus, HIV infection, and malaria were 
observed in the pooled analysis.(254)  
1.6.6 Environmental chemicals and risk of PE  
There is a small but accumulating body of evidence that suggests that 
exposure to heavy metals such as lead may play a role in the etiology of GH and 
PE. A study of 705 women found that maternal blood lead concentrations were 
significantly related to hypertension in pregnancy.(255) In a case-control study, 
amniotic fluid from women with PE showed significant differences in levels of 
lead compared to women with normal pregnancies. (256) Cadmium has been 
hypothesized to play a role in the etiology of eclampsia,(257) and PE. (258, 259) 
One study has reported that hypertension in pregnant women smokers is related 
to significantly higher blood cadmium concentrations.(260) An adverse 
association between mercury exposure at background levels and systolic blood 
pressure has been observed among non-fish-consuming young and middle-aged 
women in the US, which suggests that mercury may also impact on hypertension 
risk in pregnant women.(261) 
1.7 Dietary measurements  
1.7.1 Field methods for assessing dietary measurements 
Dietary intake measurements only provide estimates of the amounts of 
energy and nutrients available for metabolism. Several methods have been 
developed to measure dietary intake in the field, which can be characterized into 
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two broad categories: prospective records (record intake as it occurs) and 
retrospective recalls (recall intake after it has occurred). (262)  
Dietary records used in the field can be generally categorized as two types: 
estimated records, and weighed records. Estimated records require the 
respondent (or representative) to record all food consumed during a specified 
period, generally between 1 and 7 days. They provide sufficient details of food 
consumed to allow the investigator to select an appropriate food from tables of 
food composition or for laboratory analysis. The amounts of food consumed are 
provided, either by means of the measures used in the household (jugs, cups, 
bowls, and spoons) or by a set of standard measures. The principal advantage of 
estimated records using household measures is that they involve less disruption 
to normal eating patterns than the weighed records. However, precision is lost 
with estimating rather than weighing the food consumed. Weighed records can 
be either a record of food consumed (weighed inventory) or a much detailed 
record of the weights of ingredients, final cooked weights of prepared foods, the 
weights of food eaten and any plate waste (precise weighing method). The 
former approach is generally kept by the respondents for only 1-4 days. Weighed 
records provide the most accurate description of the types and amounts of food 
consumed over a specified period. However, keeping weighed record is time 
consuming and it may only reflect actual intake during the record-keeping period 
rather than habitual intake. It may also cause the respondent to change his/her 
diet to facilitate record keeping.   
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Dietary recalls can include the 24-hour diet recall, diet history, and food 
frequency questionnaire (FFQ). A 24-hour recall is usually obtained during an 
interview where the respondent is asked to provide a recall of all food consumed, 
most often, over the previous 24 hours. Recalls can be conducted by face-to-face 
interview, telephone interview, and computer assisted interview, often using aids 
such as food photographs or models to assist with quantity. The 24-hour recall 
generally has a higher response rate than food records. It can provide detailed 
information on food intake and it is suitable for use in face-to-face, telephone, 
and computer assisted interviews. The principal disadvantage of this method is 
that it cannot provide information on habitual intake, unless it is repeated on 
multiple occasions. It may not be suitable for certain groups who have 
difficulties in describing foods eaten from memory.   
The diet history, as first proposed by Burke in the 1940s, seeks to obtain a 
semi-quantitative picture of typical or habitual consumption as reflected by 
intake in the immediate past. It is often considered more appropriate to 
categorize diet history data (e.g. as high, medium, low) than provide absolute 
intake. The main advantage of this method is that it can provide an estimate of 
habitual intake for individuals if successfully carried out. The principal 
disadvantages are that the data is dependent on the time and skills of both 
respondents and interviewers and the nature of data obtained is semi-quantitative.  
Another often-used recall method is the FFQ, which is basically a list of 
foods considered relevant for the target population and the research question 
with a selection of options for reporting how often each food is consumed. A 
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semi-quantitative FFQ includes an additional variable for indicating usual 
serving size. Respondents need to indicate the most appropriate frequency option 
for each of the foods on the list by marking the appropriate column in the 
questionnaire. FFQs are designed to collect long-term dietary intake data from 
large numbers of respondents and provide a practical, cost-effective way of 
collecting information from a large number of respondents. The main 
disadvantages include the limitations to the food list and lack of details obtained 
for composite foods and cooking methods, the semi-quantitative nature of the 
data, and the large random errors.  
1.7.2 Selection of methods for dietary measurement  
The choice of the dietary measurement to be used is dependent on the 
purpose of the study. To describe the diet of a group for comparison with another 
group or groups, either short-term methods such as the 24-hour diet recall or 
record, or long-term methods such as food records obtained on multiple 
occasions, a diet history or a FFQ can be used. In studies or situations where 
information on the usual pattern of food intake rather than precise quantitative 
information is required, the diet history can be appropriate for this purpose. In 
order to assess relationships between nutrient intake and health status (e.g. diet in 
relation to the risk of cardiovascular disease) individuals’ long-term dietary 
intake data needs to be estimated.   
In general, the food intake of individuals is not a static quantity. It varies in 
both types and amounts from day to day, from week to week, and from year to 
year. In order to assess the adequacy of energy or nutrient intake in relation to 
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requirements, it is important that short-term measurements are always adjusted 
for within-person variation in intake. A single 24-hour dietary recall or dietary 
record is considered as ‘non representative’ of individual usual intake. The 
numbers of days needed to measure dietary intake reliably vary among subjects 
and for different nutrients, and depend on the level of precision. For most 
nutrients, an average of three or more 24-hour recalls or dietary records on non-
consecutive days is considered sufficient to produce a reasonably accurate 
estimate of intake for an individual. It should also include weekdays and 
weekend days to reduce bias.(263)  
1.7.3 FFQs in epidemiological studies  
The dietary measurement instrument used most often in large-scale 
epidemiological studies, particularly prospective cohort studies, is the FFQ. Two 
major FFQs, the National Cancer Institute/Block’s Questionnaire and the 
Harvard University/Willett’s questionnaire as well as their modified versions 
have been used in numerous studies. (264-270) The measurements of subjects’ 
dietary intake and the related methodological considerations have long been at 
the centre of discussion in the field of nutritional epidemiology. The major 
obstacle in epidemiological studies using questionnaire assessment is lack of 
accuracy of estimations of subjects’ habitual dietary intakes. Random errors and 
uncorrelated measurement errors can cause attenuations of risk estimates and 
reduce the statistical power.(271) This has prompted researchers to incorporate 
validation sub-studies that include more intensive, presumably more accurate 
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‘reference’ methods, typically multiple-day food records or multiple 24-hour 
dietary recalls.(272)  
1.7.4 Validation of FFQs 
‘Validation’ refers to the evaluation of whether a measuring instrument 
truely measures what it is actually intended to. A major practical problem in 
nutritional studies is that no ‘gold standard’ methods exist that can provide 
perfectly accurate measurements of the habitual intake levels.  Thus, the relative 
validity of questionnaire is generally measured by evaluating the ‘test’ 
questionnaire assessment methods against other more ‘accurate’ dietary methods. 
The issues related to design and analysis of dietary validity studies have been 
extensively discussed in the literature.(272-274) It has been concluded that the 
estimation of the validity coefficient of dietary questionnaire measurements 
requires a comparison with at least two additional measurements per person.  
In practice, the commonest approach for a dietary validity study is to obtain a 
number of replicate measurements of the actual daily food intakes at regular 
intervals during one-year period, using 24-hour dietary recalls or diet records. 
Validity studies generally include about 100-200 subjects. The relative validity 
of FFQs can be assessed using a variety of statistical approaches.(272) Most 
validation studies have commonly assessed the agreement between questionnaire 
measurements and the individuals’ averages of k daily intake records, using 
either Pearson’s correlation or Spearman’s ranked correlation analysis (Pearson’s 
correlation for normally distributed data, Spearman’s for non-normally 
distributed data). (272) This approach requires random errors to be independent 
 41
not only between questionnaire and daily intake records, but also between 
replicate measurements using same method on the same individuals. Violation of 
these assumptions will lead to either overestimation or underestimation of the 
validity coefficients. One can also calculate cross-classification or joint 
classification of nutrient intake estimated from the FFQ and the average of the 
non-consecutive food records or recalls, by dividing each nutrient intake into 
quartiles or quintiles of distribution. This method is very useful if the data are 
divided into quartiles or quintiles and compared to the likelihood of an 
association with a disease outcome, as is commonly done in large nutritional 
epidemiological studies. (272) Another approach is called as ‘Bland-Atman 
analysis’, which assesses the agreement between two dietary measurement 
methods across the range of intakes, referred as Bland-Altman limits of 
agreement (LOA: mean± two standard deviations of the difference).(274) Other 
statistical methods such as structural equation models have been extensively 
discussed in the literature as well.(271, 273) 
 It is important to note that the results of validation studies are context 
specific. The results of one validation study are not necessarily transferable to 
another population, or even other nutrients in the same population. The 
performance of a FFQ depends on both the characteristics of instruments and the 
heterogeneity of intake in the population. Moreover, certain sociodemographic, 
lifestyle, and other characteristics of the population may influence the reliability 
and accuracy of diet measurements.  
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As described by Beaton, there is not, and probably never will be, a method 
that can estimate dietary intake without error.(275) This does not mean that 
dietary data with measurement errors should not be collected. The point is to 
understand, estimate, and make the use of error structure in the analysis and to 
consider these issues in the interpretation of nutritional data.  
1.8 Summary  
Many initiating agents and multiple pathogenic mechanisms have been 
implicated in the development of PE. Increasing evidence suggests the 
hypothesis that oxidative stress plays an essential role in the development of PE. 
In response to the Chappell et al. trial,(165) we designed the International Trial 
of Antioxidants In the Prevention of Preeclampsia (INTAPP Trial) to evaluate 
the effects of prenatal antioxidant supplementation during pregnancy on the risk 
of GH and its adverse conditions.  
A vast array of risk factors have been associated with the risk of PE, 
including extremes of maternal age, primiparity, black race, maternal or 
pregnancy related risk factors, previous history or family history of hypertensive 
disorders, multiple pregnancies, obesity, and chronic medical conditions such as 
long-term hypertension, diabetes, renal diseases.(17, 220) We believe that the 
interactions between economic, nutritional, psychosocial, environmental and 
genetic factors may lead to the common biological alterations: endothelial 
dysfunction and inflammatory responses, and finally to the clinical manifestation 
of PE. Nutritional factors, as modifiable risk factors, may play a crucial role in 
the development of PE. However, nutritional intervention studies have not yet 
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provided unequivocal evidence in favour of an association between maternal 
nutrient intakes during pregnancy, in particular micronutrients (e.g. folate, 
vitamins) and the risk of PE. (Appendix: Table A)  
The measurements of subjects’ dietary intake and the related methodological 
considerations remain at the centre of discussion in the nutritional field. The 
major obstacle in epidemiological studies using questionnaire assessment is lack 
of accuracy of estimations of subjects’ habitual dietary intakes. Random errors 
and uncorrelated measurement errors can cause attenuations of risk estimates and 
reduce the statistical power.(271) Major challenges connected with assessment 
of diet in pregnancy are the large intra-individual variations due to pregnancy 
complications that may influence eating habits, e.g. nausea, vomiting, 
constipation and bed rest. Furthermore, the time periods of interest may vary, i.e. 
preconceptional, by trimester or by critical windows for fetal organ/tissue 
development. It is critically important to decide the optimal time point for 
administering the FFQ and what time period should be addressed by the diet 
questions (pre-pregnancy versus in pregnancy).   
Validation of a FFQ should always be performed in the same target group in 
which it will be used. Compared to the large number of validation studies in non-
pregnant populations, few validation studies on the use of FFQs in pregnant 
populations have been published. Until recently, there has been little knowledge 
about potential dietary changes over the course of a pregnancy or whether a 
woman changes her diet at all, and whether changes affect the pregnancy 
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outcomes. We therefore designed a prospective cohort study to assess diet 
among pregnant women.  
 CHAPTER 2   OBJECTIVES  AND HYPOTHESES  
2.1 Objectives 
2.1.1 General objective:  
The general objective of this research project is to assess the relationship 
between maternal dietary intake or supplementation during pregnancy and the 
risk of GH and PE.  
2.2.2 Specific objectives:  
The specific objectives are: 1) to investigate the effects of prenatal 
antioxidant supplementation (vitamins C and E) on the risk of GH and PE; 2) to 
prospectively examine whether maternal nutrient intake during pregnancy is 
associated with the risk of PE and GH; and 3) to longitudinally assess the 
relationship between plasma concentration of antioxidant vitamins and the risk 
of PE.  
2.2 Hypotheses  
Maternal nutrient intake or supplementation during pregnancy is associated 
with the risk of GH and PE. (Appendix: Figure 1-Hypothetical framework of 
pathogenesis of preeclampsia) 
2.2.1 Hypothesis I:  
Oral prenatal supplementation of antioxidants (vitamins C and E) 
significantly reduces the risk of GH and its adverse conditions in 1) nulliparous 
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women without additional identified major risk factors and 2) nulliparous or 
multiparous women with risk factors.  
2.2.2 Hypothesis II:  
Maternal nutrient intakes during pregnancy, in particular in early pregnancy, 
are associated with the risk of GH and PE.  
2.2.3 Hypothesis III: 
Maternal plasma concentrations of α- and γ-tocopherols (measured at 12-18, 
24-26, and 32-34 weeks of gestational age) are associated with the risk of PE.  
 CHAPTER 3   METHODOLOGY   
3.1 Study design 
3.1.1 Objective I 
To investigate the effects of prenatal antioxidant supplementation on the risk 
of GH and PE, a double blinded, multicenter trial (An International Trial of 
Antioxidants in the Prevention of Preeclampsia –INTAPP trial) was conducted in 
Canada and Mexico. Randomization was stratified by center and by risk status 
according to pre-specified clinical risk criteria. Women were at high risk if they 
were nulliparous or multiparous with pre-pregnancy chronic hypertension (or 
diastolic blood pressure > 90 mmHg before 20 gestational weeks or use of 
antihypertensive medication for hypertension), pre-pregnancy diabetes (insulin-
dependent or hypoglycemic agents), multiple pregnancy, or a history of PE in the 
previous pregnancy. Women were stratified into the low risk stratum if they 
were nulliparous without any identified clinical risk factors. Women were 
assigned either to the antioxidant supplementation group (1g of vitamin C and 
400 IU of vitamin E) or to the placebo group.  (Details provided in Chapter 4-
Article I)  
Women were eligible for the INTAPP trial if they were between 12 and 18 
completed weeks of pregnancy on the basis of last menstrual period and 
confirmed by early ultrasound examination. The exclusion criteria were: 1) 
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women who regularly consumed supplements greater than 200 mg/day for 
vitamin C and/or 50 IU/day for vitamin E; 2) women who took warfarin; 3) 
women who had known fetal abnormalities (e.g. hydatidiform mole), or known 
fetal chromosomal or major malformations in the current pregnancy; 4) women 
who had a history of medical complications including endocrine disorders (e.g., 
thyroid disease), renal disease with altered renal function, epilepsy, any collagen 
vascular disease (e.g., systemic lupus erythromatosus and scleroderma), active 
and chronic liver disease (e.g., hepatitis), heart disease, serious pulmonary 
disease, cancer, or hematologic disorder (e.g., anaemia or thrombophilia); 5) 
women with recurrent spontaneous abortion (women with a history of bleeding 
in the first trimester were included if the site documented a viable fetus at the 
time of recruitment); and 6) women who used illicit drugs during the current 
pregnancy.  
We planned to recruit 5,000 patients per group in Stratum I (low risk) for a 
total of 10, 000 patients and 1,250 women per group in Stratum II (high risk) for 
a total of 2, 500 patients in order to detect 30% reduction of PE, with a power of 
90% and alpha error of 5%. After reviewing the evidence from the trials 
conducted by the UK research group (Vitamin C and vitamin E in pregnant 
women at risk for pre-eclampsia-VIP trial)(276) and the Australian Collaborative 
Trial of Supplements (ACTS) Study group(277) as well as our internal data on 
serious adverse events, and in accordance with the recommendations of the Data 
Safety & Monitoring Committee, the Trial Steering Committee decided to stop 
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recruitment  in March 2006. A total of 2640 consenting eligible women had been 
recruited at that point.  
3.1.2 Objective II 
A nested ancillary prospective cohort study was conducted to evaluate 
whether the maternal nutrient intake in early and late pregnancy was associated 
with the risk of PE and GH. A validated FFQ was administered twice during 
pregnancy (12-18 weeks, 32-34 weeks) to assess dietary nutrient intakes during 
pregnancy. All patients recruited in the INTAPP trial were included for this 
prospective cohort study.  
3.1.3 Objective III 
A case control study ancillary to the INTAPP trial was conducted to assess 
the relationship between plasma concentration of antioxidant vitamins and the 
risk of PE. All cases identified in the INTAPP trial with available baseline 
plasma samples were included in the study. Controls were normotensive women 
from the INTAPP trial, randomly selected at a ratio of 2:1 by matching for 
country (Canada, Mexico), maternal age (within 3 years), parity (primiparous: 
yes/no), and multiple pregnancy (yes/no). Blood specimens were collected at 
each of the four INTAPP study visits (12-18 weeks, 24-26 weeks, 32-34 weeks, 
and delivery/postpartum) and stored in the trial’s central laboratory (Quebec 
Lipid Research Centre).   
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3.2 Outcomes  
The main study outcomes are GH and PE. The patient phenotype with 
regards to hypertensive disorders of pregnancy was carefully documented in the 
INTAPP trial Case Report Forms. GH was defined as at least two readings of 
diastolic blood pressure ≥90 mmHg taken 4 hours apart, but within 72 hours, 
occurring after 20 weeks of gestation.(1, 278) Severe GH was defined as two or 
more readings of diastolic blood pressure systolic≥110 mmHg or systolic blood 
pressure≥160 mmHg at least four hours apart. (1, 278)  Proteinuria was defined 
as the urinary excretion of ≥0.3g/24 hours, or ≥2+ on diagnostic strips. PE was 
defined as GH or severe GH with proteinuria.(1, 278) For women with pre-
existing hypertension, PE was classified as the new or worsening proteinuria as 
defined above. For women with pre-existing proteinuria (e.g. diabetes with renal 
involvement), the diagnosis of PE was made on clinical or biochemical grounds 
by identifying at least one additional adverse condition (e.g. abnormal liver 
enzymes, low platelets and eclampsia).(1, 278)   
3.3 Independent variables   
3.3.1 Treatment allocation 
Women in the INTAPP trial were assigned either to the antioxidant 
supplementation group (1g of vitamin C and 400 IU of vitamin E) or to the 
placebo group and provided with the vitamins C and E or placebo, respectively. 
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3.3.2 Nutritional variables   
Information on dietary intakes of nutrients (lipids, vitamins C, E, A, calcium, 
zinc, iron, selenium etc.) was obtained from the FFQ administered at trial entry 
(12-18 weeks of gestation) and repeated at 32-34 weeks of gestation. Information 
on perinatal vitamin or mineral supplements was obtained from the INTAPP 
case report forms (CRFs).  
3.3.3 Food Frequency Questionnaire (FFQ) 
The Canadian sites of the INTAPP trial used a self-administered semi-
quantitative 78-item FFQ developed by Shatenstein et al. and validated in several 
adult populations in both French and English.(279) It was modified for INTAPP 
to reflect the previous three months’ usual food consumption rather than the 
standard 12 month period and two seasonal foods in the food list were fused in 
consideration of the shortened reference timeframe. It was further validated 
among 107 pregnant women from a subset of the Canadian INTAPP cohort. (280) 
In the validation study, the research nurse aided respondents in the 
completion of their FFQ at their first INTAPP visit and provided validation study 
materials to willing recruits with instructions for completion and dates for 
completing the food records (FRs) at home. The research protocol stipulated that 
the three non-consecutive FR (two weekdays and one weekend day) were to be 
completed within the month following administration of the FFQ, and returned 
to the INTAPP study centre along with the FFQ at the participant’s second 
INTAPP visit. Participants were asked to sign and date their FFQ to confirm the 
recorded information prior to nutrient analysis. The Trial Coordination Centre 
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(TCC) sent copies of the completed FFQs and FRs to the nutritionist for data 
entry and nutrient analysis. Upon verification, the nutritionist forwarded queries 
as needed to the research nurses if participants’ instruments (FFQs and FR) were 
incomplete or showed inconsistencies. The research nurses then contacted 
respondents to clarify information, as required, and this was used to complete the 
FFQ and FR data.  
Relative validity was assessed by evaluating agreement between crude 
nutrient intakes (energy and 24 nutrients) estimated from the FFQ and the 
average of three non-consecutive FRs (3D-FR). The results indicated that 
Spearman correlation coefficients between FFQ and FR nutrients were positive 
(rS ranged from 0.17 for iron to 0.49 for folate) and generally statistically 
significant (0.05<p<0.01). (Appendix: Table B-D) Moreover, cross-classification 
of energy and 24 nutrients from the FFQ and means of the 3D-FRs placed 35% 
of them into identical quartiles, 75% into identical and contiguous quartiles, and 
only 6% were frankly misclassified. (Appendix: Table D) These results suggest 
that the FFQ is a relatively valid instrument for determining usual diet in 
pregnant women. However, variability in food intake during the course of 
pregnancy complicates assessment of its accuracy, and differences in gestational 
stage at the time of completion of the FFQ and FRs must be considered when 
assessing results to avoid misinterpretation of the accuracy of nutrient intake 
estimates. (280) 
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3.3.4 FFQ validation in Mexico 
In the Mexican sites, the Canadian FFQ was modified to reflect local foods 
and dietary habits and information from the second Mexican National Nutrition 
Survey published data.(281). The FFQ was developed and tested in Spanish and 
it was validated against three non-consecutive 24-hour food recalls. (282) 
Participants of the FFQ validation study in Mexico were selected from women in 
any of the three trimesters of pregnancy who attended the Mexican Social 
Security Institute for a prenatal visit. Participants were interviewed by a trained 
nutritionist regarding the information collected in the FFQ and 3 non-
consecutive 24 hour food recalls. Among 164 participants, a total of 85 pregnant 
women who completed the whole set of dietary interviews (1 FFQ and 3 non-
consective recalls) were included in the validation analysis. Relative validity of 
the FFQ in relation to the three 24-hour recalls was assessed by correlation 
analysis and regression models. (Appendix: Table E-G) On average, 
approximately 50% of FFQ participants were classified into the identical tertile 
of the 3 non-consecutive food recalls. (Appendix: Table G) The results of the 
validation study suggested that the Mexican FFQ could adequately measure 
habitual nutritional intakes in Mexican pregnant women and capture enough 
variability in the population studied.(282)  
3.3.5. Plasma concentration of Vitamin E 
Plasma concentrations of vitamin E (α-and γ-tocopherols) were assessed 
using High-Performance Liquid Chromatography (HPLC) with coulometric 
electrochemical detection. 
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3.3.6 Covariates   
Information on a wide range of maternal and pregnancy characteristics was 
collected and recorded in the INTAPP Case Report Forms (CRFs). Variables 
collected included maternal age, education, marital status, income, pre-
pregnancy BMI, ethnicity, previous history of hypertensive disorder during 
pregnancy, family history of hypertensive disorder during pregnancy (mother or 
sister), current medical problem (chronic hypertension, diabetes), and lifestyle 
variables such as smoking and drinking.  
3.4 Data management and quality assessment 
Data were collected on standardized forms (CRFs) on which nearly all 
responses were pre-coded. All data were entered through an Electronic Data 
Management Platform and reviewed by the Trial Coordinating Center (TCC). 
Any discrepancies or questions concerning the data were sent to the 
investigator’s site for corrections or clarification.  
3.4.1 Nutrient intake data  
Standard procedures for completing the self-administered FFQ and 
information on potential problems and strategies to resolve them were provided 
to research nurses. In the Canadian arm, an experienced research nutritionist was 
responsible for training research nurses working at each site. Participants were 
aided in the completion of the FFQ by the INTAPP research nurse at each site. 
The FFQ data was entered using a customized data entry interface using 
Microsoft Access software. Energy and nutrient values were then calculated 
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from the instrument food list, frequency options and portion sizes. Preliminary 
statistical analyses were conducted by the nutrition teams to detect outliers and 
assess the plausibility of the FFQ data. In Mexico, a similar approach was 
developed with respect to data entry, collection and quality assessment.  
Nutrient intakes were also adjusted for energy.(283) Nutrient intake values 
were replaced with their respective residuals from a regression model with each 
nutrient intake as the dependent variable and the total energy intake as the 
independent variable. A constant, the predicted nutrient intake at the mean total 
energy intake, was added to the residual for each nutrient.  
3.5 Statistical analysis  
Exploratory analyses were conducted to assess the distribution of all 
continuous study variables. Means and standard deviations (for continuous 
variables) and frequencies and proportions (for discrete variables) were used to 
describe study variables. Analyses of variance (t test) and nonparametric rank 
tests (i.e. Wilcoxon Rank-Sum (Mann-Whitney) Test, if the distribution was 
skewed), were used to assess differences in continuous variables. Chi-square or 
Fisher’s exact test, if appropriate, were used to compare the differences in rates 
between groups.  
Data analyses were conducted in accordance with the research questions. 
Regression analyses were performed and the Odds Ratios and their 95% 
confidence interval (95% CI) derived from regression models were used to 
quantify the associations between exposure variables and study outcomes. 
Variables found to be significantly associated with study outcomes at the P<0.15 
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level in the univariate analysis were considered as candidates for inclusion in the 
multivariate regression models. Interaction terms were examined based on the 
likelihood ratio test (p value<0.05) using simple logistic regression.  All analyses 
were performed using SAS version 9.2 and significance was set at two tailed 
p<0.05.  
3.5.1 Objective I 
The analysis was carried out on an ‘intention-to-treat’ basis. The baseline 
prognostic variables were compared between intervention and placebo groups.  
If there was no difference in these baseline variables, RRs and their 95% CIs 
were calculated to express the effects of the intervention. Otherwise, the Mantel-
Haenszel RRs were calculated using stratified analysis or odds ratios (ORs) were 
obtained by multivariable logistic regression adjusting for potential confounding 
variables. For the primary outcome, the effect of vitamins C and E were also 
estimated separately for the two risk strata: 1) nulliparous women without 
additional risk factors, 2) women with additional risk factors. For secondary 
outcomes, binary variables (e.g. PE, preterm birth) were analyzed using 
Cochran-Mantel-Haenszel analysis. Continuous outcome measures (e.g., birth 
weight, gestational age) were analyzed by using T-test, ANOVA or multiple 
linear regression (if necessary) for adjustment of other covariates. Stratified 
analysis and multivariable logistic regression were also performed to assess 
whether the effect estimates differed according to country, ethnic group and 
socio-economic status, smoking, maternal age (<20, >35), commercial and 
dietary vitamin C and E consumption (estimated by FFQ) at the time of 
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randomization and at 26 weeks of gestation, or patient compliance that was 
calculated as the proportion of tablets not returned in the bottles over the total 
number of tablets given to each woman and defined as compliant to treatment if 
>80% of tablets were used .  
3.5.2 Objective II 
Women were classified into 3 groups as follows: (1) normotensive pregnancy, 
(2) GH, and (3) PE. The data from the two trial arms (treatment and placebo) 
were pooled as there was no difference in the rates of hypertensive disorders of 
pregnancy.(284)   
Models for analyzing repeated dietary measurements  
Our primary exposures of interest were nutrient intakes that were categorized 
into quartiles. Models for each of the nutrient variables contained an additional 
term to adjust for the confounding effect of total energy intake. (283) Energy 
requirements depend on body size, physical activity, and metabolic efficiency of 
each individual, which may confound absolute total intake in relation to disease 
risk. Adjustments for energy intake may reduce such confounding effects. (283) 
Nutritional variables were also examined as continuous variables. A sequence of 
nested regression models (e.g. linear, quadratic, and quadratic –spline models) 
was also used to explore dose-response and trend patterns between nutritional 
variables and the risk of disease outcomes (GH and PE).(285)  
The statistical model used for the analysis of dietary intakes was logistic 
regression. The critical time window for the development of PE may be pre- or 
peri-conception period or early pregnancy. Therefore, nutrient intakes before or 
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in early pregnancy may be more important for the development of PE as opposed 
to nutrient intakes in late pregnancy, which are important for fetal growth. 
Therefore, the following approaches were used for handling repeated dietary 
measurement: 1) baseline diet (nutrient intakes estimated from FFQ collected at 
visit 1) only, in which PE or GH risks were related to baseline diet only; 2) diet 
in late pregnancy only (nutrient intakes estimated from FFQ collected at 32-34 
weeks of gestation), in which PE or GH risks were related to nutrient intakes in 
late pregnancy only; and 3) diet intakes both in early and late pregnancy models, 
in which PE or GH risks were related to both baseline nutrient intakes and 
changes of nutrient intake from early to late pregnancy (standardized as Z-scores) 
(main exposure variables).      
Non-dietary covariates  
Non-dietary covariates were grouped into blocks with same nature. Each 
block contained the variables that were found to be statistically significant in the 
previous univariate analyses (p<0.15). Five blocks were successively entered 
into the multiple logistic regression models. Each block of variables were 
examined the collinearity between variables before proceeding mutilvariate 
analysis. Potential interactions between variables, including smoking status, 
alcohol use, and obesity (pre-pregnancy BMI), and nutritional variables were 
explored using stratified analyses. The interaction terms were included in the 
final multivariate models if the interactions were observed in the previous 
analyses. Terms representing random assignment (risk stratum and treatment 
group) were treated as force-entry in each step. The fit of multiple regression 
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models were ascertained by examination of residuals. (Appendix: Figure 2. 
Multivariate analysis framework for nutrient intakes during pregnancy in 
association with GH and PE)  
3.5.3 Objective III 
Maternal characteristics in cases and controls were compared using chi-
square test, Fisher exact test or student t test where appropriate. To evaluate the 
differences in continuous variables (i.e. plasma tocopherols) between cases and 
controls, Student's t-test was used if the distribution was normal, and Wilcoxon 
test was applied if the distribution was skewed. Chi-square or Fisher’s exact tests 
were used to compare the differences in categorical variables. Plasma 
concentrations of tocopherols were examined as both continuous variables- 
standardized Z-scores - and as categorical variables by quartiles. Odds ratios and 
95% confidence intervals were estimated from logistic regression to quantify the 
associations between plasma concentrations of tocopherols and the risk of PE.  
The Mantel extension test was used to assess linear trends in the levels of 
plasma tocopherols and the risk of PE. Multivariate conditional logistic 
regression was used to assess the independent effects of plasma concentrations 
of tocopherols on the risk of PE. A covariate was retained in the model if it 
changed the estimates by >10%. Interactions were assessed by evaluating 
stratum-specific ORs, and including multiplicative interaction terms in the 
multivariable models, and assessing their statistical significance using likelihood 
ratio statistics.  
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We estimated the associations between baseline plasma concentrations of 
tocopherols and the risk of PE. Intervention status may significantly change the 
post-baseline measurements of vitamin E concentrations and therefore may have 
influenced the risk of PE. For this reason, analyses were conducted in the total 
study population as well as in the treatment and placebo groups separately. 
Analyses were repeated for plasma concentrations of tocopherols at visit 2: 24-
26 weeks, visit 3: 32-34 weeks of gestation, as well as the mean of three 
measurements at three gestational age windows. We also evaluated the patterns 
of changes in the plasma concentrations across gestational age and their effects 
on the risk of PE. (Appendix: Figure 3. Analytical framework for the case 
control study of plasma tocopherol concentrations in relation to PE risk) 
3.6. ETHICAL CONSIDERATIONS 
The Sainte Justine Hospital Research Ethics Committee (Montreal, Canada; 
number 1863, date: 01/12/2003) and the Instituto Mexicano del Seguro Social 
(IMMS) Ethics Board provided ethics approval for the INTAPP trial. Ethics 
approvals from each participating center were also obtained. All participants 
gave their written consent. These ethics approvals also covered the ancillary 
cohort and nested case control studies.  
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Condensation  
Vitamin C and E supplementation during pregnancy failed to reduce the risk 
of preeclampsia (PE) or gestational hypertension (GH), but did increase the risk 
of the composite outcome ‘fetal loss or perinatal  death’  as well as the risks of 
prelabour rupture of membranes (PROM) and preterm prelabour rupture of 
membranes (PPROM).  
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ABSTRACT 
Objective: We sought to investigate whether prenatal vitamins C and E 
supplementation reduces the incidence of gestational hypertension (GH) and its 
adverse conditions among high-and low-risk women. Study design: In a 
multicenter randomized controlled trial, women were stratified by the risk status 
and assigned to daily treatment (1g vitamin C and 400 IU vitamin E) or placebo. 
The primary outcome was GH and its adverse conditions. Results: Of the 2647 
women randomized, 2363 were included in the analysis. There was no difference 
in the risk of GH and its adverse conditions between groups (Relative Risk: 0.99, 
95% Confidence Interval 0.78-1.26). However, vitamins C and E increased the 
risk of fetal loss or perinatal death (nonprespecified) as well as preterm prelabor 
rupture of membranes (PPROM). Conclusion: Vitamin C and E supplementation 
did not reduce the risk of preeclampsia or GH, but increased the risk of fetal loss 
or perinatal death and preterm prelabor rupture of membranes. 
  
Key words: preeclampsia, randomized controlled trial, vitamins C and E 
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Introduction 
Preeclampsia (PE), defined as gestational hypertension (GH) and proteinuria, 
is a syndrome unique to, and that complicates 2%- 8% of human pregnancies.[1-3] 
It accounts for about 10%-15% of direct maternal deaths in low-, middle- and 
high- income countries and is associated with low birth weight (<2500g) infants 
and thereby perinatal deaths through both preterm birth and intrauterine growth 
restriction (IUGR).[4-10] 
Several lines of evidence support the hypothesis that oxidative stress, an 
imbalance between pro-oxidant and antioxidant forces, plays an essential role in 
the development of hypertensive disorders of pregnancy.[11-15] Markers of 
oxidative stress, such as isoprostanes and malondialdehyde, are increased in 
plasma,[16, 17]small arteries[18] and decidua basalis[19] of women with PE. In 
response to these findings, several clinical studies have been conducted that 
attempt to improve the antioxidant capability of pregnant women and thereby 
reduce the risk of PE.[20-25] A pilot randomized trial by Chappell et al.[20] reported 
a 54% reduction in PE in the group that was supplemented with vitamins C and 
E [relative risk (RR) 0.39; 95% confidence interval (CI) 0.17-0.90)] compared 
with the placebo group. Most women included in the trial were at an increased 
risk for PE as defined by abnormal uterine artery Doppler waveform or by past 
history of the disease.[20]  
In response to the Chappell et al. trial,[20] we designed the International Trial 
of Antioxidants In the Prevention of Preeclampsia (INTAPP Trial) to assess 
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whether or not vitamins C and E supplementation during pregnancy reduces the 
risk of developing gestational hypertension and its adverse conditions in 1) 
nulliparous women without additional identified major risk factors and 2) 
nulliparous and multiparous women having those risk factors.  
Methods 
Between 2004 January and 2006 March, we conducted a double blinded, 
multicenter trial in Canada (17 centers) and Mexico (10 centers). Women were 
eligible for the trial if they were between 12 and 18 completed weeks of 
pregnancy on the basis of last menstrual period and confirmed by early 
ultrasound examination. The exclusion criteria were: 1) women who regularly 
consumed supplements greater than 200 mg/day for vitamin C and/or 50 IU/day 
for vitamin E; 2) women who took warfarin; 3) women who had known fetal 
abnormalities (e.g. hydatidiform mole), or known fetal chromosomal or major 
malformations in the current pregnancy; 4) women who had a history of medical 
complications including endocrine disease (e.g., thyroid disease), renal disease 
with altered renal function, epilepsy, any collagen vascular disease (e.g., 
systemic lupus erythromatosus and scleroderma), active and chronic liver disease 
(e.g., hepatitis), heart disease, serious pulmonary disease, cancer, or hematologic 
disorder (e.g., anaemia or thrombophilia); 5) women with repeated spontaneous 
abortion (women with a previous bleeding in the first trimester were included if 
the site documented a viable fetus at the time of recruitment); and 6) women who 
used illicit drug during the current pregnancy.  
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Randomization was performed through an Electronic Data Management 
Platform, which enabled randomization and data entry over the internet through 
a secured and restricted access internet web site and stores the data in a 
centralized database. Randomization was stratified by center and by risk status 
according to pre-specified clinical risk criteria. Women were at high risk if they 
were nulliparous or multiparous with prepregnancy chronic hypertension (or 
diastolic blood pressure > 90 mmHg before 20 gestational weeks or use of 
antihypertensive medication for hypertension), prepregnancy diabetes (insulin-
dependent or hypoglycemic agents), multiple pregnancy, or a history of PE in the 
previous pregnancy. Women were stratified into the low risk stratum if they 
were nulliparous without any identified clinical risk factors. They were randomly 
allocated at a ratio of 1:1 to antioxidant supplementation (vitamins C and E) 
group or to placebo group through an Electronic Data Management Platform. 
None of the trial staff or any other person involved in the trial knew the 
treatment allocation for any women until after completion of the trial analysis. 
The Sainte Justine Hospital Ethics Research Committee (Montreal, Canada; 
number 1863, date: 01/12/2003) and the Instituto Mexicano del Seguro Sosial 
(IMMS) Ethics board provided ethics approval, and we acquired ethics approval 
from each participating center. All participants gave written consent form.  
Women were provided either with the vitamins C and E or placebo (Carlson 
Laboratories Inc. USA). Women assigned to the vitamin group were advised to 
take two soft gel capsules, each containing 500 mg vitamin C (ascorbic acid) and 
200 IU of vitamin E (100 IU d-alpha-tocopherol, 100 IU d-alpha-tocopheryl 
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acetate). The total daily dose of vitamin C was 1000 mg, and that of vitamin E 
was 400 IU. Women in the placebo group were advised to take capsules that 
were identical appearance to the active treatment capsules. Women were asked 
to swallow the capsules whole without crushing or chewing them and were 
advised not to take other antioxidant supplements.  
Women and their infants received care according to standard practice in each 
center, with surveillance for hypertension using standardized measurements of 
blood pressure. Systolic and diastolic blood pressure were measured by the 
clinical staff at each visit using a sphygmomanometer and were assessed in a 
sitting position, with the cuffed arm resting on a desk at the level of the heart. 
Korotkoff phase V was used to measure diastolic blood pressure and Korotkoff 
phase IV was utilized when a phase V was absent.  
The composite primary outcome was defined as gestational hypertension and 
its adverse conditions. Our choice of the primary outcome for the trial relied on 
definitions proposed in the the Canadian Consensus Statement of 1997.[1]   The 
goal was to assess the impact of antioxidants on clinically significant 
hypertensive disorders of pregnancy, whether or not proteinuria was present. GH 
was defined as at least two readings of diastolic blood pressure ≥90 mmHg taken 
4 hours apart but within 72 hours occurring after 20 weeks of gestation.[1, 26] 
Severe GH was defined as two or more readings of diastolic blood pressure 
systolic≥110 mmHg or systolic blood pressure≥160 mmHg at least four hours 
apart. [1, 26]  Proteinuria was defined as the urinary excretion of ≥0.3g/24 hours, 
or ≥2+ on diagnostic strips. PE was defined as GH or severe GH with 
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proteinuria.[1, 26] For women with pre-existing hypertension, PE is classified as 
the new or worsening proteinuria as defined above. For women with pre-existing 
proteinuria (e.g. diabetes with renal involvement), the diagnosis of PE was made 
on clinical or biochemical grounds by identifying at least one additional adverse 
condition (e.g. abnormal liver enzymes, low platelets and eclampsia).[1, 26]  All 
cases of GH and PE were further adjudicated by two independent investigators 
working in the Trial Coordinating Centre with failure to achieved consensus 
resolved by a third independent investigator.  
Adverse conditions were defined as one or more of the following selected 
medical conditions: 1) diastolic pressure ≥ 110 mmHg or systolic pressure ≥ 160 
mmHg; 2) proteinuria ≥ 300 mg/ 24 hours urine collection or ≥2+ on diagnostic 
strips ; 3) convulsion (eclampsia); 4) thrombocytopenia (platelet count < 100,000 
× 109/L); 5) elevated liver enzyme levels (AST or ALT >70 U/L); 6) hematocrit 
< 24% or blood transfusion; 7) IUGR (i.e., birth weight<3rd centile for 
gestational age using Canadian population based birth weight for gestational age 
as reference);[27] and 8) perinatal death (fetal death after 20 weeks or neonatal 
death within 7 days). Other maternal outcomes included maternal death, severe 
GH, severe PE, prelabor rupture of membranes, preterm prelabor rupture of 
membranes (PPROM), and hospitalization prior to giving birth. Severe PE was 
defined as PE and the presence of at least one of following adverse conditions: 1)  
diastolic pressure ≥ 110 mmHg or systolic pressure ≥ 160 mmHg; 2) proteinuria 
≥ 5g/ 24 hours urine collection or dipstick≥3+; 3) convulsion; 4) 
thrombocytopenia; 5) elevated liver enzyme levels; 6) hematocrit < 24% or 
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blood transfusion; 7) IUGR; 8) perinatal death; or 9) preterm delivery (less than 
34 weeks of gestational age).[1, 26],[28] PROM was defined as spontaneous rupture 
of the membranes at or after 37 weeks of gestation and before onset of the labor. 
PPROM was defined as spontaneous rupture of the membranes before 37 weeks 
of gestation and before onset of the labor.  
A composite outcome – ‘fetal loss or perinatal death’, was defined as any 
fetal loss at less than 20 weeks, stillbirth or neonatal death.  Other fetal or 
neonatal outcomes included: 1) preterm birth before 37 weeks of gestational age  
(gestational age corrected by early ultrasound scan); 2) preterm birth before 34 
weeks of gestational age; 3) small for gestational age (defined as < 5th, or 10th 
centile) ; 4) perinatal mortality; 5) spontaneous abortion; and 6) neonatal 
morbidity indicators such as Apgar score <4 at 5 minute, retinopathy of 
prematurity, periventricular leukomalacia, thrombocytopenia, neutropenia, sepsis, 
necrotizing enterocolitis, hypotonia, intraventricular hemorrhage, convulsion, 
sepsis, respiratory distress requiring oxygen therapy and/or assisted ventilation 
for more than 24 hours, and the need for intensive care for more than 4 days.  
Based on published data from the Trial of calcium to prevent preeclampsia 
(CPEP)  in low risk women[29] and one-year delivery records from two 
collaborating tertiary obstetric centers: the Royal Alexandra Hospital, Edmonton 
(RAH, 1996) and St-Francois d’Assise Hospital, Quebec (HSFA, 1999), we 
estimated 4% and 15% incidences of the primary outcome in the low and high 
risk strata, respectively. We planned to recruit 5,000 patients per group in 
Stratum I (low risk) for a total of 10, 000 patients and 1,250 women per group in 
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Stratum II (high risk) for a total of 2, 500 patients in order to detect 30% 
reduction of PE, with a power of 90% and alpha error of 5%. After reviewing the 
evidence from the trials conducted by the UK research group (Vitamin C and 
vitamin E in pregnant women at risk for pre-eclampsia-VIP trial)[22] and the 
Australian Collaborative Trial of Supplements (ACTS) Study group[23] as well as 
our internal data on serious adverse events, and in accordance with the 
recommendations of the Data Safety & Monitoring Committee, the Trial 
Steering Committee decided to terminate the trial. A total of 2640 consenting 
eligible women were recruited. The last woman was recruited on March 30th 
2006 and the last infant was born on September 1st 2006.  
The analysis was carried out on an ‘intention-to-treat’ basis. We used 
Student’s t tests to compare continuous variables and the Chi-squared test or 
Fisher’s exact test for categorical variables, as appropriate. The effects of the 
intervention were expressed as RR (95% CI). Participants with missing 
outcomes due to withdrawal or loss to follow-up were excluded from the 
analysis of outcomes. We assessed twin and triplet infants as if cluster 
randomized (the cluster being the mother). Neonatal outcomes were analyzed by 
adjusting for the multiplicity of the pregnancy as the main neonatal outcomes 
were strongly affected by multiple births except for the outcome of preterm birth. 
Stratified analysis and multivariable logistic regression were performed to assess 
whether the effect estimates differed according to country, ethnic group and 
socio-economic status, smoking, maternal age (<20, >35), commercial and 
dietary vitamin C and E consumption (estimated by FFQ) at the time of 
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randomization and at 26 weeks of gestation, or patient compliance that was 
calculated as the proportion of tablets not returned in the bottles over the total 
number of tablets given to each woman and defined as compliant to treatment if 
>80% of tablets were used .  
The study was registered as an International Standard Randomised 
Controlled Trial, number ISRCTN 85024310.  
Results 
Figure 1 displays the trial profile. Of the 2647 eligible women who were 
randomized, a total of 2640 women were validly randomized (randomization 
error in 3 women, recruitment halted at randomization visit in two women, two 
women non eligible after randomization). Of these, 1315 (49.81%) women were 
assigned to vitamins C and E group and 1325 women (50.19%) were allocated to 
the placebo group. Patients who were lost to follow up were excluded from the 
analyses and a total of 2363 women and their 2536 infants (vitamin group: 1167 
women and 1243 infants, placebo group: 1196 women and 1293 infants) were 
included in the final analyses.  
 At study entry, maternal baseline characteristics were similar in two groups, 
except that there was a slightly higher proportion of multiple pregnancies in the 
placebo group (Table1) There was no significant difference in patient 
compliance between the vitamin and the placebo groups (85.5% vs 86.5%, 
p=0.3640).  
There was no statistically significant difference in the risk of the primary 
outcome, GH and its adverse conditions in the treatment group and the placebo 
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group (10.11% and 10.20% respectively; RR: 0.99, 95% CI 0.78-1.26). The 
incidence of PE was similar between the two groups (5.95% versus 5.71%; RR 
1.04, 95% CI 0.75-1.44) and there was no statistically significant difference in 
the risk of GH between the two groups (21.68% vs 20.82%; RR 1.04, 95% CI 
0.89-1.22). Furthermore, there were no significant differences for any individual 
outcomes included in the primary composite outcome. (Table 2)  
Table 3 provides the results of the primary outcome, GH, and PE stratified by 
specific risk factor at enrolment. Vitamins C and E did not reduce the risk of GH 
and its adverse conditions, GH or PE, irrespective of risk at enrolment. (Table 3)  
Compared with the placebo group, women in the vitamin supplementation 
group had statistically significantly higher rates of PROM (10.17 % in the 
vitamin group versus 6.15% in placebo group; RR 1.65, 95% CI 1.23-2.22) and 
PPROM (5.97% in the vitamin group versus 3.03 in placebo group; RR 1.97, 
95%CI 1.31-2.98). There were no differences in the rates of severe GH and 
severe PE. There was no reported maternal death in the study. There were no 
differences in other maternal adverse outcomes in the vitamin group compared 
with the placebo group. (Table 4)  
 The rate of total death of the composite outcome ‘fetal loss or perinatal 
death’ was significantly higher in the vitamin supplemented group (1.69% versus 
0.78; RR 2.20, 95%CI 1.02-4.73) (Table 5).  The rates of spontaneous abortion, 
stillbirth and neonatal death before discharge were higher in the supplementation 
group, however these differences were not statistically significant. There were no 
statistically significant differences in the rates of preterm birth, IUGR (<3rd 
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centile), or small for gestational age (<5th or 10th centile) in two groups. There 
were no differences between the vitamin supplementation and placebo groups in 
neonatal morbidity indicators including respiratory distress requiring 
supplemental oxygen therapy, assisted ventilation for more than 24 hours, the 
need for intensive care for more than 4 days, Apgar score <4 at 5 minute, 
convulsion, sepsis, intraventricular hemorrhage, necrotizing enterocolitis, 
hypotonia, hypertonia, retinopathy of prematurity, leukomalacia, or neutropenia.   
Stratification analysis by risk status for PE (low versus high) and country 
(Canada and Mexico) indicated no evidence of heterogeneity between countries. 
We further assessed the effects of vitamin supplementation on the risk of PE 
adjusted by pre-selected covariates (i.e., smoking, maternal age (<20, >35), 
vitamin C and E intake at the time of randomization, and the proportion of 
patients compliant with treatment). The effect estimates remained similar.   
Discussion 
Taking into account risk profile, the rate of PE in our study was similar to 
that reported in previous trials.[22, 23] We did not find that supplementation with 
vitamins C and E reduced the risk of gestational hypertension and its adverse 
conditions among patients at high risk and low risk for PE.  The results were 
consistent with those of other recently reported RCTs,[20-25] with the exception of 
the first small trial by Chappell.[20]  Poston et al. reported no reduction of PE risk 
associated with vitamins supplementation (RR 0.97; 95% CI 0.80-1.17) in 2410 
women identified at increased risk of PE.[22] Rumbold et al. found no differences 
between the vitamin and placebo groups in the risk of PE (RR 1.20; 95% CI 
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0.82-1.75), and other adverse birth outcomes (e.g. perinatal death, small for 
gestational age) in 1877 nulliparous women recruited between 14 and 22 weeks 
of gestation.[23] The World Health Organization recently completed a multicenter 
trial  and indicated that supplementation of vitamins C and E did not reduce the 
risk of PE, eclampsia, and gestational hypertension among pregnant women with 
low socio-economic status and low nutritional status in developing countries.[25]  
In addition to the trials of combined vitamins C and E supplementation , 
Rivas et al. conducted a trial to assess the effects of aspirin, vitamin C, E and 
fish oil supplements.[30] They found that such supplements significantly reduced 
the risk of PE (RR 0.07, 95%CI 0.01-0.54). However, it is hard to infer whether 
such an effect was due to vitamins C and E, fish oil or aspirin, or the effects of 
their interaction.  Steyn et al. reported no effects of vitamin C supplementation 
on the risk of PE (RR 1.00, 95%CI 0.21-4.84). The study was stopped early 
because of an increase in spontaneous preterm labor in the treatment group.[31]  
Women in the group receiving vitamin supplementation had higher rates of 
PROM and PPROM than did the placebo group. The treatment differences 
remained significant after covariate adjustment for maternal age, smoking, body 
mass index, the patient compliance, and the presence of medical risk factors (e.g. 
chronic hypertension, multiple pregnancy, history of PE, history of diabetes). Of 
the previously reported large RCTs of vitamins C and E supplementation in the 
prevention of PE risk, only two trials reported and examined the effects of 
vitamins C and E supplementation and the risk of PPROM.[23, 24] Rumbold et al. 
reported a slight increase of PPROM risk in the supplemented group (3.2% 
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versus 2.4%; RR 1.31, 95%CI 0.77-2.25).[23] However the difference was not 
statistically significant. Spinnato et al. observed a significant increased risk of 
PPROM in the antioxidant group (10.6% versus 5.5%; adjusted RR 1.89, 95% CI 
1.11-3.23).[24] Casanueva et al. conducted a randomized trial, in which 109 
women were randomly assigned at 20 weeks of gestation either to 100 mg 
vitamin C or placebo.[32]  Despite the fact that there was no measured difference 
in plasma vitamin C concentration between two groups, there was a significantly 
lower rate of PROM in the supplemented group compared with the placebo 
group.[32]  
We did note an increase risk of the composite outcome ‘fetal loss or perinatal 
death’ (1.69% vs 0.78%; RR 2.20, 95%CI 1.02-4.73).  While this was not a pre-
specified outcome in the study protocol, it was used as an outcome for the 
monitoring of morbidity by the Data Safety Monitoring Board, and contributed 
to the decision to stop the trial early.  We noted that there were more perinatal 
deaths in the antioxidant group than the placebo group, but the effect did not 
reach statistical significance. We did not find evidence of differences between 
groups in the rates of low birth weight, preterm birth, small for gestational age, 
or low Apgar score. Poston et al. found vitamin supplements to be positively 
associated with the risk of low birth weight compared with controls. This effect 
was particularly strong among women with prepregnancy diabetes who were in 
the Vitamin supplement group (RR: 1.15; 95%CI: 1.02- 1.30). [22]  
The daily doses of 1000 mg vitamin C and 400 IU vitamin E (RRR-αlpha-
tocopherol) are certainly below the maximum recommended intake in pregnant 
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women. We do not know why supplementation of vitamins C and E at these 
doses does not reduce the risk of PE, or GH, but increased the rates of PROM 
and PPROM in our study. The dose of vitamin E that is required to suppress 
isoprostane levels (a marker of oxidative stress) has been documented in adult 
males,[33]  but not in pregnant women. Exogenous vitamin E may prevent an 
immunologic switch (Th1 to Th2) that is considered as crucial for early to late 
transition in normal pregnancy and it could be a potential interferon-gamma 
(IFN-γ) mimic, facilitating pro-inflammatory responses at the maternal-fetal 
interface.[34] It is possible that vitamin E exerts both potentially beneficial and 
detrimental effects. Therefore, vitamin E treatment might have undesirable side-
effects and may partially explain the unexpected results of the increased risks of 
PROM and PPROM. There is some evidence that high doses of alpha tocopherol 
(primary form of vitamin E in supplementation) could deplete plasma and tissue 
gamma tocopherol (major form in plant seeds and in the North American 
diet).[35-38]  Therefore, the efficacy of vitamin E supplementation (alpha 
tocopherol) may be offset by deleterious changes in the levels of other nutrients. 
In fact, our preliminary data analyses using the INTAPP population found that 
women in the supplementation group had significant higher level of alpha-
tocopherol at 32 weeks of gestation (58%; p<0.001) and lower ratio of gamma-
/alpha-tocopherol (-58%; p=0.001), compared with the baseline visit (‘visit 1’: 
week 12-16 gestation). While levels of alpha-tocopherol were significantly 
increased compared to baseline (34%; p<0.001) among women in the placebo 
group, the ratios of gamma-/alpha-tocopherol were not affected.[39] The 
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ineffectiveness of vitamin C and E in the prevention of PE and the potentially 
harmful effects emphasize the need for a better understanding of the underlying 
mechanisms and metabolism of both vitamins C and E in the human body.  
Witztum et al. hypothesized that only individuals under oxidative stress are 
likely to benefit from antioxidant supplementation.[40] Meagher et al. proposed 
that only people deficient in vitamin E may benefit from vitamin E 
supplementation.[41] To date, a series of trials have been conducted, including the 
present study, involving both low and high risk patients (e.g. presence of chronic 
hypertension, history of PE, multiple gestation, diabetes, low socio-economic 
status and low nutritional status). It is clear that irrespective of study population 
(i.e. risk profile and nutritional status), supplementation with vitamins C and E 
during pregnancy is unlikely to prevent PE, gestational hypertension, preterm 
birth or low birth weight.  
The definitions for GH and PE retained for this trial are those of the 
Canadian Consensus Statement on Hypertensive Disorders of Pregnancy.[1] This 
definition focuses on the diastolic blood pressure value for diagnosis. There is no 
universal consensus regarding the definition of GH or PE, nor studies are there 
comparing the relative validity of the different definitions. However, it is 
unlikely that the choice of an alternative definition would have modified the 
results of the trial.     
The trial was prematurely stopped with a total of 2640 eligible pregnant 
women included in the final analysis. This resulted in a significant decrease in 
power relative to the initially planned sample size. Nevertheless, in the light of 
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our results and those of other investigators, it is unlikely that further recruitment 
would have identified a difference in treatment group. Furthermore, given the 
increased risk of certain adverse outcomes (‘fetal loss/perinatal deaths and 
PPROM), we considered it unethical to continue the study. We also 
acknowledge the fact that an approximate 20% of lost to follow up occurred in 
Mexican centres. This is because a high proportion of Mexican women 
beginning prenatal care in the IMSS Centres change health care provider in the 
course of prenatal care and deliver in non-IMSS hospitals where data could not 
be accessed.  However, the proportion of lost to follow up was balanced between 
treatment and placebo groups and stratification analysis by country did not result 
in any difference for effect estimates.  
Despite the fact that the underlying mechanisms remain largely unclear, there 
is increasing concern that supplementation of vitamins C and E at the doses 
studied [i.e. 1000 mg vitamin C and 400 IU vitamin E (RRR α tocopherol)] may 
increase the risk of other adverse pregnancy outcomes such as low birth 
weight[22] and PPROM. Therefore, based on our present knowledge, vitamins C 
and E supplementation at the above doses cannot be recommended for pregnant 
women to prevent adverse pregnancy outcomes including PE.  
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Figure 1.  Trial profile 
 
2640 validly randomized
2647 women underwent randomization 
(Randomization error: 3
Recruitment halted at visit 1: 2
Non eligible after randomization: 2)
1325 assigned placebo (50.19%)
Canada: 821
Mexico: 504
129 lost to follow up (9.7%)
Canada: 28 (3.4%)
Mexico: 101 (20.0)
1196 had pregnancy outcomes (90.26 %) 
and 1293 infants including: 
1282 Live births (99.1%)
 1 early fetal deaths at <20 wk
 6 stillbirths at ≥20 wk
1315 assigned vitamins C and E (49.81%)
Canada: 813
Mexico: 502
148 lost to follow up (11.25%)
Canada: 39 (4.8%)
Mexico: 109 (21.7%)
1167 women and their 1243 infants 
analysed including:
1227 Live births (98.7%)
  6 early fetal deaths at <20 wk (0.48%)
  10 stillbirths at ≥20 wk 
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Table 1 Women’s baseline demographic and obstetric characteristics by 
treatment groupa 
 
Characteristic 
Vitamins C and E 
N=1167 
Placebo 
N=1196 
Maternal age, y 28.66 (5.57) 28.68 (5.44) 
Maternal education (years) 14.48 (3.47) 14.53 (3.62) 
Maternal pre-pregnancy BMIb 25.45 (5.69) 25.47 (2.09) 
Maternal visit1 BMIb 26.69 (5.81) 26.75 (6.21) 
Ethnic origin    
      Asian  26 (2.23) 12 (1.01) 
      South Asian  6 (0.51) 4 (0.34) 
      Caucasian 364 (31.22) 406 (34.00) 
      French Canadian 285 (24.44) 279 (23.37) 
      African 10 (0.86) 16 (1.34) 
      Hispanic 403 (34.56) 416 (34.84) 
      First Nation 7 (0.60) 5 (0.42) 
      Other  65 (5.57) 56 (4.69) 
Gestational age, wk 15.19 (2.10) 15.28 (2.09) 
Gravidity  1.65 (1.02) 1.67 (1.10) 
Nulliparous  934 (80.03) 957 (80.02) 
Employed  890 (76.33) 911 (76.36) 
Smoking before pregnancy 340 (29.16) 330 (27.64) 
Current smoker  76 (6.56) 88 (7.43) 
Current drinker 14 (1.20) 23 (1.93) 
Blood pressure    
     Systolic  108.92 (13.13) 109.27 (13.57) 
     Diastolic  67.50 (9.03) 67.33 (9.07) 
Dipstick proteinuria    
     Normal or trace 1109 (96.43) 1137 (96.85) 
     1+ 40 (3.48) 33 (2.81) 
     2+ 1 (0.09) 4 (0.34) 
High risk group (stratum) 338 (28.96) 346 (28.93) 
     Chronic hypertension 78 (6.68) 70 (5.85) 
     Diabetes 82 (7.03) 76 (6.35) 
     Multiple pregnancy c 67 (5.74) 93 (7.78)c 
     History of preeclampsia 147 (12.60) 148 (12.37) 
     Multiple risk factors 33 (2.83) 38 (3.18) 
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Table 1 Women’s baseline demographic and obstetric characteristics by 
treatment groupa (continued) 
 
 
Characteristic 
Vitamins C and E
N=  1167 
Placebo 
N= 1196 
Use of supplements   
     Multivitamins  711 (61.29) 756 (63.26) 
     Vitamin C 20 (1.72) 10 (0.84) 
     Vitamin E 2 (0.17) 1 (0.08) 
     Folate 527 (45.35) 519 (43.54) 
     Calcium 164 (14.11) 163 (13.67) 
     Iron 272 (23.41) 271 (22.75) 
Family history of PE, 
eclampsia or GH 
156 (13.37) 143 (11.96) 
Family history of PE 95 (8.14) 84 (7.02) 
Family History of Eclampsia 16 (1.37) 10 (0.84) 
Family History of GH 89 (7.63) 82 (6.86) 
Obstetrical history   
     History of abortion 316 (27.10) 315 (26.36) 
     History of stillbirth 17 (1.46) 11 (0.92) 
     History of preterm birth 97 (8.32) 84 (7.03) 
     History of low birth weight 60 (5.15) 48 (4.02) 
 
BMI, body mass index; GH, gestational hypertension; PE, preeclampsia 
a: Data are presented as mean (S.D.) or n (%)  
b: Maternal BMI = weight (kilo)/height2 (m2) 
c: p<0.05 
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Table 2. Primary outcomes  
 
Characteristic 
Vitamins C and E
N=1167 
Placebo 
N= 1196 
 
RR(95%CI) 
 
P 
GH and its adverse 
conditions a 
118 (10.11) 122 (10.20) 0.99 (0.78-1.26) .94
GH 253 (21.68) 249 (20.82) 1.04 (0.89-1.22) .61
Preeclampsia 69 (5.95) 68 (5.71) 1.04 (0.75-1.44) .81
Eclampsia 1 (0.10) 0 -- .50
Diastolic pressure ≥110 
mm Hg 
32 (2.74) 27 (2.26) 1.21 (0.73-2.01) .45
Systolic pressure≥160  
mm Hg 
53 (4.54) 68 (5.69) 0.80 (0.56-1.13) .21
Hematocrit <24% 3 (0.26) 5 (0.42) 0.61 (0.15-2.57) .50
Blood transfusion 3 (0.26) 6 (0.50) 0.51 (0.13-2.04) .33
Thrombocytopenia 7 (0.60) 7 (0.59) 1.02 (0.36-2.91) .96
Elevated liver enzymes 
levels (AST or ALT>70 
U/L) 
9 (0.77) 7 (0.59) 1.32 (0.49-3.53) .58
IUGR (<3 rd percentile)b 18 (1.54) 15 (1.25) 1.23 (0.62-2.43) .55
Perinatal deathc 5 (0.43) 1 (0.08) 5.12 (0.60-43.79) .10
 
ALT, alanine amniotransferase; AST, aspartate amniotransferase;  
CI, confidence interval; GH, gestational hypertension; IUGR, intrauterine growth 
restriction; RR, relative risk 
Data are presented as mean (S.D.) or n (%)  
a. GH and > 1 of the following: 1) diastolic pressure ≥ 110 mmHg or systolic 
pressure ≥ 160 mmHg; 2) proteinuria > 300mg/24 hours urine collection or 
dipstick≥2+; 3) convulsion (eclampsia); 4) thrombocytopenia (platelet count < 
100,000 × 109/L); 5) elevated liver enzyme levels (AST or ALT >70 U/L); 6) 
hematocrit < 24% and blood transfusion; 7) intrauterine growth restriction <3rd 
centile; and 8) perinatal death(fetal death after 20 weeks or neonatal death within 
7 days) ; b only singleton pregnancy was considered in the primary composite 
outcome; c Counted as the number of pregnancies (mothers) 
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Table 3. Primary outcome, gestational hypertension, and preeclampsia 
stratified by risk at enrolment 
Characteristic, n(%) Vitamins C and E Placebo RR (95%CI) 
GH and its adverse 
conditions 
   
High-risk stratum  68 (20.12) 70 (20.23) 0.99 (0.74-1.34)
    Chronic hypertension  28 (35.90) 27 (38.75) 0.93 (0.61-1.41)
    Diabetes 11 (13.41) 15 (19.74) 0.68 (0.33-1.39)
    Multiple pregnancy 9 (13.43) 13 (13.98) 0.96 (0.44-2.12)
    History of PE 33 (22.45) 29 (19.59) 1.15 (0.74-1.79)
    Multiple risk factors 11 (33.33) 13 (34.21) 0.97 (0.51-1.87)
 Low risk stratum     50 (6.03) 52 (6.12) 0.99 (0.68-1.44)
GH    
High risk stratum  114 (33.73) 119 (34.39) 0.98 (0.80-1.21)
    Chronic hypertension  44 (56.41) 39 (55.71) 1.01 (0.76-1.35)
    Diabetes 20 (24.39) 23 (30.26) 0.81 (0.48-1.34)
    Multiple pregnancy 13 (19.40) 15 (16.13) 1.20 (0.61-2.36)
    History of PE 57 (38.78) 57 (38.51) 1.01 (0.76-1.34)
    Multiple risk factors 18 (54.55) 14 (36.84) 1.48 (0.88-2.49)
 Low risk stratum     139 (16.77) 130 (15.29) 1.10 (0.88-1.37)
PE    
High risk stratum  41 (12.17) 38 (11.05) 1.10 (0.73-1.67)
    Chronic hypertension  16 (20.51) 11 (15.71) 1.31 (0.65-2.62)
    Diabetes 6 (7.32) 11 (14.47) 0.51 (0.20-1.30)
    Multiple pregnancy 4 (6.06) 6 (6.52) 0.93 (0.27-3.16)
    History of PE 24 (16.33) 16 (10.88) 1.50 (0.83-2.71)
    Multiple risk factors 7 (21.21) 5 (13.16) 1.61 (0.56-4.60)
 Low risk stratum     28 (3.40) 30 (3.55) 0.96 (0.58-1.59)
 
CI, confidence interval; GH, gestational hypertension; PE, preeclampsia; 
RR, relative risk.  
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Table 4.  Secondary maternal outcomes  
 
Characteristic, n (%) 
Vitamins C and E
N=1167 
Placebo 
N= 1196 
 
RR(95%CI) 
Severe GHa 70 (6.0) 78 (6.52) 0.92 (0.67-1.26) 
Severe PEb 33 (2.83) 39 (3.26) 0.87 (0.55-1.37) 
PROMc 109 (10.17) 67 (6.15) 1.65 (1.23-2.22)e
PPROMd 64 (5.97) 33 (3.03) 1.97 (1.31-2.98)e
Maternal infection 20 (1.73) 29 (2.46) 0.71 (0.40-1.24) 
Delivery method    
   Spontaneous delivery  526 (45.11) 551 (46.15)  
    Instrumental delivery 120 (10.29) 126 (10.55) -- 
    Caesarean  520 (44.60) 517 (43.30)  
Antepartum hemorrhage  4 (0.34) 2 (0.17) 2.05 (0.38-11.17)
ICU admission  16 (1.37) 18 (1.51) 0.91 (0.47-1.78) 
Predelivery hospitalization 333 (28.63) 341 (28.66) 0.99 (0.88-1.14) 
 
CI, confidence interval; GH, gestational hypertension; PE, preeclampsia; 
PROM, prelabor rupture of membranes; PPROM, preterm prelabor rupture of 
membranes; RR, relative risk.  
 
a. Defined as > 2 readings of diastolic blood pressure systolic≥110 
mmHg or systolic blood pressure≥160 mmHg at least four hours apart; 
b. Defined as PE and >1 of following adverse conditions: 1) diastolic 
pressure ≥ 110 mmHg or systolic pressure ≥ 160 mmHg; 2) proteinuria 
≥ 5g/ 24 hours urine collection or dipstick≥ 3+; 3) convulsion 
(eclampsia); 4) thrombocytopenia (platelet count < 100,000 × 109/L); 5) 
elevated liver enzyme levels (AST or ALT >70 U/L); 6) hematocrit < 
24% or blood transfusion; 7) IUGR (i.e., birth weight<3rd centile for 
gestational age); 8) perinatal death (fetal death after 20 weeks or 
neonatal death within 7 days); or 9) preterm delivery less than 34 
weeks of gestation. 
c. Defined as spontaneous rupture of the membranes at or after 37 weeks 
of gestation and before onset of the labor 
d. Defined as spontaneous rupture of the membranes before 37 weeks of 
gestation and before onset of the labor 
e. P<0.05 
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Table 5. Secondary Neonatal outcomes 
 
 
Characteristic, n(%) 
Vitamins C and E
N= 1243 
Placebo 
N= 1293 
 
RR(95%CI) 
Fetal loss or death of infantsa,b 21 (1.69) 10 (0.78) 2.20 (1.02-4.73) 
  Spontaneous abortion 6 (0.48) 1 (0.08) 6.25 (0.72-54.52)
  Stillbirth 10 (0.80) 6 (0.47) 1.73 (0.63-4.78) 
  Neonatal death before discharge 5 (0.40) 3 (0.23) 1.73 (0.41-7.25) 
IUGR (<3rd percentile) 60 (4.87) 60 (4.67) 1.05 (0.72-1.51) 
Preterm birthc    
    <37 weeks 193 (16.57) 184 (15.48) 1.07 (0.89-1.29) 
    <34 weeks 67 (5.75) 65 (5.47) 1.05 (0.76-1.47) 
Small for gestational age    
    <5th percentile 91 (7.38) 102 (7.93) 0.93 (0.69-1.25) 
    <10th percentile 173 (14.03) 194 (15.09) 0.92 (0.73-1.15) 
Convulsion 5 (1.07) 2 (0.42) 2.55 (0.49-13.19)
Respiratory distress requiring 
oxygen 
267 (21.87) 281 (22.02) 0.99 (0.81-1.21) 
Assisted ventilation≥24 hours  55 (4.51) 54 (4.25) 1.07 (0.67-1.69) 
NICU care >4 d  46 (4.08) 48 (4.09) 1.00 (0.62-1.61) 
Congenital anomalies  37 (3.03) 30 (2.35) 1.30 (0.78-2.19) 
Sepsis  13 (1.07) 6 (0.47) 2.28 (0.77-6.80) 
Intraventricular hemorrhage  11 (0.90) 8 (0.63) 1.44 (0.53-3.94) 
Necrotizing enterocolitisb 1 (0.08) 9 (0.71) 0.12 (0.01-0.91) 
Hypertonia 6 0 - 
Hypotonia 7 (0.57) 6 (0.47) 1.22 (0.41-3.63) 
Retinopathy of prematurity 4 (0.33) 3 (0.24) 1.39 (0.16-12.46)
Leukomalacia 1 (0.08) 0 - 
Neutropenia  6 (0.50) 3 (0.24) 2.09 (0.52-8.38) 
Apgar score <4 at 5 min 9 (0.73) 6 (0.47) 1.57 (0.56-4.44) 
 
CI, confidence interval; IUGR, intrauterine growth restriction; NICU, neonatal 
intensive care unit; RR, relative risk 
a. Defined as spontaneous abortion, stillbirth or neonatal death  
b. P<0.05  
c. Counted as number of pregnancies    
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Abstract 
Objective: To assess effects of perinatal nutrient intakes on the risk of 
hypertensive disorders (gestational hypertension and preeclampsia) of pregnancy 
in Canada and Mexico.  
Study design: We analyzed nutrient intakes of women enrolled in a randomized 
trial of antioxidants for the prevention of preeclampsia (PE) conducted in 17 
centres in Canada (n=1537) and 10 centres in Mexico (n=799). Validated Food 
Frequency Questionnaires (FFQs) were administered in the 1st and 3rd 
trimesters of pregnancy to assess usual dietary intakes over the previous three 
months.  
Results: Of 1537 Canadian and 799 Mexican women included in the final 
analysis, 498 (21.3%) developed gestational hypertension (GH), and 136 (5.82%) 
developed preeclampsia (PE). There were significant heterogeneities in various 
nutrient intakes between Canadian and Mexican women. Therefore, risk models 
were developed separately for the two populations. After adjusting for pre-
pregnancy body mass index, treatment, risk stratum (high versus low) and other 
baseline risk factors, we found that the lowest quartiles of potassium (adjusted 
OR 1.79, 95% CI 1.03-3.11) and zinc (adjusted OR 1.90, 95% CI 1.07-3.39) 
intakes were significantly associated with an increased risk of PE among 
Canadian women. The lowest quartile of polyunsaturated fatty acids was 
associated with the risk of GH (adjusted OR 1.49, 95% CI 1.09-2.02). None of 
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the nutrients analyzed were found to be associated with PE and GH risk among 
Mexican women.  
Conclusion: Lower intakes of potassium and zinc were moderately associated 
with the risk of PE in Canadian women. There was significant heterogeneity in 
nutrient intakes between Canada and Mexico.   
Key words: Preeclampsia, FFQ, Nutrient Intake 
 
Introduction  
Hypertensive disorders of pregnancy including preeclampsia (PE) and 
gestational hypertension (GH) are associated with significantly increased risks of 
perinatal morbidity and mortality [1-4] as well as an increased risk for 
subsequent chronic hypertension or cardiovascular disease for mothers in the 
long term.[5, 6]  
PE is a multisystem disorder that is specific to human pregnancy and its 
etiology remains largely unknown. Although there is little evidence to support 
routine prenatal dietary intervention or supplementation, it is generally believed 
that maternal diet may be important in reducing the risk of adverse pregnancy 
outcomes. Certain nutrients, such as vitamins C and E, calcium and omega-3 
fatty acids, have been proposed to decrease the risk of PE.[7-15] The 
International Trial of Antioxidant supplementation in the Prevention of 
Preeclampsia (INTAPP),[16] and other similar studies[14, 15] failed to provide 
evidence of an effect of prenatal vitamins C and E supplementation on the 
incidence and severity of GH or PE. However, the INTAPP cohort offered a 
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unique opportunity to assess the impact of nutrient intakes on well-defined 
hypertensive disorders of pregnancy in a prospective cohort (early and late 
pregnancy) as well as in two different ecological settings (Canada and Mexico). 
The aim of the study was to investigate maternal nutrient intakes in early and late 
pregnancy in relation to the risk of hypertensive disorders of pregnancy in 
Canada and Mexico. 
Methods  
We analyzed nutrient intake data from a prospective pregnancy cohort of 
women enrolled in the INTAPP study - a randomized controlled trial that 
investigated the effects of vitamins C and E supplementation in the prevention of 
PE.[16] The trial was conducted in Canada (17 centers) and Mexico (10 centers) 
between January 2004 and March 2006. The design of the trial has been 
described in detail elsewhere.[16] Briefly, women at 12-18 completed weeks of 
gestation were randomly assigned either to the antioxidant treatment (1g vitamin 
C and 400 IU vitamin E daily) or the placebo group. Randomization was 
stratified by center and by risk status according to pre-specified clinical risk 
criteria. Women were at high risk if they were nulliparous or multiparous with 
pre-pregnancy chronic hypertension (diastolic blood pressure > 90 mmHg before 
20 gestational weeks or use of antihypertensive medication for hypertension), 
pre-pregnancy diabetes (insulin-dependent or hypoglycemic agents), multiple 
pregnancy, or a history of PE in the previous pregnancy. Women were stratified 
into the low risk stratum if they were nulliparous without any identified clinical 
risk factors. Women and their babies received care according to standard practice 
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in each center, with surveillance for hypertension using standardized 
measurements of blood pressure.  
Assessment of nutrient intake 
Nutrient intake among women in the INTAPP trial was assessed by 
information gathered through self-administered food frequency questionnaires 
(FFQs) that were country-specific and that were  administered at trial entry (12-
18 weeks of gestation) and repeated at 32-34 weeks of gestation to ensure 
capture of pre-pregnancy diet as well as changes during pregnancy. The data 
from the FFQ furnished estimates of absolute nutrient values and food group 
consumption, and permitted ranking of individual intakes. Similar approaches 
were used in both Mexico and Canada to ensure accuracy in data collection, data 
entry, and FFQ quality assessment and to ensure comparability between the 
Canadian and Mexican dietary data. 
In the Canadian sites, a semi-quantitative 78-item FFQ developed by 
Shatenstein et al. and validated in several adult populations in both French and 
English,[17] was modified for the INTAPP trial to include all food sources of 
vitamins C and E, and to reflect usual intakes over the previous 3-months rather 
than the standard 12-month time period. It was validated for use in a subset of 
107 pregnant women from the Canadian INTAPP cohort.[18] Participants’ 
estimation of consumption frequency and portions was aided by detailed 
instructions for completion and food-specific photos of sample portion sizes.  
In the Mexican sites, the Canadian FFQ was modified to reflect current local 
foods and diets using information from the second Mexican National Nutrition 
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Survey published data [19] and a survey conducted in 4 clinics and 2 
gynecological hospitals from the Mexican Social Security Institute. The FFQ 
was developed and tested in Spanish. It was validated against three non-
consecutive 24-hour food recalls administered to 85 pregnant women. [20] 
Standard procedures for completing the self-administered FFQ and 
information on potential problems and strategies to resolve them were provided 
to research nurses. An experienced research nutritionist was responsible for 
training research nurses working at each site. After completion, the FFQ was 
signed and dated by the participant to confirm the accuracy of the recorded 
information. In the Canadian arm of the study, the FFQs were entered using 
Microsoft Access software for customized data entry, and analysis was based on 
the algorithms developed to compute energy and nutrient values from the 
instrument food list, frequency option and portion size. Data-entry took 
approximately 10 minutes per FFQ, with double entry done systematically to 
verify accuracy. Nutrient values were calculated from the reference food nutrient 
composition values (Canadian Nutrient File-CNF2001b, Health & Welfare 
Canada, 1982) incorporated into the FFQ data entry utility. In the Mexican arm, 
nutrient values were calculated based on the United States Department of 
Agriculture (USDA) food composition tables using a previously validated and 
patented computerized system.[21-23] Preliminary analyses were conducted by 
the nutrition teams in both countries to detect outliers, and the quality of FFQ 
data was assessed by the trained nutritionists using a score, ranging from ‘1’ 
indicating ‘good quality’ to ‘4’ indicating ‘ poor quality’.  
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To collect information on perinatal vitamin or mineral supplements, women 
were asked the following question at trial entry (gestational age of 12-18 weeks) 
and at 32-34 weeks of gestation: “In the past 3 months, have you taken any 
multivitamins or prenatal vitamins regularly?”. Women were classified as users 
or non- users of vitamin or mineral supplements. The majority of patients 
reported daily supplement use and the composition of the most commonly used 
multivitamin supplements was reported to be similar. However, we had no 
information on product name or formulation in most cases.  
Study outcomes   
The main study outcomes were GH and PE. GH was defined as at least two 
readings of diastolic blood pressure ≥90 mmHg taken 4 hours apart but within 72 
hours occurring ≥ 20 weeks of gestation.[24, 25] PE was defined as GH with 
proteinuria.[24, 25] Proteinuria was defined as the urinary excretion of >0.3g/24 
hours, or ≥2+ on diagnostic strips. For women with pre-existing hypertension, 
PE was classified as new or worsening proteinuria as defined above. For women 
with pre-existing proteinuria (e.g. diabetes with renal involvement), the 
diagnosis of PE was based on clinical or biochemical grounds by identifying at 
least one additional adverse condition (e.g. hypertension, abnormal liver 
enzymes, low platelets and eclampsia).[24, 25]  All cases of GH and PE were 
further adjudicated by two independent investigators in the Trial Coordinating 
Centre. Failures to achieve consensus were resolved by a third independent 
investigator.  
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Statistical analysis 
Data on socio-demographic and clinical characteristics were obtained from 
the INTAPP trial. Nutrient intakes were categorized by quartiles. Exploratory 
analyses were conducted to assess the distribution of all continuous variables. 
Means and standard deviations (for continuous variables) and frequencies and 
proportions (for discrete variables) were used to describe study variables. 
Analyses of variance and nonparametric rank tests (Wilcoxon test if the 
distribution was skewed) were used to assess differences in continuous variables. 
Chi-square tests were used to compare the differences in rates between groups. 
The data from the two trial arms (treatment and placebo) were pooled as there 
was no difference in the rates of hypertensive disorders of pregnancy.[16] 
Univariate logistic regression analyses were conducted to test for the effect of a 
single maternal characteristic or nutritional factor on the outcomes (PE, GH). 
Nutrients included in the models were adjusted for the potential confounding 
effect of total energy intake.[26] Tests for trend across ordered categories for 
nutrient intakes were conducted by modeling variables of nutrient intakes as 
continuous variables. Dichotomous variables were used for each nutrient intake 
(exposed -lowest intake quartile vs. non-exposed - other quartiles) in final 
logistic regression models since there were no significant risk gradients among 
the three higher quartiles in most nutrients. The statistical significance was 
assessed by the likelihood ratio test statistic. The odds ratios (OR) and 95% 
confidence intervals (95%CI) were obtained from logistic regression models to 
quantify the associations. Socio-demographic and clinical variables (at trial entry) 
 102
and nutritional variables found to be significantly associated with PE at the 
P<0.15 level in the univariate analysis were considered as candidates for 
inclusion in a parsimonious multivariate model identified using forward 
selection as well as stepwise selection procedures. Terms representing the 
treatment assignment and total energy intake as well as the quality score of FFQ 
data were forced into the model at every step. Analyses were repeated for the 
following models: 1) baseline diet (nutrient intakes estimated from FFQ 
collected at visit 1) only , in which PE or GH risks were related to baseline diet 
only (analysis based on women with plausible FFQ at trial entry, n=2336) ; 2) 
diet in late pregnancy only (nutrient intakes estimated from FFQ collected at 32-
34 weeks of gestation), in which PE or GH risks were related to nutrient intakes 
in late pregnancy only (analysis based on women with plausible FFQ in the third 
trimester, n=1887) ; and 3) diet intakes both in early and late pregnancy models, 
in which PE or GH risks were related to both baseline nutrient intakes and 
changes of nutrient intake from early to late pregnancy (standardized as Z-scores) 
(n=1887). Analyses were performed using SAS version 9.2 and significance was 
set at two tailed p<0.05.  
Results  
Of the 2640 women randomized, 277 women were lost to follow up and 4 
women terminated their pregnancies at less than 20 weeks of gestation, and were 
excluded from the analysis. Among the remaining 2352 patients, a total of 2336 
patients - including 1537 from Canada and 799 from Mexico - with complete 
and plausible FFQ data at the first study visit were included in the final analysis. 
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Among these, GH occurred in 284 (18.5%) women from Canada and 214 (26.8%) 
women from Mexico, PE occurred in 68 women (4.4%) in Canada and 68 (8.5%) 
women in Mexico.  
There was significant heterogeneity in most nutrient intakes between 
Canadian and Mexican women (Table 1). The proportion of regular users of 
mineral or vitamin supplements (i.e. multivitamin, folate, iron, calcium, etc) was 
significantly higher in Canadian women than in Mexican women. Regarding any 
specific supplement, the proportions of regular users of multivitamin and 
calcium supplements were significantly higher in Canadian women than 
Mexican women. However, the frequencies of regular users of folate and iron 
supplements were significantly higher in Mexican women. Therefore, all 
analyses were conducted separately for the two study populations. 
Table 2 shows the socio-demographic and clinical characteristics (at trial 
entry) of the whole cohort, women with GH and PE, and women with normal 
blood pressure in the two cohorts. Women with GH or PE were more likely to be 
nulliparous or with higher pre-pregnancy body mass index (BMI), higher mean 
baseline diastolic and systolic blood pressure. There were no differences in 
ethnicity, marital status, employment status, socioeconomic status and lifestyle 
factors (drinking and smoking) between hypertensive and normotensive patients. 
Similar distributions of baseline characteristics between hypertensive and 
normotensive patients were observed in Canada and Mexico.    
As expected, the proportions of hypertensive disorders were comparable 
between antioxidant and placebo groups (Table 3). The proportion of the 
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presence of risk factors (i.e. high risk stratum) was significantly higher in women 
with GH and PE compared to overall cohort and normotensive women. The 
proportions of regular users of mineral or vitamin supplements (i.e. multivitamin, 
folate, iron, calcium, etc) were similar between hypertensive and normotensive 
patients. Among Canadian women, the proportion of regular baseline users of 
multivitamin, vitamins C and E was slightly lower in women with PE and GH.  
In Canadian women, univariate analysis showed that quartile distributions of 
dietary intakes of fiber, maganesium, potassium, sodium, zinc, vitamins A, C, E, 
thiamine, and folate  were associated with PE at pre-defined p<0.15 level. There 
were significant trends toward an increased risk of PE with decreasing quartiles 
of fiber, zinc, maganesium, potassium, vitamins A, C, E, thiamine, and folate 
(p<0.05). The quartile distributions of dietary intakes of protein, pantothenic acid, 
polyunsaturated fatty acid were associated with GH at p<0.15 level among 
Canadian women. In the Mexican pregnant cohort, univariate analysis indicated 
that no quartiles of any nutrient intake were associated with GH or PE at the 
level of p<0.15. (Appendix: Table I- The risk of GH or PE according to quartile 
distributions of nutrient intakes estimated from FFQ administered at 12-18 
weeks of gestational age; Table J: Unadjusted Odds ratios of dietary nutrients 
intake in association with preeclampsia (PE) and gestational hypertension (GH) 
in Canadian and Mexican pregnancy cohorts) 
As there were no significant risk gradients among the three higher quartiles 
in most nutrients, logistic regression models were therefore used to assess 
dichotomous exposure variables (lowest quartile versus the three higher quartile 
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groups) of nutrient intakes in association with the risks of PE and GH. For 
Canadian women, univariate analysis found that compared to the higher three 
quartiles, the lowest quartile of intake of magnesium, potassium, vitamin A, 
vitamin C, and folate were significantly associated with PE (p<0.05). The lowest 
quartiles of intakes of calcium, zinc, vitamin E, and vitamin B6 were found to be 
associated with PE at the preselected p<0.15 level. The lowest quartiles of 
protein and polyunsaturated fatty acid were found to be associated with GH at p 
<0.05 level. For Mexican women, there was no association between the lowest 
quartile of any nutrient intake and the risk of PE at p<0.05 level. The lowest 
quartiles of carbohydrate, calcium and magnesium were associated with PE at 
p<0.15 level. Only the lowest quartile of vitamin B12 was found to be related to 
the risk of GH among Mexican women (OR 0.58, 95%CI 0.39-0.86). (Table 4) 
A total of 1217 women in Canada and 670 women in Mexico had plausible 
FFQ data that were collected at the third trimester to reflect nutrient intake 
during pregnancy. (Table 5) Quartile distributions of lipoprotein, 
monounsaturated fatty acids, and vitamin A were significantly associated with 
PE (p<0.05) among Canadian women. (Appendix: Table K) Only protein 
quartiles were found to be significantly associated with risk of GH in Canadian 
women. In the Mexican pregnant cohort, quartile distributions of vitamin B6, 
pantothenic acid, monounsaturated fatty acids, and thiamine were associated 
with PE. Also, only thiamine quartiles were associated with GH. (Appendix: 
Table K- The risk of GH or PE according to quartile distributions of nutrient 
intakes estimated from FFQ administered at 32-34 weeks of gestational age) We 
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further calculated changes of nutrients intake from early to late pregnancy, which 
were standardized as Z-scores. However, we found no associations between 
changes of intakes of any specific nutrient and the risk of PE and GH. Thus these 
variables were not included in the final models. (Appendix: Table L- Unadjusted 
Odds ratios of changes in nutrient intakes (standardized as Z score) in 
association with preeclampsia (PE) and gestational hypertension (GH) in 
Canadian and Mexican cohorts) 
Multivariate logistic regression models for the outcomes of PE and overall 
GH were constructed from baseline risk factors and dichotomous variables of 
nutrient intakes, for the variables found to be significant at p<0.15 in the 
univariate analysis. After adjusting for pre-pregnancy BMI, the presence of 
clinical risk factors (i.e. chronic hypertension, diabetes, history of PE, multiple 
pregnancy), family history of PE or GH, nulliparity, quality score of FFQ, and 
treatment group (antioxidants versus placebo), the lowest quartiles of potassium 
(adjusted OR 1.79, 95%CI 1.03-3.11) and zinc (adjusted OR 1.90, 95%CI 1.07-
3.39) intakes were significantly associated with an increased risk of PE among 
Canadian women. Furthermore, the lowest quartile of polyunsaturated fatty acids 
was associated with an increased risk of GH (adjusted OR 1.49, 95%CI 1.09-
2.02). Among Mexican women, we found no associations between any nutrient 
intake and the risk of PE and GH using multivariate regression models.  
Discussion  
The present prospective cohort study assessed relationships between 
perinatal nutrient intakes and the risk of hypertensive disorders in pregnancy. We 
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observed an increased risk of PE associated with low intake of potassium, zinc, 
and polyunsaturated fatty acids among Canadian women. However, we found no 
associations between any nutrient intake and the risk of PE and GH among 
Mexican women.  
Potassium is an essential dietary mineral and electrolyte. The richest sources 
of potassium are fruits and vegetables (e.g. potato, tomato, carrot, prune, etc.) as 
well as protein foods (e.g. beans and tuna).[27] Potassium intake has been 
reported to be inversely associated with blood pressure or risk of hypertension 
among non pregnant populations in observational studies, and clinical trials have 
tended to find that potassium had the strongest hypotensive effects.[28, 29] 
However, the role of potassium intake on pregnancy outcomes including PE 
remains is not well established. A prospective cohort study found that low 
plasma potassium level during the first half pregnancy is associated with the 
reduced risk for PE. The authors suggested that low potassium level may be an 
indicator for appropriate high insulin concentration, increased glomerular 
filtration ratio and systematic vasodilatation.[30] In the present study, we found 
that an inverse association between potassium intake and the risk of PE. The 
result is consistent with the previous published case control study of 172 
preeclamptic women and 339 normotensive controls.[31] The authors found that, 
compared to the lowest quartile (< 2.4 g/d), the top quartile of potassium intake 
(> 4.1 g/d) was associated with the reduced risk for PE (adjusted OR 0.49, 95% 
CI 0.24-0.99).[31]  
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Zinc is an essential mineral that is naturally present in some foods, added to 
others, and available as a dietary supplement. There are a variety food that 
contain zinc, including oysters, red meat, poultry, beans, nuts, certain types of 
seafood (such as crab and lobster), whole grains, fortified breakfast cereals, and 
dairy products.[27] We found the low intake of zinc was significantly associated 
with PE (adjusted OR 1.90, 95%CI 1.07-3.39). It has been suggested that 
alterations in zinc homeostasis might have a devastating effect on pregnancy 
outcome.[32] Several clinical studies have reported an inverse relationship 
between serum zinc concentrations and the risk of PE.[33, 34]   
We noted significant differences in nutrient intakes between Canadian and 
Mexican pregnant women. These could be explained by population differences 
in dietary habits between the two countries or among pregnant women in Canada 
and Mexico. For instance, Mexico is a country with a rich variety of locally-
grown fruits and vegetables. Compared to Canadian women, Mexican pregnant 
women eat more yellow fruits (e.g. papaya, melon, mango, etc.), which provide 
excellent sources of vitamin A and other vitamins and may explain significant 
higher levels of vitamin A among Mexican pregnant women. The FFQs used in 
the Canadian and Mexican cohorts may differ in their ability to accurately 
capture nutrient intakes. It is very likely that a differential reporting bias exists 
between two countries. For example, women in Mexico may tend to report 
higher milk intake as they are counseled to drink a lot of milk during pregnancy.  
Although the underlying mechanisms of PE remain largely unknown, it has 
been generally hypothesized as a 'two stage' disease described as pre-clinical 
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(poor placentation) and clinical features. The disease process may have occurred 
in a very early stage, even before placentation. Therefore, assessment of nutrient 
intakes at an early stage may be the optimal approach for unravelling the actual 
causal associations between nutrient intakes and the risk of hypertensive 
disorders of pregnancy. 
 Dietary assessment in pregnancy is challenging as the diet of pregnant 
women is likely to be highly variable compared to usual pre-pregnant patterns, 
and may fluctuate according to their state of comfort and well-being along with 
changes in food preferences during the course of pregnancy. In the present study, 
the FFQ was administered twice, once in the first trimester and again in the third 
to capture nutrient intakes at early pregnancy as well as changes from early to 
late pregnancy. The FFQ is designed to assess long term usual intakes rather than 
intakes on a few specific days, and is thus better able to capture day to day 
variability in food intakes than quantitative methods such as food records or 24 
hour diet recalls. It also permits ranking of respondents by their usual intakes. 
Although the FFQ in the present study was pre-tested and validated in several 
adult populations in both French and English,[17] and  the results of our 
validation studies indicated that the FFQ is a relatively valid instrument for 
determining usual diet in pregnant women,[18] it is also possible that some 
nondifferential misclassification of nutrient intakes from the FFQ may have 
occurred and therefore have underestimated the true effects. However, nutrient 
intakes were grouped into quartiles, and results are therefore less likely to be 
affected by errors in intake estimates.  
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It is notable that, both in Canada and Mexico, the majority of participating 
women took vitamin or mineral supplements regularly early in gestation or even 
before pregnancy. In Canada, it is recommended that vitamin supplementation 
begin early in gestation, optimally before conception. As shown in the present 
study, approximately 80% of women from the Canadian cohort were regular 
users of multivitamin supplements, while the proportions of using folate and 
calcium supplements were 30% and 16% respectively. In the Mexican cohort, 
approximately 70% of women took folate supplements and 60% women took 
iron supplements. It is possible that we did not detect an association between 
dietary micronutrient intakes and GH or PE since most women had generally 
adequate micronutrient intakes through supplements.  
We also obtained detailed information on a number of other maternal factors 
that have been shown to be important risk factors for GH and PE (i.e. pre-
pregnancy BMI). After adjustment for these potential factors, only lower intakes 
of potassium and zinc were found to be associated with PE risk and lower intake 
of polyunsaturated fatty acid was associated with GH risk among Canadian 
women. We found no association between nutrient intakes and the risk of GH 
and PE among Mexican women. It should be noted that the present study 
outcomes were also the primary outcomes for the INTAPP trial, in which 
rigorous research criteria for definition of GH and PE were applied based on the 
published Canadian consensus statement,[24] and the cases of GH and PE were 
further adjudicated independently by a team of clinicians specialized in the area.  
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Given the fact that there were significant differences in dietary habits 
between Canada and Mexico and that the ecological settings of the two countries 
were significantly different, the data were not pooled together and parallel 
analyses were performed. Thus we might have had insufficient power to detect 
moderate associations. The powers for the current sample size (n=1537) for an 
odds ratio of 1.79 for potassium and 1.90 for zinc in association with PE risk 
among Canadian women were approximately 70% and 76% respectively to 
allow a two sided alpha error of 5%. On the other hand, parallel analyses 
conducted in two countries provided a unique opportunity to assess and compare 
the effects of nutrient intakes on the risks of hypertensive disorders in two 
ecologically different settings. It is worth pointing out that the study populations 
in the present study were patients enrolled from a clinical trial with specific 
inclusion and exclusion criteria. Therefore one should be prudent in generalizing 
the findings to other populations.    
It has been suggested that diet plays a role in the risk of PE. Much of the 
clinical and basic research into nutritional causes of hypertensive disorders of 
pregnancy has paralleled research conducted on hypertension focused on 
nutrients such as calcium, sodium, magnesium, and fatty acids. The results 
derived from previous studies were inconsistent, which may be partially 
explained by the methods used to estimate dietary intake, the time in pregnancy 
at which diet is assessed, inconsistent definition of PE and GH, or population 
differences (i.e. lifestyle, heterogeneity in nutrient intake, socio-demographic 
factors).[35-37] Our recent review of published dietary intervention trials found 
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no evidence that increasing or restricting energy or protein intake, sodium 
restriction, or supplementation of magnesium, zinc, iron, vitamins C and E, or 
fish oil reduces the risk of PE or GH.[37]  
In summary, we found that, among Canadian women, lower intakes of 
potassium and zinc were moderately associated with the risk of PE. Among 
Mexican women, we found no nutrient intakes during pregnancy in relation to 
the risk of GH and PE. There was significant heterogeneity in nutrient intakes 
between Canada and Mexico.   
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Table1. Maternal Dietary intake from Food Frequency Questionnaire (FFQ) administered at trial entry (12-18 weeks of 
gestational age) and in the third trimester (32-34 weeks of gestational age) in Canada and Mexico  
Canada Mexico  
Dietary Intake  FFQ11,3 FFQ21, 4 Change5,6 FFQ11,3 FFQ21, 4 Change5,6 
Energy (Kcal)2 1962.6±811.0 1962.5±733.3 7.6(-0.04) 2667.1±1065.5 2496.5±923.3 -79.6(0.08) 
Protein (g)2 88.5± 38.6  89.4±33.4 0.8(-0.02) 78.6±32.4 76.9±31.3 -0.35(0.04) 
Total carbohydrate (g)2 246.5±110.9 244.2±106.5 0(-0.02) 374.0±164.3 350.1±146.8 -15.2(0.05) 
Total lipid (g)2 73.4±32.2  74.1±29.1 2.6(0.02) 102.4±46.5 94.2±38.9 -5.7(0.05) 
Total fiber (g)2 16.2±7.4  15.7±7.0 -0.2(0.01) 27.2±13.2  25.5±12.7 -1.8(0.01) 
Total cholesterol (mg)2 261.5±136.4 267.5±123.4 7.2(-0.01) 242.2±138.4 244.4±131.5 3.5(0.02) 
Calcium (mg)2 1111.6±553.1 1187.0±538.0 61.5(-0.04) 1309.9±748.7 1350.7±776.5 33.3(-0.01) 
Iron (mg)2 11.12±4.79  10.7±4.2 -0.2(0.02) 18.92±12.77  17.1±10.7 -1.1(0.06) 
Magnesium (mg)2 289.9±119.4 295.6±114.0 2.1(-0.05) 381.3±169.5 366.7±161.9 -3.6(0.07) 
Potassium (mg)2 3135.5±1328.1 3169.7±1254.1 65.4(0.01) 3425.3± 1421.6 3371.3±1399 17.1(0.04) 
Sodium (mg)2 3011.3±1618.4 2848.0±1224.7 -77.4(0.03) 2212.3±1032.4  2115.0±945.9 -31.2(0.06) 
Zinc (mg)2 10.7±4.7  10.8±4.2 0.2(0.004) 10.3±4.3  9.9±4.1 -0.2(0.04) 
Vitamin A (mcg)2 2582.5±1707 8525.2±5597.6 -4.8(0.01) 6563.1±4309.6 6546.9±3728 187.3(0.04) 
Vitamin C (mg)2 192.6±121.7 184.2±121.1 -4.6(0.02) 261.4±152.1 255.4±162.8 -4.0(0.01) 
Vitamin E (mg)2 2.1±1.6  2.1±1.5 -0.03(0.03) 17.1±10.2 15.3±8.5 -1.0(0.09) 
Vitamin D (mcg)2 4.9±3.6  5.6±3.6 0.4(-0.09) 36.9±62.6 40.8±75.3 0.2(-0.03) 
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Table 1 (Continued) 
 
 
1. Data presented as Mean±Standard Deviation; 2. p<0.05; 3. FFQ estimated at 12-18 weeks of gestational age; 4. FFQ estimated at 
32-34 weeks of gestational age; 5. Change=FFQ2-FFQ1; 6. Data presented as median in change from FFQ1 to FFQ3 (median in 
standardized Z score of change from FFQ1 to FFQ3)  
 
Canada Mexico  
Dietary Intake  FFQ11,3 FFQ21, 4 Change5,6 FFQ11,3 FFQ21, 4 Change5,6 
Vitamin B6 (mg)2 2.1±1.0  2.2±1.0 0.1(-0.02) 2.5±1.4 2.4±1.3 -0.005(0.06) 
Vitamin B12 (mcg)2 4.4±2.5 4.7±2.5 0.2(-0.03) 5.8±4.8 6.2±4.7 0.37(-0.004) 
Folate (mcg)2 342.0±158.0 328.9±150.1 -9.5(0.004) 582.3±312.6 549.7±285.0 -18.8(0.06) 
Thiamine (mg)2 1.5±0.6  1.5±0.6 0(0.001) 1.7±1.0  1.6±0.9 -0.03(0.06) 
Riboflavin (mg)2 1.9±0.8  2.1±0.8 0.08(-0.005) 2.2±1.32 2.2±1.2 0.01(0.01) 
Niacin (mg)2 18.2±8.0 17.9±7.0 -0.07(0.03) 22.7±12.8 21.1±11.1 -0.9(0.06) 
Pantotenic acid (mg)2 5.2±2.2 5.3±2.1 0.16(-0.01) 5.5±2.4 5.5±2.3 0.1(0.02) 
Saturated fatty acid (g)2 24.9±12.0 25.8±11.0 1.07(-0.03) 31.8±18.1 32.1±18.5 0.08(-0.03) 
Monounsaturated fatty 
acid (g) 
28.7±12.6 29.0±11.8 0.72(0.004) 28.3±14.6 25.7±11.8 -2.2(0.02) 
Polyunsaturated fatty 
acid (g)2 
13.4±6.9 12.9±6.2 -0.17(0.02) 28.3±18.0 24.6±14.8 -2.2(0.10) 
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Table 2.  Socio-demographic and clinical characteristics of total cohort, women with hypertensive disorders, and women with 
normal blood pressure in Canada and Mexico1 
 Canada Mexico 
 
Characteristic 
Total   
N=1537 
Normal BP
N=1253 
GH 
N=284 
PE 
N=68 
Total   
N=799 
Normal BP
N=585 
GH 
N=214 
PE 
N=68 
Maternal age (yrs) 30.0 (5.2) 29 (5.1) 30.0 (5.2) 31.0 (5.2) 26.0 (5.2) 25.6 (5.0) 27.2 (5.9)2 27.1 (4.8) 
Maternal education (yrs) 15.9 (3.0) 16.0 (3.1) 15.6 (2.7) 15.3 (2.6) 11.8 (2.8) 11.9 (2.8) 11.5 (3.0) 11.6 (2.7) 
Maternal pre-pregnancy 
BMI 
25.5 (6.3) 24.8 (5.8) 28.9 (7.4)2 28.8 (7.3)2 25.3 (4.8) 24.5 (4.1) 28.2 (5.6)2 27.5 (6.0)2 
Ethnic origin          
        Caucasian 1315 (85.7) 1071 (85.6) 244 (85.9) 57 (83.8) 0 0 0 0 
        Hispanic 20 (1.3) 15 (1.2) 5 (1.8) 2 (2.9) 796 (99.6) 583 (99.7) 213 (99.5) 68 
       Other  200 (13.0) 165 (13.2) 35 (12.3) 9 (13.2) 3 (0.4) 2 (0.3) 1 (0.5) 0 
Marital status         
  Married/common law 1417 (93.0) 1154 (93.0) 263 (93.3) 61 (89.7) 618 (77.4) 442 (75.6) 176 (82.6) 57 (83.8) 
   Single 106 (7.0) 87 (7.0) 19 (6.7) 7 (10.3) 181 (22.6) 143 (24.4) 37 (17.4)2 11 (16.2) 
Employed 1270 (82.7) 1029 (82.2) 241 (84.9) 56 (82.4) 511 (64.0) 383 (65.5) 128 (60.1) 44 (64.7) 
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Table 2 (continued)  
 Canada Mexico 
 
Characteristic 
Total   
N=1537 
Normal BP
N=1253 
GH 
N=284 
PE 
N=68 
Total   
N=799 
Normal BP
N=585 
GH 
N=214 
PE 
N=68 
Annual household 
income  
        
    <20000 62 (4.6) 53 (4.8) 9 (3.6) 4 (6.2) 195 (26.9) 141 (26.7) 54 (27.6) 20 (31.3) 
    20-34999 123 (9.1） 100 (9.2) 23 (9.1) 8 (12.3) 317 (43.8) 235 (44.5) 82 (41.8) 23 (35.9) 
   35-49999 167 (12.4） 129 (11.8) 38 (15.1) 12 (18.5) 121 (16.7) 89 (16.9) 32 (16.3) 9 (14.1) 
   50-74999 335 (24.9) 271 (24.8) 64 (25.4) 16 (24.6) 46 (6.4) 31 (5.9) 15 (7.7) 6 (9.4) 
   >75000 658 (49.0) 540 (49.4) 118 (46.8) 25 (38.5) 45(6.2) 32 (6.1) 13 (6.6) 6 (9.4) 
Smoking before 
pregnancy 
367 (24.0) 303 (24.2) 64 (22.5) 13 (19.1) 297 (37.2) 222 (38.0) 75 (35.2) 21 (30.9) 
Current smoker 149 (9.8) 126 (10.1) 23 (8.2) 7 (10.3) 13 (1.6) 8 (1.4) 5 (2.4) 2 (3.0) 
Current drinker 32 (2.1) 28 (2.2) 4 (1.4) 1 (1.5) 4 (0.5) 2 (0.3) 2 (0.9) 2 (2.9) 
Gestational age (wks) 15.1 (2.1) 15.2 (2.1) 15.0 (2.1) 15.1 (2.0) 15.4 (2.1) 15.3 (2.1) 15.7 (2.1) 15.5 (2.0) 
Nulliparous  1227 (79.8) 1036 (82.7) 191 (67.3)2 36 (52.9)2 644 (80.6) 500 (85.2) 146 (68.2) 45 (66.2) 
Baseline systolic BP 113.1 (12.8) 111.0 (11.9) 122.2 (12.0)2 123.3 (13.4)2 101.3 (10.6) 99.4 (9.9) 106.4 (10.7)2 107.1 (11.6)2 
Baseline diastolic BP 68.5 (9.2) 67.0 (8.5) 75.1 (9.3)2 75.0 (8.7)2 65.2 (8.4) 63.9 (8.1) 69.0 (7.8)2 68.9 (8.8)2 
Family history of PE or 
GH 
172 (11.2) 115 (9.2) 57 (20.1)2 14 (20.6)2 122 (15.3) 88 (15.0) 34 (15.9) 10 (14.7) 
1. Data presented as mean (SD) or N(%)   
2. P<0.05 
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Table 3. Treatment allocation, risk status at trial entry, and vitamins or mineral supplementation of total cohort, women with 
hypertensive disorders, and women with normal blood pressure 1 
 Canada Mexico 
 
Characteristic 
Total   
N=1537 
Normal BP
N=1253 
GH 
N=284 
PE 
N=68 
Total   
N=799 
Normal BP
N=585 
GH 
N=214 
PE 
N=68 
Treatment         
  Antioxidant group 762 (49.6) 616 (49.2) 146 (51.4) 33 (48.5) 394 (49.3) 288 (49.2) 106 (49.5) 35 (51.5) 
  Placebo group 775 (50.4) 637(50.8) 138 (48.6) 35 (51.5) 405 (50.7) 297 (50.8) 108 (50.5) 33 (48.5) 
High risk group (stratum) 489 (31.8) 346 (27.6) 143 (50.4)2 47 (69.1)2 185 (23.2) 97 (16.6) 88 (41.2)2 31 (45.6)2 
     Chronic hypertension 97 (6.3) 44 (3.5) 53 (18.7)2 15 (22.1)2 47 (5.9) 18 (3.1) 29 (13.6)2 11 (16.2)2 
     Diabetes 132 (8.6) 100 (8.0) 32 (11.3) 13 (19.1)2 26 (3.3) 15 (2.6) 11 (5.1) 4 (5.9) 
     Multiple pregnancy 144 (9.4) 122 (9.7) 22 (7.8) 8 (11.8) 13 (1.6) 7 (1.2) 6 (2.8) 2 (3.0) 
     History of PE 181 (11.8) 114 (9.1) 67 (24.0)2 24 (35.3)2 110 (13.8) 64 (10.9) 46 (21.5)2 16 (23.5)2 
     Multiple risk factors 59 (3.8) 31 (2.5) 28 (9.9)2 10 (14.7)2 11 (1.4) 7 (1.2) 4 (1.9) 2 (2.9) 
 
 1. Data presented as mean (SD) or N (%);  
` 2. P<0.05  
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Table 3 (continued) 1 
 
 Canada Mexico 
 
Characteristic 
Total   
N=1537 
Normal BP
N=1253 
GH 
N=284 
PE 
N=68 
Total   
N=799 
Normal BP
N=585 
GH 
N=214 
PE 
N=68 
Use of vitamin or mineral 
supplements  
1458 (95.1) 1188 (95.0) 270 (95.4) 65 (95.6) 708 (88.6) 519 (88.7) 189 (88.3) 60 (88.2) 
     Multivitamin  1280 (83.7) 1052 (84.4) 228 (80.6) 52 (76.5) 166 (20.8) 128 (21.9) 38 (17.8) 13 (19.1) 
     Vitamin C 22 (1.4) 22 (1.8) 02 02 7 (0.9) 4 (0.7) 3 (1.4) 2 (2.9) 
     Vitamin E 2 (0.1) 2 (0.2) 02 02 1 (0.1) 1 (0.2) 0 0 
     Folate 468 (30.6) 370 (29.7) 98 (34.6) 29 (42.7)2 574 (71.8) 420 (71.8) 154 (72.0) 49 (72.1) 
     Calcium 249 (16.3) 185 (14.8) 64 (22.6)2 14 (20.6) 77 (9.6) 54 (9.2) 23 (10.8) 9 (13.2) 
     Iron 57 (3.7) 47 (3.8) 9 (3.2) 2 (2.9) 484 (60.7) 343 (58.6) 141 (66.2) 42 (61.8) 
    Vitamin A 1 (0.1) 1  0 0 1 (0.1) 1 (0.2) 0 0 
Other supplement  90 (5.9) 74 (6.0) 16 (5.7) 4 (5.9) 50 (6.3) 35 (6.0) 15 (7.0) 6 (8.8) 
 
 
 1. Data presented as mean (SD) or N (%);  
` 2. P<0.05  
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Table 4. Unadjusted Odds ratios of dietary nutrients intake (lowest quartile vs other quartiles, 12-18 weeks of gestational age) 
in association with preeclampsia (PE) and gestational hypertension (GH) in Canadian and Mexican pregnancy cohorts  
 Canada Mexico 
Characteristic PE GH PE GH 
Protein   0.78(0.43-1.43) 0.73(0.53-1.00)1 1.24(0.72-2.14) 0.94 (0.65-1.36) 
Lipoprotein 0.76(0.42-1.38) 1.12(0.84-1.50) 1.29(0.75-2.22) 0.91 (0.64-1.31) 
Carbohydrate 1.01(0.58-1.77) 1.08(0.81-1.45) 0.57(0.29-1.12)2 0.93 (0.65-1.34) 
Fiber 1.44(0.86-1.77) 0.96(0.71-1.30) 1.44(0.84-2.48) 1.08 (0.75-1.56) 
Total cholesterol   0.91(0.51-1.61) 0.86(0.63-1.16) 1.21(0.70-2.10) 1.02 (0.71-1.46) 
Saturated fatty acids 0.93(0.52-1.64) 0.88(0.65-1.19) 1.18(0.68-2.04) 0.92 (0.64-1.32) 
Pantothenic acid   1.45(0.86-2.44) 0.99(0.73-1.33) 1.09(0.62-1.89) 1.05 (0.73-1.50) 
Monounsaturated fatty acid 0.99(0.56-1.73) 0.98(0.73-1.33) 1.42(0.83-2.43) 0.80 (0.55-1.16) 
Polyunsaturated fatty acid  0.99(0.57-1.74) 1.38(1.04-1.83)1 0.96(0.54-1.71) 1.12 (0.78-1.59) 
Calcium 1.47(0.87-2.47)2 0.98(0.73-1.32) 0.56(0.29-1.09)2 0.93 (0.65-1.35) 
Iron 1.25(0.73-2.13) 1.24(0.93-1.65) 1.16(0.66-2.05) 1.18 (0.82-1.69) 
Magnesium 2.16(1.32-3.56)1 1.11(0.83-1.48)  0.56(0.29-1.09)2 0.90 (0.62-1.31) 
 
  1. p<0.05 
2. p<0.15 
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Table 4. (Continued) 
 
 Canada Mexico 
Characteristic PE GH PE GH 
Potassium  2.48(1.51-4.05)1 1.02(0.76-1.37) 1.19(0.69-2.05) 1.05 (0.73-1.51) 
Sodium   0.91(0.52-1.62) 1.09(0.81-1.46) 1.40(0.81-2.41) 1.10 (0.77-1.57) 
Zinc  1.60 (0.96-2.69)2 1.00(0.74-1.35) 0.91(0.51-1.63) 0.93 (0.64-1.34) 
Vitamin A 2.00(1.21-3.29)1 1.06(0.79-1.43) 0.57(0.29-1.11)2 0.89 (0.62-1.29) 
Vitamin C  1.93(1.17-3.20)1 1.03(0.77-1.39) 1.10(0.63-1.94) 1.09 (0.76-1.56) 
Vitamin E 1.48(0.88-2.49)2 1.06(0.79-1.43) 1.33(0.77-2.28) 1.13 (0.79-1.61) 
Vitamin D  1.07 (0.58-1.78) 1.00(0.74-1.34) 1.39(0.81-2.39) 0.93 (0.65-1.34) 
Vitamin B6  1.47(0.87-2.47)2 0.85(0.63-1.16) 1.03(0.58-1.83) 1.08 (0.76-1.56) 
Vitamin B12  1.38(0.81-2.33) 0.86(0.63-1.17) 1.14(0.66-1.99) 0.58 (0.39-0.86)1 
Folate  1.95(1.18-3.22)1 1.25(0.93-1.66)2 0.74(0.39-1.38) 1.10 (0.77-1.59) 
Thiamine  1.18(0.69-2.03) 0.92(0.68-1.24) 1.19 (0.68-2.07) 1.13 (0.79-1.62) 
Riboflavin  1.28(0.75-2.18) 0.90(0.67-1.22) 0.88 (0.49-1.57) 1.14 (0.79-1.64) 
Niacin  1.08(0.62-1.88) 0.93(0.69-1.26) 0.96 (0.54-1.73) 1.06 (0.73-1.52) 
 
  1. p<0.05 
2. p<0.15 
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Abstract 
Objective: To investigate the levels of maternal plasma concentrations of 
vitamin E (α- and γ-tocopherol) during pregnancy in relation to the risk of 
preeclampsia (PE).  
Design: A nested case control study using the pregnancy cohort from a trial of 
antioxidant supplementation for the prevention of PE. Vitamin E concentrations 
were measured longitudinally at 12-18 weeks (prior to supplementation), 24-26 
weeks, and 32-34 weeks of gestation using high-performance liquid 
chromatography (HPLC) with coulometric electrochemical detection. A total of 
115 women with PE and 229 matched controls were included. 
Result: After multivariate adjustment, we observed a direct association between 
the baseline γ-tocopherol concentrations, when examined as a continuous 
variable, and the risk of PE (OR 1.35, 95%CI 1.02-1.78). Analyses of repeated 
measurements indicated that elevated γ-tocopherols were associated with an 
increased risk of PE when examined as categorical variables [highest vs. lowest 
quartile at 24-26 weeks: OR 2.99 (95% CI 1.13-7.89); at 32-34 weeks: 4.37 
(1.35-14.15)]. We found no associations between α-tocopherol concentration 
and the risk of PE.  
Conclusion: The present study found that higher γ-tocopherol concentrations 
during pregnancy were associated with a greater risk of PE, contradicting the 
presumed protective effects of γ-tocopherol in some studies.  
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Introduction  
Preeclampsia (PE), a syndrome unique to human pregnancy, remains a 
significant cause of maternal and perinatal morbidity and mortality.[1-6] The 
etiology of PE is multifactorial and has not been clearly defined. It has been 
proposed that the pathophysiology involves a combination of immunologic, 
environmental, and genetic factors that result in shallow endovascular 
cytotrophoblast invasion and impaired remodelling of spiral arteries. These in 
turn cause a reduction in uteroplacental perfusion pressure and placenta 
ischemia/hypoxia. [7-9] Placental hypoxia then stimulates the activity of 
xanthine or nicotinamide adenine dinucleotide phosphate-oxidase (NAD(P)H ) in 
placenta, which leads to superoxide generation, and contributes to maternal 
endothelial cell activation, enhanced apoptosis of trophoblast, and an increased 
inflammatory response.[7-9] All of these are believed to eventually leading to 
endothelial and vascular dysfunction associated with PE.  
Vitamin E is a lipid soluble antioxidant of dietary origin. Its antioxidant 
property has been ascribed to its ability to chemically act as a lipid-based free 
radical chain-breaking molecule, thereby inhibiting lipid peroxidation and 
oxLDL formation.[10] Of the 8 isomers of vitamin E that occur naturally, α-
tocopherol is the most abundant in plasma, cell membranes and other human 
tissues. It is the major isomer in micronutrient supplements which have been 
examined in clinical trials, whereas γ-tocopherol is the primary form of the 
nutrient in the human diet. Recently, several clinical trials have been conducted 
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to assess the potential benefits of antioxidant supplementation in the reduction of 
adverse pregnancy outcomes including PE.[11-17] With the exception of the first 
small trial by Chappell et al, [11] the results of other clinical trials found no 
effect of vitamins E and C supplementation on the prevention of PE. However, 
concerns have been raised concerning the potential harmful effects of 
supplementation with these nutrients associated with the increased risk of low 
birth weight, small for gestational age and preterm premature ruptures of 
membranes.[12, 14, 17, 18] Previous studies suggested that α-tocopherol may 
present pro-oxidant propensity depending on oxidative conditions and presence 
of other co-antioxidants.[19, 20] It has been proposed that high doses of α-
tocopherol could deplete plasma and tissue γ-tocopherol which is considered an 
important antioxidant, and hence may actually increase oxidation.[21-24] 
However, there is a lack of information on longitudinal measures of plasma 
concentrations of α-and γ-tocopherols in relation to the risk of PE. We carried 
out a longitudinal analysis of plasma concentrations of α- and γ-tocopherols (at 
12-18, 24-26, and 32-34 weeks of gestational age) in association with the risk of 
PE.[17]  
Methods 
Study design and population  
This is a case control study ancillary to a randomized, placebo-controlled 
trial of antioxidants supplementation (vitamins C and E) for the prevention of PE, 
which was conducted in Canada (17 centers) and Mexico (10 centers) between 
January 2004 and March 2006. The design and methods of the trial have been 
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described in details elsewhere. [17] Briefly, women at 12-18 completed weeks of 
gestation were randomly assigned either to antioxidant treatment (1 g vitamin C 
and 400 IU vitamin E daily) or placebo group. Randomization was stratified by 
center and by risk status according to pre-specified clinical risk criteria. Women 
were at high risk if they were nulliparous or multiparous with pre-pregnancy 
chronic hypertension (diastolic blood pressure > 90 mmHg before 20 gestational 
weeks or use of antihypertensive medication for hypertension), pre-pregnancy 
diabetes, multiple pregnancy, or a history of PE in the previous pregnancy. 
Women were stratified into the low risk stratum if they were nulliparous without 
any identified clinical risk factors.Women and their infants received care 
according to standard practice in each center, with surveillance for hypertension 
using standardized measurements of blood pressure. Women were excluded from 
the trial if they were taking a multivitamin preparation at a daily dose of > 200 
mg vitamin C or >50 IU vitamin E at the time of enrollment.  
The cases of PE were defined as gestational hypertension (de novo 
hypertension occurring at ≥20 weeks of gestation) with proteinuria.[25, 26] 
Proteinuria was defined as the urinary excretion of ≥0.3g in 24-hours urine 
collection, or ≥2+ on urine dipstick test. For women with pre-existing 
hypertension, PE was diagnosed on the basis of new or worsening proteinuria as 
defined above. For women with pre-existing proteinuria (e.g. diabetes with renal 
involvement), the diagnosis of PE was made on clinical or biochemical grounds 
by identifying at least one additional adverse condition (e.g. abnormal liver 
enzymes, low platelets and eclampsia). [25, 26] All cases of PE were adjudicated 
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by two independent investigators in the Trial Coordinating Centre. In the case of 
disagreement, a third independent investigator was consulted. A total of 115 PE 
cases (63 in Canada and 52 in Mexico) with baseline plasma samples available 
were identified. Normotensive controls were randomly selected at a ratio of 2:1 
by matching for country (Canada, Mexico), maternal age (within 3 years), parity 
(primiparous: yes/no), and multiple pregnancy (yes/no). A total of 229 controls 
were selected as only one eligible control could be identified for a Mexican case.  
 
Specimen collection and tocopherols assays 
Blood specimens were collected prior to randomization (12+0-18+6 weeks of 
gestation), at 24-26 weeks of gestation, at 32-34 weeks of gestation and after 
delivery. Venous blood was drawn into EDTA tubes and plasma samples were 
immediately separated by centrifugation at 500 g for 10 minutes at 4°C. Plasma 
samples were rapidly frozen at -80°C for analyses. Simultaneous monitoring of 
ubiquinols-9 and -10 was carried out using High-Performance Liquid 
Chromatography (HPLC) with coulometric electrochemical detection. Plasma 
samples were extracted using a method adapted from Menke et al.[27] The 
HPLC protocol has been described in details elsewhere.[28, 29] Briefly, after the 
addition of internal standards (4 ng of γ-tocotrienol and 5 ng of ubiquinol-9) for 
post-HPLC quantification purpose, 300 μL plasma sample was thawed at 4°C in 
the dark and processed immediately by addition of 2 ml of methanol/ethanol (1:1 
mixture) and vigorous shaking, then followed by addition of 10 ml of hexane. 
The solvent was evaporated under a nitrogen stream, and the dry sample was re-
dissolved in 700 μL of ethanol and injected (10 μL) in a Gold HPLC system 
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(Beckman Coulter Canada, Mississauga, Canada) with an autosampler connected 
to a Prontosil column (4.0 mm X 150 mm, 3 μm particle size; Bischoff 
Chromatography, Atlanta, GA). The HPLC mobile phase contained sonicated 
methanol/ethanol/isopropanol (88/24/10 v/v/v) and 15 mmol of lithium 
perchlorate at a flow of 1mL/min. The α- and γ- tocopherols were detected by 
the coulometric electrochemical detector (Coulochem III, ESA, Bedford, MA). 
The concentrations of lipophilic antioxidants were determined by use of 
calibration standard curves. No oxidation of the ubiquinol-9 standard was 
detected after plasma extraction and HPLC analysis.  
Statistical analysis  
Maternal characteristics in cases and controls were compared using Chi-
square test, Fisher exact test or Student’s t test where appropriate. To evaluate 
the differences in continuous variables (i.e. plasma tocopherols) between cases 
and controls, Student's t-test was used if the distribution was normal, and 
Wilcoxon test was applied if the distribution was skewed. Chi-square or Fisher 
exact tests were used to compare the differences in categorical variables. Plasma 
concentrations of tocopherols were examined as both continuous variables- 
standardized Z-scores - and as categorical variables by quartiles. Odds ratios and 
95% confidence intervals were estimated from logistic regression to quantify the 
associations between plasma concentrations of tocopherols and the risk of PE.  
The Mantel extension test was used to assess linear trends in the levels of 
plasma tocopherols and the risk of PE. Multivariate conditional logistic 
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regression was used to assess the independent effects of plasma concentrations 
of tocopherols on the risk of PE. A covariate was retained in the model if it 
changed the estimates by >10%. Interactions were assessed by evaluating 
stratum-specific ORs, and including multiplicative interaction terms in the 
multivariable models, and assessing their statistical significance using likelihood 
ratio statistics.  
We estimated the associations between baseline plasma concentrations of 
tocopherols and the risk of PE. Intervention status may significantly change the 
post-baseline measurements of vitamin E concentrations and therefore may have 
influenced the risk of PE. For this reason, analyses were conducted in the total 
study population as well as in the treatment and placebo groups separately. 
Analyses were repeated for plasma concentrations of tocopherols at visit 2: 24-
26 weeks, visit 3: 32-34 weeks of gestation, as well as the mean of three 
measurements at three gestational age windows. We also evaluated the patterns 
of changes in the plasma concentrations across gestational age and their effects 
on the risk of PE. All analyses were performed using SAS software, version 9.2 
(SAS Institute, Cary, NC).  
Results  
There were no differences between cases and controls in years of schooling, 
annual household income, and family history of PE or GH, periconceptional 
vitamin or mineral supplementation, lifestyle factors (i.e. smoking or drinking) 
or ethnic origin (Table 1). However, cases tended to have higher pre-pregnancy 
body mass index (BMI), and higher mean systolic and diastolic blood pressure at 
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trial entry compared to normotensive controls. The proportion of patients with 
pre-existing chronic hypertension or history of PE was significantly higher in 
cases than in controls.  
There were no significant differences in plasma concentrations of total 
tocopherols (α- plus γ-) and α-tocopherol between cases and controls across all 
the three gestational age windows (table 2). However, the plasma concentrations 
of γ-tocopherol as well as the ratios of γ-/α-tocopherol were significantly higher 
in women with PE compared to normotensive controls throughout the three 
gestational age periods. There were progressive and significant increases in total 
plasma vitamin tocopherols and α-tocopherols from baseline (12-18 weeks) to 
visit 3 (32-34 weeks) in both cases and controls, while no such significant 
changes were observed for γ-tocopherol.  
Table 3 displays the plasma concentrations of tocopherols for cases and 
controls stratified by intervention status, e.g. vitamin supplementation versus 
placebo. Regardless of the intervention or case control status, plasma levels of α-
tocopherol increased significantly from baseline visit 1 at 12-18 weeks to visit 3 
at 32-34 weeks of gestational age. It is interesting to note that a significant 
decrease in plasma concentrations of γ-tocopherol was found in women in the 
supplementation group. In contrast, for women in the placebo group, plasma 
concentrations of γ-tocopherol increased. Ratios of γ-/ α-tocopherol showed no 
significant changes across gestational age in the placebo group, but were 
significantly decreased in the supplementation group.  
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After adjustment for smoking, the presence of pre-selected clinical risk 
factors (i.e. chronic hypertension, history of preeclampsia, diabetes), regular 
prenatal use of vitamins or mineral supplementation, intervention status, 
gestational age and baseline BMI, we found no associations between the quartile 
distributions of α-and γ-tocopherols at trial entry and the risk of PE. However, 
when examined as a continuous variable, after adjusting for the same covariates, 
baseline plasma concentration of γ-tocopherol (standardized as Z-score) showed 
a significant positive linear relationship to the risk of PE (adjusted odds ratio 
1.35, 95%CI 1.02-1.78). (Table 4) 
 Concentrations of α-tocopherol at all the three gestational age windows 
were not associated with the risk of PE. (Table 4, 5) Compared to the reference 
lowest quartile, the highest quartile of the average of all three measurements of 
γ-tocopherol was associated with a significant increased risk of PE (adjusted OR 
4.02; 95% CI 1.63-9.93). The multivariate analyses indicated that the highest 
quartiles of γ-tocopherol measured at both 24-46 weeks and 32-34 weeks of 
gestation were associated with an increased risk of PE (highest vs. lowest 
quartiles at 24-26 weeks: adjusted OR 2.99, 95%CI 1.13-7.89; at 32-34 weeks: 
adjusted OR 4.37; 95%CI 1.35-14.15). When γ-tocopherol levels were examined 
as a continuous variable, elevated plasma concentrations of γ-tocopherol (z-score) 
were significantly associated with an increased risk for PE (average 
measurement: adjusted OR 1.47, 95% CI 1.11-1.95; at 24-26 weeks: adjusted 
1.69, 95% CI 1.14-2.51; at 32-34 weeks: adjusted OR 1.94, 95%CI 1.23-3.06).  
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We also observed positive associations between the incremental changes 
across gestation (from baseline to visit 2 and visit 3) in plasma γ-tocopherol 
concentrations and the risk of PE (from baseline to visit 2: adjusted OR 1.62, 
95%CI 1.06-2.46; from baseline to visit 3: adjusted OR 2.02, 95%CI 1.24-3.31). 
The result is consistent with the finding that plasma concentration of γ-
tocopherol at visit 3 has the strongest association with PE risk.    
Discussion  
The principal findings are: 1) no association between α-tocopherol levels in 
pregnancy and the risk of PE; 2) high plasma γ-tocopherol level was associated 
with an increased risk of PE; 3) plasma concentrations of α-tocopherol increased 
progressively across gestational age regardless of the treatment; 4) plasma γ-
tocopherol concentrations decreased during pregnancy in the supplemented 
group but increased in the placebo group.    
All previous studies of the association of serum or plasma concentrations of 
tocopherols with PE risk used a single measurement only (mostly at baseline) 
and have shown mixed results.[30-35] Several studies have reported that, 
compared to normotensive controls, preeclamptic women had lower α-
tocopherol concentrations.[31, 33, 35, 36] Other investigators, however, have 
suggested that women with PE have higher mean α-tocopherol levels compared 
to normotensive controls.[30, 37, 38] Some studies also report no association 
between α-tocopherol and the PE risk.[39-41] The variability in results across 
studies may be explained by differences in study design, population 
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characteristics (e.g. ethnicity, dietary habits, use of prenatal multivitamin 
supplements, smoking, etc.), technical differences in assay protocols, and 
statistical power. We found no association between α-tocopherol and the risk of 
PE. These results are consistent with the results of our and other reported clinical 
trials. [12, 14, 16-18] The observed progressive increase in both α- and γ-
tocopherols across gestational ages, in particular in the placebo group, could 
perhaps reflect a natural compensatory mechanism against oxidative stress in 
human pregnancy or that women could have taken undocumented micronutrient 
supplements during pregnancy in anticipation of potential benefits, despite 
reports to the contrary. Our study confirmed the reduction of γ-tocopherol after 
oral supplementation of α-tocopherol in pregnancy women, which has been 
consistently reported in previous studies.[42, 43]    
Compared to the α-tocopherol form of the vitamin, γ-tocopherol has received 
less attention although it is estimated that approximately 70% of the food source 
vitamin E intake in the American diet is in the form of γ-tocopherol. This is due 
to the high intake in the American diet of soybean and other vegetable oils rich in 
γ-tocopherol, such as canola oil.[44] It has been suggested that γ-tocopherol 
could be a more potent antioxidant than α-tocopherol [45] as it has been shown 
that γ-tocopherol supplementation alone or in combination with α-tocopherol 
significantly reduces biomarkers of oxidative stress and inflammation.[45] To 
our knowledge, unlike α-tocopherol which is the major form of nutritional 
supplements, no intervention studies with clinical disease endpoints have been 
conducted on γ-tocopherol. Only a few observational studies have examined the 
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relationship between γ-tocopherol and the risk of PE or gestational hypertension. 
There was no clear pattern observed between the serum or plasma concentrations 
of γ-tocopherol and the risk of PE in previous studies. [34, 37, 46]  Paradoxically, 
we found that the plasma γ-tocopherol was associated with an increased risk of 
PE at all the three gestational age windows, contradicting its presumed potential 
protective effects in some studies. There are a number of possible explanations 
for these findings. A recent study found that γ-tocopherol was associated with an 
increased risk of myocardial infarction.[47] The authors noted that dietary intake 
of γ-tocopherol is associated with the consumption of trans-fatty acids, which are 
known to promote atherosclerosis. The authors suggested that since tocopherols 
were strongly associated with lipoproteins, residual confounding by elevated 
lipids could contribute to the observed positive association despite statistical 
adjustment.[47] A study by Kabat et al. reported that, after multivariate 
adjustment, an increased risk of breast cancer was associated with elevated 
serum γ-tocopherol levels.[48] Another recent study observed an association 
between elevated plasma γ-tocopherol levels and an increased risk of 
spontaneous preterm birth, but no similar association was seen with trans-fatty 
acids.[49] Other investigators also raised questions concerning the anti-
inflammatory capacity of γ-tocopherol. [50] [51] An animal study by Berdnikovs 
et al. demonstrated the opposing function of D-γ-tocopherol compared to the D-α-
tocopherol isoforms in experimental asthma. The study reported that D-γ-
tocopherol not only elevates inflammation but also ablates the anti-inflammatory 
benefit of D-α-tocopherol isoform.[51] The authors pointed out that there was 
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little benefit of α-tocopherol for inflammation in the presence of elevated plasma 
γ-tocopherol. [51] Thus, a possible explanation for our findings is that elevated 
plasma γ-tocopherol levels could be a marker of trans fat intake which has in turn 
been shown to represent a risk factor for PE.[7] Furthermore, plasma 
concentrations of tocopherols are influenced by the plasma lipoproteins that act 
as transport molecules of the antioxidants. Unfortunately, plasma lipoprotein was 
not measured in the present study. It is also possible that there is a real 
association between γ-tocopherol and PE risk. Our data provide a relative strong 
case: the average concentration of γ-tocopherol showed a progressively stronger 
association with PE risk over advancing gestational age, as the repeated 
measurements over the follow up period may improve exposure classification 
and precision, and be an indicator of accumulated exposure in later measures.  
This study has several strengths. The disease status itself is unlikely to have 
been influenced by the measured plasma tocopherol concentrations as all 
samples were collected before disease onset. We included repeated 
measurements of plasma concentration of both α-and γ-tocopherols in multiple 
gestational age windows. The baseline, follow up measurements, and average 
measurements analyses provided a relatively complete picture of the influence of 
tocopherols on the risk of PE. The sample size is relatively large. Plasma 
concentrations of tocopherols were assayed by staff blinded to pregnancy 
outcomes.   
Potential limitations of our study include the possibility of residual 
confounding. It has been suggested that the  plasma concentrations of 
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tocopherols are influenced by plasma lipoprotein that are transport molecules of 
the antioxidant. Plasma lipoprotein was not measured and therefore was not 
adjusted in analyses.   
In summary, this is the first report indicating that elevated γ-tocopherol levels 
may be associated with an increased risk of PE. Further epidemiologic and 
intervention studies are needed to better understand the potential role of γ-
tocopherol in the etiology of PE.   
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Table 1 Socio-demographic and clinical characteristics of PE cases and normotensive controls at trial entry (12-18 weeks of 
gestational age )1 
 
PE Control     
Characteristics  N=115 N=229 P 
Maternal age (years) 29.19 (5.70) 29.00 (5.64) NS 
Maternal education (years) 13.42 (3.24) 14.05 (3.76) NS 
Maternal pre-pregnancy BMI 27.97 (6.46) 25.76 (6.57) <0.05
Maternal visit1 BMIb 30.02 (7.88) 26.87 (6.51) <0.05
Ethnic origin     
        Caucasian 52 (45.22) 105 (45.85)  
        Hispanic 53 (46.09) 104 (45.41) NS 
        Other 10 (8.70) 20 (8.73)  
Married  98 (85.22) 205 (90.31) NS 
Employed  86 (74.78) 156 (68.12) NS 
Smoking before pregnancy 29 (25.22) 61 (26.64) NS 
Current smoker 8 (6.96) 12 (5.24) NS 
Current drinker 2 (1.74) 3 (1.31) NS 
Gestational age (weeks) at trial entry 15.32 (1.97) 15.35 (2.11) NS 
Antioxidant treatment  58 (50.43) 117 (51.09) NS 
High risk group (stratum) 67 (58.26) 102 (44.54) <0.05
Mean systolic BP at trial entry 116.0 (14.66) 108.5 (13.63) <0.05
Mean diastolic BP at trial entry 72.20 (8.91) 67.31 (9.17) <0.05
Family history of GH, PE 20 (17.39) 30 (13.10) NS 
Prenatal vitamin or mineral supplementation 105 (91.30) 207 (90.39) NS 
1. Data presented as Mean (SD) or N (%) 
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Table 2. Plasma concentrations of antioxidant vitamins among preeclamptic women and normotensive controls1 
 
   V1 (12- 18 weeks) 4 V2 (24-26 weeks)5 V3 (32-34 weeks)6 P3  P3  
 Characteristics Group N=344  N=308  N=275  (1 vs 2) (1 vs 3)
Total tocopherols Case  31.66±9.51(29.63) 43.19±13.68(40.50) 47.90±16.26(45.34) <0.05 <0.05 
 Control 30.81±10.20(29.39) 43.98±16.08(41.44) 49.12±17.72(46.61) <0.05 <0.05 
 P2 NS NS NS   
α-tocopherol Case  28.84±8.99(26.82) 40.34±13.61(38.55) 44.79±15.97(41.84) <0.05 <0.05 
 Control 28.40±9.52(27.05) 41.91±16.19(38.47) 46.72±17.83(43.54) <0.05 <0.05 
 P2 NS NS NS   
γ-tocopherol Case  2.83±1.52(2.29) 2.85±2.43(2.19) 3.10±2.35(2.60) NS NS 
 Control 2.40±1.22(2.13) 2.07±1.30(1.74) 2.40±1.49(2.03) <0.05 NS 
 P2 <0.05 <0.05 <0.05   
γ-/α-tocopherol Case  0.10±0.06(0.09) 0.08±0.06(0.07) 0.08±0.05(0.07) <0.05 <0.05 
 Control 0.09±0.03(0.08) 0.06±0.04(0.05) 0.06±0.04(0.05) <0.05 <0.05 
 P2 <0.05 <0.05 <0.05   
 
1. Data present as mean±SD (median); 2. Wilcoxon-Mann Whitney test; 3. Wilcoxon signed ranks test  
4.  115 cases and 229 controls; 5. 100 cases and 208 controls;  6. 88 cases and 187 controls 
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Table 3. Plasma concentrations of antioxidant vitamins among preeclamptic women and normtensive controls stratified by 
treatment group1 
  V1 (12- 18 weeks)4 V2 (24-26 weeks)5 V3 (32-34 weeks)6 P3  P3  
 Characteristics Group N=344  N=308 N=275  (1 vs 2) (1 vs 3) 
Total tocopherols       
Supplemented Case 31.48±10.07(29.24) 47.54±15.25(45.79) 51.58±18.28(49.47) <0.05 <0.05 
 Control 30.62±10.38(28.53) 50.51±17.24(49.55) 56.75±18.30(55.48) <0.05 <0.05 
 p2 NS NS <0.05   
Placebo  Case 31.85±8.99(29.89) 39.01±10.51(36.98) 44.53±13.50(45.07) <0.05 <0.05 
 Control 31.00±10.06(29.81) 37.20±11.39(36.09) 41.57±13.46(41.19) <0.05 <0.05 
 p2 NS NS NS   
α-tocopherol       
Supplemented Case 28.75±9.51(27.50) 45.35±15.59(44.20) 49.12±18.44(45.67) <0.05 <0.05 
 Control 28.25±9.68(26.72) 49.02±17.27(48.08) 55.13±18.32(54.32) <0.05 <0.05 
 P2 NS NS <0.05   
Placebo  Case 28.92±8.51(26.67) 35.33±9.01(34.15) 40.84±12.25(40.17) <0.05 <0.05 
 Control 28.56±9.39(27.59) 34.52±10.91(33.54) 38.40±12.76(37.82) <0.05 <0.05 
 P2 NS NS NS   
 
1. Data present as mean±SD (median); 2. Wilcoxon-Mann Whitney test; 3. Wilcoxon signed ranks test ; 4. 115 cases and 229 controls;  
5. 100 cases and 208 controls; 6. 88 cases and 187 controls 
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Table 3. (Continued) 1 
 
 
  V1 (12- 18 weeks)4 V2 (24-26 weeks)5 V3 (32-34 weeks)6 P3  P3  
 Characteristics Group N=344  N=308 N=275  (1 vs 2) (1 vs 3) 
γ-tocopherol       
Supplemented Case 2.73±1.47(2.26) 1.99±1.87(1.41) 2.45±2.39(1.65) <0.05 <0.05 
 Control 2.37±1.16(2.08) 1.49±1.13(1.16) 1.61±1.18(1.34) <0.05 <0.05 
 P2 NS NS NS   
Placebo  Case 2.93±1.58(2.46) 3.68±2.63(3.04) 3.69±2.17(3.09) <0.05 <0.05 
 Control 2.44±1.29(2.23) 2.68±1.19(2.46) 3.17±1.35(2.94) <0.05 <0.05 
 P2 NS <0.05 NS   
1. Data present as mean±SD (median); 2. Wilcoxon-Mann Whitney test; 3. Wilcoxon signed ranks test ; 4. 115 cases and 229 controls;  
5. 100 cases and 208 controls; 6. 88 cases and 187 controls 
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Table 4. Baseline plasma concentrations of tocopherols in relation to the 
risk of preeclampsia 1,2,3 
 
Baseline analyte  COR (95%CI) AOR(95%CI) 
Total tocopherols   
Q1 1.00 1.00 
Q2  1.30(0.67-2.52) 1.60(0.78-3.27) 
Q3  1.13(0.54-2.37) 1.17(0.54-2.53) 
Q4  1.45(0.65-3.23) 1.34(0.58-3.08) 
 P trend NS NS 
 Z-score 1.11(0.85-1.46) 1.11 (0.83-1.49) 
α-tocopherol   
Q1 1.00 1.00 
Q2 0.96(0.50-1.83) 1.07(0.54-2.11) 
Q3 0.90(0.44-1.85) 1.01(0.48-2.14) 
Q4 1.06(0.49-2.32) 1.00(0.44-2.24) 
 P trend NS NS 
 Z-score  1.05(0.81-1.37) 1.06 (0.79-1.42) 
γ-tocopherol   
Q1 1.00 1.00 
Q2 1.34(0.65-2.76) 1.24(0.58-2.64) 
Q3 1.02(0.49-2.11) 1.00(0.46-2.10) 
Q4 2.00(0.95-4.23) 1.63(0.75-3.57) 
 P trend <0.05 <0.05 
 Z-score  1.48 (1.13-1.92)4 1.35(1.02-1.78)4 
γ-/α-tocopherol ratio - - 
Q1 1.00 1.00 
Q2 1.10(0.58-2.09) 1.08(0.56-2.10) 
Q3 0.80(0.41-1.59) 0.80(0.39-1.67) 
Q4 1.88(0.94-3.76) 1.49(0.71-3.10) 
 P trend <0.05 <0.05 
Z-score  1.52 (1.16-2.00)4 1.43(1.08-1.90)4 
 
1. COR: Crude odds ratio; 2. AOR: Adjusted odds ratio;  
3. Adjusted variables: smoking, the presence of pre-selected clinical risk condition 
(i.e. chronic hypertension, history of preeclampsia, diabetes), prenatal regular using 
of vitamins or mineral supplementation, intervention status (vitamins 
supplementation vs placebo), gestational age and baseline BMI; 4. p<0.05. 
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Table 5. Repeated measurements of concentrations of tocopherols in the relation to the risk of preeclampsia1,2,3,4 
 
 Average5 Visit 2( 24-26 wks of gestation) Visit 3( 32-34 wks of gestation) 
Aanalyte  COR (95%CI) AOR(95%CI) COR (95%CI) AOR(95%CI) COR (95%CI) AOR(95%CI) 
Total tocopherols       
Q1 1.00 1.00 1.00 1.00 1.00 1.00 
Q2 1.65(0.86-3.15) 1.69(0.85-3.33) 1.41(0.65-3.07) 1.46(0.62-3.43) 1.52(0.67-3.45) 1.58(0.67-3.76) 
Q3 1.23(0.62-2.45) 1.23(0.59-2.57) 1.14(0.50-2.56) 1.19(0.46-3.07) 1.42(0.60-3.37) 1.46(0.58-3.70) 
Q4 1.11(0.52-2.35) 1.14(0.48-2.67) 1.15(0.48-2.72) 1.28(0.45-3.68) 0.90(0.37-2.21) 0.78(0.26-2.31) 
  P trend NS NS NS NS NS NS 
  Z-score  0.93(0.71-1.22) 1.02(0.78-1.33) 0.98(0.73-1.31) 1.00(0.70-1.43) 0.91(0.67-1.24) 0.88(0.60-1.29) 
α-tocopherol       
Q1 1.00 1.00 1.00 1.00 1.00 1.00 
Q2 1.25(0.65-2.41) 1.23(0.62-2.43) 1.34(0.61-2.94) 1.60(0.69-3.74) 1.75(0.77-3.98) 1.76(0.74-4.21) 
Q3 1.14(0.58-2.24) 1.01(0.49-2.10) 1.24(0.57-2.71) 1.21(0.49-2.98) 1.16(0.49-2.76) 1.18(0.46-3.00) 
Q4 0.81(0.39-1.67) 0.83(0.37-1.87) 1.11(0.48-2.58) 1.33(0.48-3.69) 0.91(0.38-2.16) 0.80(0.28-2.29) 
  P trend  NS NS NS NS NS NS 
  Z-score 0.87(0.67-1.14) 0.94(0.72-1.21) 0.91(0.68-1.22) 0.94(0.65-1.34) 0.85(0.63-1.16) 0.82(0.55-1.21) 
1. COR: Crude odds ratio; 2. AOR: Adjusted odds ratio; 3. Regression models were repeatedly conducted, in which plasma 
concentrations at each visit or average measurements as main independent variables; 4. Adjusted variables: smoking, the presence of 
pre-selected clinical risk condition (i.e. chronic hypertension, history of preeclampsia, diabetes), prenatal regular using of vitamins or 
mineral supplementation, intervention status vitamins supplementation vs placebo), gestational age and baseline BMI; 5. Average of 
three measurements at baseline, visit2 and visit 3; 6. P<0.05  
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Table 5. (Continued) 
 Average5 Visit 2( 24-26 wks of gestation) Visit 3( 32-34 wks of gestation) 
Aanalyte  COR (95%CI) AOR(95%CI) COR (95%CI) AOR(95%CI) COR (95%CI) AOR(95%CI) 
γ-tocopherol       
Q1 1.00 1.00 1.00 1.00 1.00 1.00 
Q2 1.72(0.83-3.56) 1.93(0.89-4.19) 1.19(0.54-2.62) 1.19(0.51-2.77) 1.17(0.49-2.78) 1.27(0.48-3.32) 
Q3 1.47(0.72-3.02) 1.76(0.79-3.92) 1.71(0.78-3.74) 2.04(0.79-5.24) 2.07(0.94-4.56) 2.59(0.91-7.40) 
Q4 3.41(1.58-7.37)6 4.02(1.63-9.93)6 2.42(1.07-5.47)6 2.99(1.13-7.89)6 3.07(1.22-7.73)6 4.37(1.35-14.15)6 
  P trend  <0.05 <0.05  <0.05  <0.05  <0.05  <0.05  
Z-score 1.79(1.33-2.40)6 1.47(1.11-1.95)6 1.73(1.23-2.42)6 1.69(1.14-2.51)6 1.86(1.29-2.69)6 1.94(1.23-3.06)6 
γ-/α-tocopherol ratio - - - - - - 
Q1 1.00 1.00 1.00 1.00 1.00 1.00 
Q2 1.44(0.70-2.94) 1.50(0.72-3.15) 1.02(0.47-2.20) 1.20(0.52-2.76) 1.41(0.59-3.37) 1.99(0.73-5.45) 
Q3 1.28(0.64-2.58) 1.31(0.60-2.85) 1.25(0.57-2.73) 1.40(0.55-3.61) 2.82(1.22-6.51)6 8.00(2.33-27.49)6 
Q4 2.56(1.23-5.31)6 2.40(1.04-5.55)6 2.58(1.17-5.71)6 2.72(1.03-7.18)6 2.93(1.17-7.33)6 5.68(1.54-20.90)6 
  P trend  <0.05 <0.05  <0.05  <0.05  <0.05  <0.05  
Z-score  1.71(1.29-2.28)6 1.28(0.98-1.68) 1.59(1.19-2.14)6 1.58(1.12-2.22)6 1.66(1.19-2.31)6 1.82(1.18-2.82)6  
1. COR: Crude odds ratio; 2. AOR: Adjusted odds ratio; 3. Regression models were repeatedly conducted, in which plasma 
concentrations at each visit or average measurements as main independent variables; 4. Adjusted variables: smoking, the presence of 
pre-selected clinical risk condition (i.e. chronic hypertension, history of preeclampsia, diabetes), prenatal regular using of vitamins or 
mineral supplementation, intervention status vitamins supplementation vs placebo), gestational age, and baseline BMI; 5. Average of 
three measurements at baseline, visit2 and visit 3; 6. P<0.05  
CHAPTER 7 DISCUSSION 
7.1 Nutrition and PE 
Preeclampsia (PE) is a multisystem disorder that is specific to pregnancy and 
only can be resolved by delivery. The underlying mechanisms are complex and 
remain poorly understood. A causal network of socioeconomic, genetic, maternal 
health and nutritional factors likely contributes to the etiology of PE. It has been 
suggested that maternal nutritional imbalance may lead to altered gene 
methylation and expression, altered homocysteine metabolism, inflammatory 
responses and oxidative stress, all of which may lead to adverse pregnancy 
outcomes including PE.(286)  
Encouraged by the results of Chappell et al. (165) that reported a 54% 
reduction in PE in the group supplemented with vitamins C and E compared with 
the placebo group [RR 0.39; 95% CI 0.17-0.90)], we conducted the International 
Trial of Antioxidants in the Prevention of Preeclampsia to assess the effects of 
antioxidants (vitamins C and E) in the reduction of PE among high and low risk 
populations. We found no evidence that supplementation with vitamins C and E 
reduced the risk of GH and its adverse conditions among patients at high risk and 
low risk for PE. The results are consistent with those of other recently reported 
RCTs.(165, 167, 276, 277, 287, 288) We also observed unexpected increased 
risk of PROM and PPROM. It is not clear why the prenatal supplementation with 
vitamins C and E was unsuccessful in the reduction of risk of GH and PE in our 
study or in other studies. It is possible that although oxidative stress is present in 
PE, it may not be fundamental to the pathophysiology of the condition. It is 
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possible that oxidative stress may be relevant to the pathogenesis of a subgroup 
of patients. It has been hypothesized that only individuals under oxidative stress 
are likely to benefit from antioxidant supplementation.(289) In our study, a 
significant proportion of the population was taking prenatal multivitamin at the 
time of randomization. The dose of vitamin E that is required to suppress 
oxidative stress has not been well determined in pregnant women. It is also 
possible that vitamin E (pharmaceutical form: α-tocopherol) may have a pro-
oxidant propensity, depending on oxidative conditions and presence of other co-
antioxidants (290, 291).  
It is important to note that recruitment for Chappell et al.’s trial was stopped 
early due to the significant main treatment effect observed at interim 
analysis.(165) The primary endpoint in the trial was the ratio of plasminogen-
activator inhibitor 1 (PAI-1) and placental dysfunction (PAI-2).Therefore, the 
observed effect in Chappell et al.’s trial may be higher than the true treatment 
effect and the results may suffer from the type I error.(292) The majority of 
women recruited in the trial had an abnormal two-stage uterine-artery doppler 
screening, which indicating inadequate uteroplacental blood flow and probable 
defective placentation.(165) The results from the Chappell et al.’s trial can be 
only generalized to their specific study population.  
Several large trials designed to evaluate the effects of vitamin E and C in the 
prevention of PE have been also conducted. These trials are from several 
countries including the United Kingdom, the United States, as well as from 
developing countries. The UK study (VIP trial) enrolled 2410 women identified 
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at increased risk of PE.(276) Women were randomly assigned either to the 
experimental group (1000mg vitamin C and 400 IU RRR alpha tocopherol) or to 
a matched placebo group. The incidence of PE was similar in treatment and 
control groups (15% versus 16%; RR 0.97; 95% CI 0.80, 1.17). However, the 
incidence of low birth weight was higher in women with antioxidant treatment 
than in controls (28% versus 24%; RR: 1.15; 95% CI: 1.02, 1.30). Plasma 
concentrations of vitamin C and E did not differ between groups. In the placebo 
group, plasma concentrations of vitamin C were lower throughout the gestational 
period studied in women who developed PE than those who did not. Furthermore, 
the highest quartile of baseline vitamin C intake was associated with a reduced 
risk of small for gestational age (OR 0.42, 95% CI 0.26-0.67), low birth weight 
(OR 0.39, 95% CI 0.24-0.63), and PE (OR 0.59, 95% CI 0.38-0.93) after 
adjusting for risk group, degree of education, housing status, and smoking status. 
 An Austrian multicentre trial was conducted among 1877 nulliparous women 
recruited between 14 and 22 weeks of gestation.(277) The results indicated that 
there were no significant differences between the vitamin and placebo groups in 
the risk of PE (6 vs 5%; RR 1.20; 95% CI 0.82-1.75), death or serious infant 
outcomes (9.5% vs 12.1%; RR 0.79; 95% CI 0.61-1.02), or small for gestational 
age (8.7% vs 9.9%; RR 0.87; 95% CI 0.66-1.16). Women in the vitamin group 
were more likely than those in the placebo group to be admitted antenatally with 
hypertension and to be treated with antihypertensive drugs. This finding may be 
due to chance. However, research has suggested that antioxidants may promote 
DNA oxidation by interacting with metal ions.(293) Spinnato II reported the 
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results of an antioxidant (vitamins C and E) trial in women recruited between 12 
and 19 weeks of gestation and diagnosed as having chronic hypertension or a 
prior history of PE.(287) There was no evidence of a reduction in the risk of PE 
in the supplementation group compared to placebo (adjusted RR 0.87, 95% CI 
0.61-1.25). There were no differences in mean gestational age and rates of 
perinatal mortality, abruptio placentae, preterm delivery, and small for gestational 
age (SGA) or low birth weight infants.(287) The World Health Organisation 
recently completed a multicentre trial that was conducted among pregnant 
women with low socio-economic status and low nutritional status from 
developing countries (e.g. India, Peru, South Africa, and Viet Nam).(288) The 
trial followed the research protocol that was used in the VIP trial(276) with only 
minor adaptation to local resources. The result showed that supplementation of 
vitamins C and E did not reduce the risk of PE (RR: 1.0; 95% CI: 0.9-
1.3),eclampsia (RR: 1.5; 95% CI: 0.3-8.9), and GH(RR: 1.2; 95% CI: 0.9-
1.7).(288)   
In addition to the trials of combined vitamins C and E supplementation, Steyn 
et al. reported no effects of vitamin C supplementation alone on the risk of PE 
(RR 1.00, 95% CI 0.21-4.84). (294) Rivas et al. conducted a trial, in which 
supplements of aspirin, vitamin C, E and fish oil were used, and found that such 
supplements significantly reduced the risk of PE (RR 0.07, 95% CI 0.01-0.54). 
However, it is hard to infer whether such an effect was due to vitamins C and E, 
fish oil or aspirin, or the effects of their interaction.(295) Our group has recently 
updated the meta analysis by Polyzos et al.(296), involving eight trials, of which 
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one trial assessed the effect of vitamin C alone(294), six trials evaluated the 
combined effect of vitamins C and E supplementation,(165, 167, 276, 277, 287, 
288) and one trial examined the benefits of vitamin C and E, combined with fish 
oil.(295) Overall, we were unable to detect any benefits of vitamin C alone, or 
vitamin C combined with vitamin E, or vitamin C and E with other supplements 
in reducing the risk for PE (random effects model, RR 0.93, 95% CI 0.76-1.13).  
The literature suggests that vitamin E may exert both beneficial and 
detrimental effects. The ineffectiveness of vitamin C and E in the prevention of 
PE emphasizes the need for understanding the underlying mechanisms and 
metabolism of both vitamins C and E in the human body. It is noteworthy that 
vitamin E also has non-antioxidant pleiotropic effects in addition to its 
antioxidant capacity.(297) Exogenous vitamin E may prevent an immunologic 
switch (Th1 to Th2) that is considered as crucial for early to late transition in 
normal pregnancy and it could be a potential interferon-gamma (IFN-γ) mimic, 
facilitating pro-inflammatory responses at the maternal-fetal interface. Therefore, 
vitamin E treatment might have undesirable side-effects and may partially 
explain the conflicting results of previously published trials.(165, 167, 276, 277) 
There is some evidence that high doses of alpha-tocopherol (primary form of 
vitamin E in supplementation) could deplete plasma and tissue gamma-
tocopherol (major forms in plant seeds and in the North American diet).(298-301)  
Therefore, efficacy of vitamin E supplementation (alpha-tocopherol) may be 
offset by deleterious changes of other nutrients.  
Although the INTAPP trial failed to provide evidence of a beneficial effect 
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of prenatal vitamins C and E supplementation on the risk of PE, it offered a 
unique opportunity to investigate the role of maternal dietary factors in relation 
to the risk of PE and GH. In our study, the FFQ was administered both in early 
pregnancy and late pregnancy to assess usual dietary intake prior to the three 
month period. There was significant heterogeneity in nutrient intake between 
participants in Canada and Mexico. Among Canadian women, we found that the 
lowest quartiles of potassium (adjusted OR 1.79, 95%CI 1.03-3.11) and zinc 
(adjusted OR 1.90, 95%CI 1.07-3.39) intakes were significantly associated with 
an increased risk of PE among Canadian women. The lowest quartile of 
polyunsaturated fatty acids was associated with an increased risk of GH 
(adjusted OR 1.49, 95%CI 1.09-2.02). None of the nutrients analyzed were 
found to be associated with PE or GH risk among Mexican women. 
Several studies have been conducted to investigate the nutritional risk factors 
for hypertensive disorders of pregnancy, and have yielded inconsistent results. 
For instance, Morris et al. conducted a prospective cohort study of 4157 women 
at 13-21 weeks gestation that had been enrolled in a randomized controlled trial 
of calcium supplementation in the prevention of PE.(99) A 24-hour dietary recall 
was administered to assess nutrient intake at the time of random assignment (at 
13-21 of weeks of gestation).. After adjustment for baseline risk factors, none of 
the 28 nutritional factors analyzed were significantly related to either PE or 
pregnancy-associated hypertension.(99) A Norwegian team conducted a 
prospective, population based study of 3771 women pregnancy women to 
investigate maternal nutrient intake in relation to the risk of PE. A semi-
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quantitative FFQ was administered to women in the secondary trimester to 
assess dietary intake.(98) The risk of PE was increased among women with a 
high energy intake (adjusted OR: 5.4, 95% CI: 2.3-12.4, for the 4th quartile) and 
a high intake of polyunsaturated fatty acids (adjusted OR: 2.3, 95% CI: 1.1-4.6). 
Moreover, the authors observed a stronger association for early onset PE. (98)  
The discrepancies between the findings from our study and those of other 
published studies may be partially explained by the methods used to estimate 
dietary intake, the time in pregnancy at which diet is assessed, different 
definitions of PE and GH, or population differences (i.e. lifestyle, heterogeneity 
in nutrient intake, socio-demographic factors). Our project is the first to assess 
maternal diets longitudinally in both early and late pregnancy and to conduct 
parallel analyses to evaluate dietary factors in the development of GH and PE in 
two different ecological settings. The present research project makes a novel 
contribution to the understanding of the role of maternal nutrient intakes in early 
pregnancy in relation to the risk of PE.    
Several clinical studies have been carried out to examine the associations 
between maternal α-tocopherol concentrations and the risk of PE with 
inconsistent results. (154, 155, 164, 169, 170, 172) No clear patterns have been 
observed between the serum or plasma concentrations of γ-tocopherol and the 
risk of PE in previous studies. (172, 302, 303) Ours is the first study to 
investigate longitudinal measurements of plasma α-and γ-tocopherols in relation 
to the risk of PE. We found no association between maternal plasma α-
tocopherol levels and the risk of PE, but an increased risk of PE was associated 
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with high plasma γ-tocopherol levels during pregnancy. It has been suggested 
that γ-tocopherol could be a more potent antioxidant than α-tocopherol.(304) 
However, it is not known why γ-tocopherol is associated with an increased risk 
for PE. Recently, studies on non pregnant populations have reported that 
elevated γ-tocopherol levels were associated with the increased risk of cancer 
and cardiovascular disease. (305) (306) It is possible that in addition to its 
antioxidant effect, it may also have pro-inflammatory effect. (307) (308) Another 
possible explanation for our findings is that elevated plasma γ-tocopherol levels 
could be a marker of trans fat intake which in turn has been shown to represent a 
risk factor for PE. (286) Plasma concentrations of tocopherols are influenced by 
the plasma lipoproteins that act as transport molecules of the antioxidants. 
Concentrations of trans fatty acids and lipoproteins were not measured and 
therefore were not adjusted in our study. It has been suggested that it may be 
optimal to evaluate plasma concentrations of tocopherol corrected for 
apolipoprotein B (apo B). In our previous study, the lipid composition did not 
vary between PE cases and controls. The plasma levels of triglycerides, total 
cholesterol, LDL cholesterol, HDL cholesterol and LDL apolipoprotein B (apo B) 
were not statistically different between PE and normotensive controls. (309) 
Furthermore, correlations between ratio of prostacyclin (PGI2)-a vasodilator / 
thromboxane A2 –a potent vasoconstrictor and total vitamin E were similar 
when plasma vitamin E concentration corrected for apoB or not.(309) Therefore, 
it is very likely that there is a real association between γ-tocopherol and PE risk 
although plasma lipoprotein was not measured in the present study. 
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7.2 Application of FFQ in epidemiological studies 
Dietary intake measurements only provide estimates of the amounts of 
energy and nutrients available for metabolism. Several methods have been 
developed to measure dietary intake, including dietary records, the 24-hour 
dietary recall, diet history, and FFQs.(262)  
 The dietary measurement instrument used most often in large-scale 
epidemiological studies, particularly prospective cohort studies, is the FFQ. 
Compared to quantitative methods such as food records or recalls, the FFQ is 
more powerful to capture day-to-day variability in food intakes. This is 
particularly relevant in a dietary assessment among pregnant women whose diet 
is likely to be highly variable as food intakes generally change from usual pre-
pregnant patterns, and may fluctuate according to their state of comfort and well-
being as well as changes in food preferences during the course of pregnancy. 
Therefore, the food records or recalls may not be enough to capture this dietary 
variability. On other hand, FFQs are designed to cover a broader period than 
food records or recalls and thus are more suited to capturing usual intake of 
foods and nutrients that may be missed by the quantitative methods.(310) It also 
provides a practical, cost-effective way of collecting information from a large 
number of respondents.  
We used a pre-validated self-administered semi-quantitative 78-item FFQ in 
the Canadian study population, which was modified for INTAPP to reflect the 
previous three months’ usual food consumption rather than the standard 12 
month period. The FFQ was further validated among 107 pregnant women from 
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a subset of the Canadian INTAPP cohort.(280) The results of validation study 
suggest that the FFQ is a relatively valid instrument for determining usual diet in 
pregnant women.(280)  
In the Mexican study population, the Canadian FFQ was modified to reflect 
local foods and dietary habits and information from the second Mexican 
National Nutrition Survey published data.(281).The FFQ was developed and 
tested in Spanish and it was validated against three non-consecutive 24 hour food 
recalls among 85 pregnant women. The results of the validation study suggested 
that the Mexican FFQ could adequately measure habitual nutritional intakes in 
Mexican pregnant women and capture enough variability in the population 
studied.(282)  
Nevertheless, it is important to recognize the limits of the FFQs in accurately 
estimating subjects’ habitual dietary intakes. Random errors and uncorrelated 
measurement errors exist, which can cause attenuations of risk estimates and 
reduce statistical power.(271) As described by Beaton, there is not, and probably 
never will be, a method that can estimate dietary intake without error.(275) It 
does not mean that dietary data with measurement errors should not be collected. 
7.3 Methods for analyzing repeated dietary measurements 
We used logistic regression for analyses of repeated dietary measures, which 
is similar to the approaches suggested by Hu et al.(311). Biologically, the diet in 
early pregnancy may be more important to the development of PE, as opposed to 
the diet in late pregnancy which may be more important for fetal growth. Thus, it 
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is not appropriate to simply treat FFQ data as repeated measurements, in which 
the generalized estimating equation model (e.g. SAS PROC GENMOD) or 
mixed effects model can be used (e.g.SAS PROC MIXED). Instead, the effects 
at each exposure time window should be assessed separately, although the 
effects at the late gestational age window may need to consider early exposures 
as covariates.   
Advantages and disadvantages of survival analysis with time-dependent 
covariates have been discussed in the literature.(312) One of main advantages of 
time-dependent covariates is that you can incorporate important events that occur 
during the study period. The main disadvantages include over-adjustment and 
decreased usefulness for clinicians. With time-dependent covariates, "effect-
cause" may be a problem by including factors that are proximal to outcomes than 
baseline exposure measurements. One way to deal with this problem is to "lag" 
the time-dependent measurements substantially before the outcome but still after 
the baseline. In our study, all participants are pregnant women, with relatively 
short and approximately constant follow up time (from trial entry to delivery). 
Furthermore, unlike chronic disease such as cancer for which the incidence tends 
to rise over time, it may be inappropriate to apply cox regression model in 
modelling PE as an outcome since the assumption of increasing risk over time 
does not hold– typical PE cases tend to occur earlier.  
Another conventional method for analyzing repeated measures on risk factors 
is the pooling of repeated observations (PRO) method, which pools observations 
over all intervals to examine the short term development of disease. There are 
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several important assumptions underlying PRO method including 1) the 
underlying risk of outcome in each interval is the same; 2) the relationship 
between risk factors and outcome is the same for every interval; and 3) only 
current risk profile is needed to predict outcome.(313) Thus, it is inappropriate to 
apply the PRO method in our study since such assumptions do not hold.  
 
7.4 Strengths and limitations  
Measurement error in explanatory variables and unmeasured confounders 
can cause considerable problems in epidemiological studies.  In the present 
project, the FFQ in the present study was pre-tested and validated in pregnant 
women and the results of our validation studies indicated that the FFQ is a 
relatively valid instrument for determining usual diet in pregnant women. (280) 
However, it is still possible that some nondifferential misclassification of 
nutrient intakes from the FFQ may have occurred and therefore may lead a bias 
towards the null. Nutrient intakes in our study were grouped into quartiles, and 
results are therefore less likely to be affected by errors in intake estimates.  In 
our study, nutrients included in the models were adjusted for the potential 
confounding effect of total energy intake.(283) Energy requirements depend on 
body size, physical activity, and metabolic efficiency of each individual, which 
may confound absolute total intake in relation to disease risk. Adjustments for 
energy intake may reduce such confounding effects. (283)  In addition, 
measurements of absolute intake that contain a substantial degree of 
measurement errors may be eliminated by energy adjustments. 
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Our effect estimates may be further biased by unmeasured or unknown 
confounders and/or measurement error in the covariate data we collected. Indeed, 
many of our measured covariates such as smoking status, alcohol use, income, 
parity, pre-pregnancy BMI (pre-pregnancy weight), and family history of PE, 
were from interview-based self report and misclassification was possible.  
Information on certain variables such as physical activity, infection, and 
psychosocial profiles was not collected in our study. For instance, it has been 
suggested that the risk of PE was approximately doubled among women with 
stress or anxiety during pregnancy.(250) Studies have suggested that the 
pregnant women with depressive disorders tended to have lower or undesirable  
nutrient intakes.(314) Therefore, the reported ORs in our study may be 
overestimated without adjusting for psychosocial stress as a potential confouding 
factor.  The validity of our study may be threatened and care should be taken in 
generalizing our results.  
Another common issue encountered in the analysis of a cohort study is 
missing data. Missed visits and/or loss to follow up can be extremely 
problematic if missingness is related to the outcome and exposure of interest. In 
the INTAPP trial, approximately 4% of participants were lost to follow up in the 
Canadian arm and 20% were lost to follow up in the Mexican arm. Participants 
with missing outcomes due to withdrawal or loss to follow-up were excluded 
from the analysis. However, it is unlikely that loss to follow up was affected by 
treatment group or the study outcomes and thus it is unlikely to have greatly 
biased our risk estimations. We further compared the baseline characteristics of 
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women who were included in the final analysis of the INTAPP trial with that of 
women who were lost to follow up. There were no significant differences in 
most baseline characteristics. Canadian women included in the analysis had 
slightly higher maternal age and were less likely to smoke before pregnancy or 
during pregnancy compared to women who were lost to follow up. Mexican 
women included in the analysis had lower education level compared to Mexican 
women lost to follow up. It is also true that we have a small proportion of 
missing data with respect to several important covariates such as pre-pregnancy 
BMI and family history of PE or GH. However, the proportion of missind data 
with respect to these covariates was less than 5%. Our results indicated that 
baseline characteristics were comparable between two treatment groups 
(antioxidant versus placebo).  
To assess the association between nutrient intakes during pregnancy and the 
risk of GH or PE, we analyzed nutrient intake data from a prospective pregnancy 
cohort of women enrolled in the INTAPP study. A total of 2336 women had 
complete and plausible FFQ data at the first study visit. Nonresponse is not an 
issue in the analyses using baseline diet only because only complete baseline 
dietary data were included in all analyses (n=2336). Approximately 80 percent of 
baseline population completed the repeated dietary questionnaires at the third 
trimester (n=1887). Analyses were conducted in this subgroup of population to 
assess whether nutrient intakes in late pregnancy or changes of nutrient intakes 
are associated with the risk of PE and GH. We found no associations between 
nutrient intakes in late pregnancy and changes of nutrient intakes from early to. 
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late pregnancy and the risks of GH and PE. The main multivariate analysis was 
on the basis of baseline diet only.  
Several methods have been proposed for handling missing data in 
epidemiological studies such as multiple imputation and weighting methods like 
inverse probability weighted augmented (IPWA) estimating equations and 
doubly robust locally efficient IPWA methods. (315) In our study, participants 
with missing outcomes due to withdrawal or loss to follow-up were excluded 
from the analysis. It is unlikely that loss to follow up was affected by treatment 
group or the study outcomes and thus it is unlikely to have greatly biased our 
risk estimations. However, power in our study may further be compromised with 
such approach and external validity of our results may be threatened by missing 
data and care should be taken into consideration in the generalization of our 
results. 
It is well known that the incidence odds ratio approximates the risk ratio (RR) 
when the disease of interest is rare, but increasingly overestimates the risk ratio 
as the disease becomes more common. The OR is a very convenient measure of 
effect with many appealing statistical properties including estimability in a case-
control study. The cumulative incidences of GH and PE are approximately 20% 
and 5% respectively in our study. Thus, the ORs reported in our study tend to 
overestimate true RRs.  
Nonetheless, our study had several notable strengths, including its large 
sample size, prospective design, and adjudicated PE outcome. The main study 
outcomes of PE and GH were carefully documented in the INTAPP trial Case 
 168
Report Forms (CRFs). Measurements and evaluations of the study outcomes 
were standardized across clinical centres. The diagnosis of GH and PE was 
further adjudicated by a team of three independent investigators. Unlike most 
investigations, our study assessed nutrient intakes in early pregnancy, which 
provides novel data in relation to PE. INTAPP participants were recruited from 
different regions with varying socio-demographic characteristics, which 
increases the generalizability of study results. On the other hand, results may 
only be generalized to women with those characteristics similar to those of study 
participants.  
7.5 Recommendations and future directions  
Encouraged by the positive results of a small pilot randomized trial by 
Chappell et al, (165) several large clinical trials, including the INTAPP trial, 
were subsequently conducted and all yielded negative results. The available 
evidence does not support the use of combined vitamin C and E supplementation 
during pregnancy for the prevention of PE. Furthermore, the safety of such 
supplementation, more specifically the effects on infant outcome (e.g. low birth 
weight), is still uncertain. At this stage, the supplementation of vitamin C and E 
during pregnancy should be discouraged. In the context of negative results from 
several trials, it is unlikely that further trials of Vitamins E will be conducted.. 
An important lesson here is that, additional evidence of biological plausibility of 
an effect and data on the dose-response is needed before undertaking a large-
scale trial. Further studies are necessary required to investigate the potential 
adverse effects of an intervention, including both short and long-term effects.  
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It has been suggested that maternal characteristics at enrolment could affect 
the risk of PE as well as potentially modifying the effect estimate of studied 
treatment. The characterization of high-risk populations will permit the 
documentation of the nutritional profiles of these women. This may lead to new 
intervention strategies to prevent PE. Currently, studies are underway that aim to 
develop predictive models of PE. For example our research group was recently 
funded to develop a biochemical screening model based on circulating maternal 
pro- and antiangiogenic factors in combination with an endothelial injury marker 
(e.g. free vEGF, PlGF, cFN and endostatin).   
More studies including both animal models and human studies are needed to 
better understand the etiology of PE. As knowledge regarding the underlying 
mechanism of PE advances, there will be opportunities to explore the impact of 
nutritional factors on specific causal pathways. Moreover, we found in our study 
that elevated γ-tocopherol was associated with the risk of PE. Further 
epidemiologic and intervention studies are needed to better understand the 
potential role of γ-tocopherol in the risk of PE. In addition, further studies are 
needed to confirm the association between potassium intake and the risk of PE 
reported in our study.   
Studies exploring the role of maternal vitamin D status in adverse pregnancy 
outcomes are scarce. In our study, we did not find an association between 
vitamin D intake and the risk of PE. To date, only one observational study 
observed that there is an association between vitamin D status and the risk of PE. 
Further studies are necessary to unravel the association between vitamin D status 
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during pregnancy and adverse pregnancy outcomes.  
We did not find an association between calcium intake or supplementation 
and the risk of PE or GH. Based on our review, calcium supplementation during 
pregnancy was found to significantly reduce the risk of PE for women at high 
risk and among those with low baseline dietary calcium intake. There was no 
evidence of a protective effect of prenatal calcium supplementation on adverse 
neonatal outcomes (e.g. preterm birth, neonatal death, IUGR). Further studies are 
required to substantiate the evidence that calcium supplementation during 
pregnancy significantly reduces the risk of perinatal mortality or morbidity 
without showing any long-term adverse effects. Current evidence suggests that 
calcium supplementation in pregnancy would appear to be justified, particularly 
in patients with low nutritional intake. However, additional data is required in 
terms of long-term effects as well as the optimal dose of supplementation.  
Given the promising effect of folic acid on the risk of PE shown in previous 
observational studies, well-designed randomized controlled trials are urgently 
needed to assess the effect of folic acid supplementation during early pregnancy 
on PE. It seems that there is a limited time window to implement such a trial, as 
there is tendency that more and more pregnant women receive folic acid 
supplementation during early pregnancy. In addition, to prevent neural tube 
defects, commercial baking and pasta products have been fortified with folic acid 
since the late 1990s.   
In summary, it is important to conduct well designed studies and obtain data 
on the following aspects: 1) delineation of the dose-response relationship of 
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important nutrient candidates (e.g. folate, Omega-3 fatty acids) with 
physiological markers of PE as well as with the risk of PE; 2) examination of the 
potential nutrient-nutrient, nutrient-environment (e.g. tobacco, alcohol and drug 
use) and nutrient-genetic interactions as well as elucidation of their interplay on 
the risk modifications of PE; and 3) identification of the critical time windows 
during which nutrient intake or supplementation may alter the risk of PE. As new 
knowledge emerges, we must recall that large randomized clinical trials of 
nutritional interventions to prevent PE are extremely costly and should be 
undertaken only when there is strong plausibility of a potential benefit of a novel 
intervention.  
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APPENDIX 
Figure 1. Hypothetical framework on Pathogenesis of Preeclampsia 
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Figure 2. Multivariate analysis approach for nutrient intakes during 
pregnancy and the risk of GH and PE.  
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Figure 3. Analytical framework for the case control study of plasma 
tocopherol concentrations in relation to the risk of PE  
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Table A: A summary of RCTs of certain micronutrient supplementations during pregnancy and the risk of Preeclampsia 
 
 
Micronutrient Intervention  Participants Summary of findings  
Calcium  Type: Calcium (dose  varied from 
1.5 to 2.0 grams)  versus placebo; 
Initiation: varied from 18-22 
weeks of gestation.  
  
Most women were at 
low risk for PE and with 
low calcium intake 
A total of 12 trials have been carried out. Most trials 
conducted in women with low calcium status showed the 
protective effect of calcium supplementation on the risk 
of PE. Most trials conducted in women with adequate 
calcium status failed to show any beneficial effects of 
calcium supplementation.(142) 
Vitamin C only  Type: vitamin C ( 500mg daily) 
versus placebo; Initiation: less 
than 26 weeks of gestation 
Women were at high risk 
for preterm birth 
(previous abortion or 
preterm birth)  
Only one trial was conducted and found no reduced risk 
of PE associated with vitamin C supplementation.(294) 
Vitamins C and 
E 
Type: 1000mg vitamin C and 400 
IU vitamin E daily versus placebo 
Initiation: Trial entry varied at 
each trial (18-22,14-20,14-21,12-
20 of weeks of gestation) 
Women at high and low 
risk for PE 
A total of six trials evaluated the combined effects of 
vitamins C and E supplementation.(165, 167, 276, 277, 287, 288) 
Except the first trial by Chappell et al.(165)reported a 
significant reduction of PE associated with vitamins C 
and E supplementation, the following trials failed to 
provide evidence of beneficial effects of vitamins C and 
E.(167, 276, 277, 287, 288) 
 xxiv
 
 Table A. (Continued) 
 
Micronutrient Intervention Participants  Summary of findings  
Vitamin C, E, 
fish oil 
Type: 500 mg vitamin C per day, 
400 IU vitamin E per day, 1g fish 
oil three times per day and 100 
mg aspirin three times a week 
versus placebo 
Initiation: Less than 29 weeks of 
gestation 
Women at high risk 
for PE 
Rivas et al. reported that there was a significant 
reduction of PE associated with supplementation of 
vitamins C, E and fish oil.(295)  
Vitamin A To date, no trial has been conducted to assess the effects of vitamin A on the risk of PE. 
Vitamin D Evidence from trial is not available. 
Folic acid 
(folate) 
Direct evidence from trials is not available. A re-analysis of a large RCT indicated that folate supplementation 
(200µg/day and 5mg/day versus placebo) was associated with a reduced risk of PE.(186) 
 
 
 
 xxv
 
 
Table A. (Continued)  
 
Micronutrient Intervention Participants  Summary of findings  
Zinc  Type: zinc versus no zinc (dose 
varied from 20 mg to 44 mg 
daily) or placebo  
Initiation: trial entry varied at 
each trial (<20,<24, <26,<27,15-
25 weeks of gestation)  
Normal pregnant 
women with no 
systemic illness with 
normal and low zinc 
status 
A total of seven trials were conducted including 5 
trials in women with low zinc status and 2 trials of 
women with normal zinc status.(199)Only one trial 
conducted in women with low zinc status found that 
zinc supplementation significantly reduced the risk of 
PE.  
Magnesium Type: Magnesium (dose of 500 
mg or 365 mg daily) versus 
control; Initiation: <4 months of 
gestation, 13-24 weeks of 
gestation) 
Nulliparous and 
multiparous women  
Two trials reported no reduction of PE associated 
with magnesium supplementation. However, 
methodological quality is questionable.(193) 
Iron  Type: Iron (27 mg daily) versus 
placebo; Initiation: <13 weeks of 
gestation 
Healthy pregnancy 
women 
Eskeland et al. reported no reduction of PE associated 
with oral iron supplementation. However, the sample 
size is very small (N=90).(200)  
 xxvi
Table B. Nutrients estimated by Food Frequency Questionnaire (FFQ) and average of three non-consecutive Food Records 
(3D-FR)1 (FFQ validation study in Canada)   
Nutrients FFQ Average of 3D-FR Median differences in means (%)2 
Energy (kcal) 1963±610 (1860) 2320±607 (2354) -13.1 
Carbohydrate (g) 237±83 (220) 298±97 (301) -21.0 
Total fat (g) 77±28 (72) 88±30 (85) -14.3 
Protein (g) 91±29 (87) 98±28 (97) -7.1 
Saturated fatty acids (g) 26±9.7 (24) 30±12 (29) -11.6 
Polyunsaturated fatty acids (g) 14±6.9 (12) 14±5.8 (14) 0.7 
Monounsaturated fatty acids (g) 30±11.9 (28) 33±13.6 (31) -10.3 
Cholesterol (mg) 259±101 (248) 290±123 (273) -13.1 
Fibre (g) 17±6.9 (15) 22±11.7 (20) -23.1 
Calcium (mg)  1180±461 (1135) 1358±567 (1327) -13.0 
Iron (mg) 11.4±4.1 (10.9) 18.1±10.5 (16.7) -31.8 
Zinc (mg) 11.1±3.9 (10.6) 13.3±7.1 (12.1) -12.8 
Potassium (mg) 3231±1084 (3099) 3894±1333 (3800) -16.6 
Sodium (mg) 3006±1102 (2802) 3531±1206 (3414) -18.6 
 xxvii
 
Table B. Continued  (FFQ validation study in Canada) 
 
Nutrients FFQ Average of 3D-FR Median differences in means (%)2 
Magnesium (mg) 305±107 (283) 405±195 (372) -20.8 
Vitamin A (IU) 8544±4970 (7589) 14540±20001 (10452) -27.3 
Vitamin E (mg) 2.4±2.1 (1.9) 2.7±3.2 (1.8) -4.4 
Vitamin C (mg) 184±103 (161) 204±101 (192) -10.2 
Vitamin D (ug) 5.2±2.9 (5.1) 5.4±3.3 (4.7) -10.7 
Thiamine (mg) 1.6±0.6 (1.4) 2.1±0.9 (2.0) -28.6 
Riboflavin (mg) 1.9±0.7 (1.9) 2.5±0.9 (2.4) -17.2 
Niacin (mg) 18.9±7.1 (17.3) 23.3±7.3 (22.9) -15.6 
Vitamin B6 (mg) 2.1±0.7 (1.9) 2.3±1.3 (2.1) -4.8 
Folate (ug) 343±138 (318) 409±210 (371) -15.5 
Vitamin B12 (ug) 4.5±1.8 (4.3) 5.9±7.0 (4.5) -11.9 
 
1. Data presented as Mean±Standard Deviation (Median)  
2. Determined as ([(FFQ-3DFR)/3DFR] *100) 
Shatenstein B, Xu H, Luo Z-C, Fraser W. Relative validity of a food frequency questionnaire for Canadian pregnant women. Canadian 
Journal of Dietetic Practice and Research (accepted) 2010. 
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Table C.  Association between nutrients estimated by Food Frequency 
Questionnaire (FFQ) and three non-consecutive Food Records (3D-FRs)- 
(FFQ validation study in Canada) 
 
Nutrients Spearman correlation 
coefficient (r) 
Energy (kcal) 0.36** 
Carbohydrate (g) 0.31** 
Total fat (g) 0.41** 
Protein (g) 0.44** 
Saturated fatty acids (g) 0.45** 
Polyunsaturated fatty acids (g) 0.35** 
Monounsaturated fatty acids (g) 0.43** 
Cholesterol (mg) 0.38*** 
Fibre (g) 0.41** 
Calcium (mg)  0.46** 
Iron (mg) 0.17 
Zinc (mg) 0.37** 
Potassium (mg) 0.45** 
Sodium (mg) 0.19 
Magnesium (mg) 0.45** 
Vitamin A (IU) 0.30** 
 
 
Shatenstein B, Xu H, Luo Z-C, Fraser W. Relative validity of a food frequency 
questionnaire for Canadian pregnant women. Canadian Journal of Dietetic 
Practice and Research (accepted) 2010. 
 xxix
 
 
 
 
 
Table C (Continued)   
 
Nutrients Spearman correlation 
coefficient (r) 
Vitamin E (mg) 0.17 
Vitamin C mg) 0.44** 
Vitamin D (ug) 0.36* 
Thiamine (mg) 0.19* 
Riboflavin (mg) 0.39** 
Niacin (mg) 0.41** 
Vitamin B6 (mg) 0.34** 
Folate (ug) 0.49** 
Vitamin B12 (ug) 0.29** 
Mean correlation (energy and 24 
nutrients) 
0.36 
 
        * p<0.05 
       ** p<0.01 
Shatenstein B, Xu H, Luo Z-C, Fraser W. Relative validity of a food frequency 
questionnaire for Canadian pregnant women. Canadian Journal of Dietetic 
Practice and Research (accepted) 2010. 
 xxx
 
Table D. Proportions (%) of participants ranked into the same quartile of 
the distribution according to nutrient estimates obtained from the Food 
Frequency Questionnaire (FFQ) and three non-consecutive Food Records 
(3D-FR)  (FFQ validation study in Canada)  
 
Nutrients Identical 
quartile (%) 
Identical and 
contiguous 
quartile (%) 
Opposite 
quartile1 
(%) 
Energy (kcal) 40 74 5 
Carbohydrate (g) 36 71 7 
Total fat (g) 37 74 5 
Protein (g) 35 76 4 
Saturated fatty acids (g) 37 83 3 
Polyunsaturated fatty acids (g) 37 79 7 
Monounsaturated fatty acids (g) 36 79 2 
Cholesterol (mg) 39 78 5 
Fibre (g) 25 76 0 
Calcium (mg)  33 79 4 
Iron (mg) 34 69 11 
Zinc (mg) 34 74 4 
Potassium (mg) 33 77 3 
Sodium (mg) 35 72 9 
Magnesium (mg) 37 79 6 
 
Shatenstein B, Xu H, Luo Z-C, Fraser W. Relative validity of a food frequency 
questionnaire for Canadian pregnant women. Canadian Journal of Dietetic 
Practice and Research (accepted) 2010. 
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 Table D (Continued) 
 
Nutrients Identical 
quartile (%) 
Identical and 
contiguous 
quartile (%) 
Opposite 
quartile1 
(%) 
Vitamin A (IU) 34 71 6 
 
Vitamin E (mg) 29 66 9 
Vitamin C mg) 37 80 6 
Vitamin D (ug) 38 78 7 
Thiamine (mg) 34 72 11 
Riboflavin (mg) 38 76 6 
Niacin (mg) 33 78 6 
Vitamin B6 (mg) 37 71 6 
Folate (ug) 38 78 6 
Vitamin B12 (ug) 31 66 6 
Mean % classification 
(energy and 24 nutrients) 
35 75 6 
 
1 Frank misclassification: lowest quartile in one method but classified as highest 
quartile in the other method. 
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Table E: Nutrients estimated by Food Frequency Questionnaire (FFQ) and three non-consecutive Food Recalls1  
(FFQ validation study in Mexico)  
 
 
Nutrients  
FFQ  
(n=105) 
1st Food Recall 
(n=86) 
2nd Food Recall 
(n=86) 
3rd Food Recall 
(n=72) 
Average of Food 
Recalls (n=72) 
Energy (kcals) 2098.0±545.0 2089.1± 778.0 1875.8± 709.6 2041.7± 771.1 2507.3±507.3 
Carbohydrate (g) 264.6±78.5 289.6±78.5 250.6±120.5 263.8±107.7 267.1±74.0 
Protein (g) 71.3±18.0 68.5±28.2 66.1±30.2 68.8±30.2 67.2±19.9 
Total lipid (g) 89.1±27.2 77.1±39.1 70.6±30.7 83.2±43.7 77.6±27.1 
Total fiber (g) 22.6±8.9 21.5±13.4 17.3±10.6 18.6±11.5 19.0±8.7 
Calcium (mg) 1211.6±444.2 1110±762.9 976.6±532.6 1129.0±659.6 1077.0±444.5 
Iron (mg) 11.4±3.3 15.3±17.8 12.1±13.6 16.8±18.9 14.9±11.1 
Magnesium (mg) 325.3±96.0 298.2±167.2 280.5±177.8 287.2±143.1 281.3±102.2 
Potassium(mg) 3245.1±996.8 2962.1±1381.6 2678.9±1806.2 2735.7±1596.5 2706.8±981.7 
Zinc (mg) 8.6±2.1 9.5±7.1 7.6±3.4 8.6± 4.0 8.6±3.3 
Vitamin A (IU) 6296.1±3560.3 5003.1±5463.1 5046.3±10246.1 6564.1±11640.7 5711.0±5896.3 
Vitamin D (mcg) 26.9±15.4 51.1±94.7 42.3±67.5 66.0±217.6 39.4±82.2 
Vitamin E (mg) 12.5±5.5 10.1±7.5 9.6±6.9 10.9±9.1 10.0±4.6 
Vitamin C (mg) 231.7±124.0 30.8±497.4 164.8±172.8 165.4±148.1 214.1±199.8 
Thiamine (mg) 1.3±0.4 1.4±1.1 1.1±0.7 1.5± 1.1 1.3±0.6 
Riboflavin (mg) 1.8±0.6 1.8±1.1 1.6±1.0 2.0±1.4 1.8±0.7 
1. Data presented as Mean (SD) 
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Table E. (Continued)1 
 
 
 
Nutrients  
FFQ 
(n=105) 
1st Food Recall 
(n=86) 
2nd Food Recall 
(n=86) 
3rd Food Recall 
(n=72) 
Average of Food 
Recalls (n=72) 
Niacin (mg) 15.0±4.3 17.4±13.1 17.7±14.6 19.4±14.8 17.7±8.1 
Pantotenic acid (mg) 5.5±1.8 4.7±2.2 4.7±2.6 4.7±1.6 4.7±1.6 
Vitamin b6 (mg) 1.7±0.5 2.0±1.4 1.7±1.1 2.2±1.6 2.0±0.9 
Folate(mcg) 348.7±113.8 396.1±306.9 306.4±202.5 405.7±303.0 371.3±171.1 
Vitamin B12 (mg) 8.0±5.8 4.2±3.4 4.4±12.3 4.9±11.1 4.5±5.7 
Saturated fatty acid (g) 32.4±10.7 29.9±16.2 26.5±12.8 33.0±19.1 30.1±11.2 
Polyunsaturated fatty acid (g) 20.2±10.2 15.5±13.2 15.5±11.1 18.1±15.3 16.1±8.0 
Monounsaturated fatty acid (g)  23.9±7.9 21.5±12.1 19.1±9.8 22.2±13.9 21.1±8.5 
 
1.  Data presented as Mean (SD) 
 
 
 
 
 
 
 
 
 
 xxxiv
Table F. Pearson’s correlation coefficients between FFQ and the 24-hour recalls for energy and selected nutrients (FFQ 
validation study in Mexico) 
 
 Pearson’s correlation coefficients 
Nutrients  1st Food Recall 2nd Food Recall 3rd Food Recall Average of Food 
Recalls 
Energy (Kcals) 0.24 1 0.28 2 0.17 0.62 2 
Carbohydrate (g) 0.23 0.251 0.02 0.48 2 
Protein (g) 0.16 0.06 0.372 0.77 2 
Total lipid (g) 0.13 0.30 2 0.28 2 0.75 2 
Total fiber (g) 0.312 0.282 0.22 0.742 
Calcium (mg) 0.11 0.251 0.15 0.602 
Iron (mg) 0.14 0.221 0.712 1.00 
Zinc (mg) 0.241 0.002 0.17 0.602 
Vitamin A (IU) 0.03 -0.02 0.01 0.722 
Vitamin E (mg) 0.01 0.16 0.06 0.632 
Vitamin C (mg) 0.18 0.241 0.11 0.251 
1. P<0.05  
2. P<0.01 
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Table F. (Continued) 
 Pearson’s correlation coefficients 
Nutrients 1st Food Recall 2nd Food Recall 3rd Food Recall Average of Food Recalls 
Thiamine (mg) 0.14 0.005 -0.03 0.642 
Riboflavin (mg) 0.03 0.04 0.01 0.672 
Niacin (mg) -0.01 -0.03 0.04 0.692 
Pantotenic acid (mg) 0.251 0.18 0.20 0.692 
Vitamin B6 (mg) 0.16 0.04 0.14 0.712 
Folate (mcg) 0.11 0.00 -0.01 0.652 
Magnesium (mg) 0.23 0.09 0.16 0.742 
Potassium (mg) 0.23 0.08 0.332 0.792 
Vitamin D (mcg) -0.311 0.612 0.09 0.862 
Saturated fatty acid (mg) 0.312 0.282 0.21 0.732 
Vitamin B12 (mcg) 0.31 0.282 0.21 0.732 
Monounsaturated fatty acid (g) 0.12 0.18 0.251 0.762 
Polyunsaturated fatty acid (g) -0.11 0.12 -0.08 0.642 
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Table G. Proportions (%) of participants ranked into the same tertile of the 
distribution according to nutrient estimates obtained from the Food 
Frequency Questionnaire (FFQ) and three non-consecutive Food Recalls 
(FFQ validation study in Mexico) 
 
 Identical tertiles (%) 
Nutrients 2st Food Recall 2 nd Food Recall 3rd Food Recall 
Energy 53 35 45 
Carbohydrate 52 36 43 
Protein 41 33 33 
Total lipid 50 53 43 
Total fiber 59 33 74 
Calcium 46 42 47 
Iron 57 29 48 
Magnesium 56 47 56 
Potassium 59 39 28 
Zinc 42 28 26 
Vitamin A 50 39 32 
Vitamin D 32 50 31 
Vitamin E 38 30 39 
Vitamin C 42 35 55 
Thiamine 56 41 52 
Riboflavin 41 43 40 
Pantotenic acid 42 35 45 
Vitamin B6 50 33 53 
Folate 48 36 43 
Vitamin B12 35 38 26 
Saturated fatty acid 34 33 26 
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Table H : Baseline characteristics of women included in the analysis of INTAPP trial and women lost to follow up1  
 
 Canada Mexico 
Characteristics Lost2  Included3 Lost2  Included3 
Maternal age, y 28.35(6.03) 30.03(5.14)4 26.50(5.25) 26.02(5.21) 
Maternal education (years) 15.06(3.20) 15.92(3.02) 12.73(3.27) 11.76(2.79)4 
pre-pregnancy BMI 24.74(5.05) 25.53(6.27) 25.20(4.62) 25.33(4.79) 
Gestational age, wk 14.98(1.88) 15.15(2.11) 15.32(2.09) 15.40(2.06) 
Nulliparous  62(86.11) 1245(79.71) 173(84.39) 646(80.65) 
Employed  54(75.0) 1288(82.62) 135(65.85) 513(64.13) 
Smoking before pregnancy 30(41.67) 372(23.85)4 81(39.71) 298(37.25) 
Current smoker  16(22.22) 151(9.77)4 5(2.45) 13(1.63) 
Current drinker 4(5.56) 33(2.12) 2(0.98) 4(0.50) 
Blood pressure      
     Systolic  112.1(12.98) 113.1(12.81) 102.5(10.27) 101.3(10.64) 
     Diastolic  67.56(9.28) 68.56(9.18) 65.92(8.49) 65.19(8.36) 
Dipstick proteinuria      
     Normal or trace 68(100) 1487(97.64) 199(97.07) 759(94.76) 
     1+ 0 33(2.17) 6(2.93) 40(4.99) 
     2+ 0 3(0.20) 0 2(0.25) 
 
1.Data presented as Mean (S.D.) or n (%); 2. Women who were lost to follow up or withdrew from the trial; 3. Women 
who were included in the final analysis of the INTAPP trial; 4. P<0.05 
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Table H. Continued1  
 
 Canada Mexico 
Characteristics Lost 2 Participants3 Lost2  Participants3 
High risk group (stratum) 20(27.78) 499(31.95) 41(20.0) 185(23.10) 
     Chronic hypertension 6(8.33) 101(6.47) 10(4.88) 47(5.87) 
     Diabetes 6(8.33) 132(8.45) 5(2.44) 26(3.25) 
     Multiple pregnancy  5(6.94) 147(9.41) 6(2.93) 13(1.62) 
     History of preeclampsia 4(5.56) 185(11.84) 21(10.24) 110(13.73) 
     Multiple risk factors 1(1.39) 60(3.84) 1(0.49) 11(1.37) 
Family history of PE, 
eclampsia or GH 
5(6.94) 177(11.33) 30(14.63) 122(15.23) 
Use of supplements 70(97.22) 1479(94.99) 179(87.32) 710(88.64) 
     Multivitamins  62(86.11) 1300(83.66) 49(23.90) 167(20.85) 
     Vitamin C 4(5.56) 23(1.48)4 0 7(0.88) 
     Vitamin E 3(4.17) 2(0.13)4 0 1 (0.12) 
     Folate 12(16.67) 470(30.26)4 148(72.20) 576(71.91) 
     Calcium 13(18.06) 250(16.10) 9(4.39) 77(9.61) 
     Iron 5(6.94) 57(3.67) 110(53.66) 486(60.75) 
 
1.Data presented as Mean (S.D.) or n (%); 2. Women who were lost to follow up or withdrew from the trial; 
3. Women who were included in the final analysis of the INTAPP trial; 4. P<0.05 
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Table I: The risk (cumulative incidence, %) of GH or PE according to 
quartile distributions of nutrient intakes estimated from FFQ administered 
at 12-18 weeks of gestational age1 
 
 Canada Mexico 
Characteristics PE GH PE GH 
Protein     
   1Q2 3.69 15.04 9.95 29.56 
   2Q  6.44 20.62 6.97 26.34 
   3Q 2.59 16.28 10.94 26.29 
   4Q 4.96 21.93 6.74 24.87 
Chi-Square test P NS <0.05 NS NS 
Trend P NS NS NS NS 
Lipoprotein      
   1Q 3.60 19.79 10.19 26.79 
   2Q  6.25 19.27 4.76 28.50 
   3Q 3.40 15.93 9.18 27.98 
   4Q 4.46 18.90 9.48 23.86 
Chi-Square test P NS NS NS NS 
Trend P NS NS NS NS 
Carbohydrate     
   1Q 4.45 19.37 5.73 22.96 
   2Q  4.42 17.88 10.00 30.41 
   3Q 5.22 19.32 9.55 26.50 
   4Q 3.63 17.36 9.22 27.27 
Chi-Square test P NS NS NS NS 
Trend P NS NS NS NS 
Fiber     
   1Q 5.67 18.04 10.99 25.77 
   2Q  5.76 20.68 4.76 28.87 
   3Q 3.36 19.33 9.18 24.24 
   4Q 2.90 15.83 9.48 28.17 
Chi-Square test P NS NS NS NS 
Trend P <0.05 NS NS NS 
Total cholesterol       
   1Q 4.13 16.80 9.80 26.09 
   2Q  4.72 15.97 10.88 27.27 
   3Q 4.72 20.47 7.89 28.80 
   4Q 4.13 20.67 6.00 25.12 
Chi-Square test P NS NS NS NS 
Trend P NS NS NS NS 
1. Data only reflect food intake only, nutrient intakes from supplements 
not included; 2. Quartile distributions of nutrient intakes; 3. Data 
presented as risk (%) 
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Table I- Continued 1 
 
 Canada Mexico 
Characteristics PE GH PE GH 
Saturated fatty acids     
   1Q2 4.19 17.02 9.62 31.43 
   2Q  3.86 18.97 5.74 23.92 
   3Q 5.84 16.45 8.33 25.38 
   4Q 3.87 21.39 11.24 26.23 
Chi-Square test P NS NS NS NS 
Trend P NS NS NS NS 
Pantotenic acid       
   1Q 5.68 18.35 9.13 28.10 
   2Q  5.51 16.54 6.32 24.35 
   3Q 2.93 16.71 7.46 27.94 
   4Q 3.57 22.19 11.70 26.56 
Chi-Square test P NS NS NS NS 
Trend P NS NS NS NS 
Monounsaturated fatty acid      
   1Q 4.38 18.30 10.84 28.02 
   2Q  6.23 21.56 9.64 27.14 
   3Q 3.42 15.53 7.61 28.86 
   4Q 3.66 18.49 6.32 22.92 
Chi-Square test P NS NS NS NS 
Trend P NS NS NS NS 
Polyunsaturated fatty acid      
   1Q 4.40 22.28 8.42 25.73 
   2Q  5.66 21.59 6.67 25.95 
   3Q 3.40 14.36 11.17 29.15 
   4Q 4.22 15.57 8.17 26.32 
Chi-Square test P NS <0.05 NS NS 
Trend P NS <0.05 NS NS 
Calcium     
   1Q 5.74 18.28 5.64 26.90 
   2Q  3.94 17.59 10.15 29.50 
   3Q 4.12 16.97 8.70 25.71 
   4Q 3.91 21.09 10.11 25.00 
Chi-Square test P NS NS NS NS 
Trend P NS NS NS NS 
1.Data only reflect food intake only, nutrient intakes from supplements not 
included; 2. Quartile distributions of nutrient intakes; 3. Data presented as 
risk (%) 
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Table I- Continued 1 
 
 Canada Mexico 
Characteristics PE GH PE GH 
Iron     
   1Q2 5.17 20.93 9.57 28.27 
   2Q  4.21 19.16 8.08 27.09 
   3Q 4.13 17.05 7.46 28.92 
   4Q 4.19 16.75 9.50 22.89 
Chi-Square test P NS NS NS NS 
Trend P NS NS NS NS 
Magnesium      
   1Q 7.24 19.64 5.61 25.76 
   2Q  3.65 17.45 8.25 28.14 
   3Q 3.94 17.80 10.53 24.21 
   4Q 2.86 19.01 10.14 28.77 
Chi-Square test P <0.05 NS NS NS 
Trend P <0.05 NS NS NS 
Potassium      
   1Q 7.79 18.70 9.66 29.05 
   2Q  4.19 18.54 6.63 25.00 
   3Q 2.58 16.02 6.77 24.87 
   4Q 3.14 20.68 11.46 28.06 
Chi-Square test P <0.05 NS NS NS 
Trend P <0.05 NS NS NS 
Sodium      
   1Q 4.15 19.43 10.77 31.31 
   2Q  2.62 18.32 5.85 24.08 
   3Q 4.69 17.66 10.34 26.57 
   4Q 6.25 18.49 7.46 25.12 
Chi-Square test P NS NS NS NS 
Trend P NS NS NS NS 
Zinc      
   1Q 6.08 18.52 8.08 27.86 
   2Q  5.43 16.28 9.50 27.36 
   3Q 2.35 17.71 9.18 25.76 
   4Q 3.87 21.39 7.77 26.13 
Chi-Square test P <0.05 NS NS NS 
Trend P <0.05 NS NS NS 
 
1. Data only reflect food intake only, nutrient intakes from supplements not 
included; 2. Quartile distributions of nutrient intakes; 3. Data presented as 
risk (%) 
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Table I- Continued 1 
 
 Canada Mexico 
Characteristics PE GH PE GH 
Vitamin A     
   1Q2 6.91 19.18 5.70 21.94 
   2Q  4.26 18.09 10.34 30.24 
   3Q 3.35 18.25 10.36 30.30 
   4Q 3.15 18.37 8.08 24.50 
Chi-Square test P <0.05 NS NS NS 
Trend P <0.05 NS NS NS 
Vitamin C      
   1Q 6.81 18.85 9.23 27.36 
   2Q  3.94 19.37 7.73 25.51 
   3Q 4.37 19.28 7.04 25.13 
   4Q 2.60 16.41 10.55 29.06 
Chi-Square test P <0.05 NS NS NS 
Trend P <0.05 NS NS NS 
Vitamin E     
   1Q 5.77 19.16 10.40 28.99 
   2Q  5.91 18.46 6.70 23.98 
   3Q 3.58 17.90 8.65 26.98 
   4Q 2.40 18.40 8.74 27.05 
Chi-Square test P <0.05 NS NS NS 
Trend P <0.05 NS NS NS 
Vitamin D      
   1Q 4.47 19.18 10.71 25.00 
   2Q  3.90 18.09 9.19 26.84 
   3Q 4.69 18.25 6.97 30.69 
   4Q 4.65 18.37 7.80 24.64 
Chi-Square test P NS NS NS NS 
Trend P NS NS NS NS 
Vitamin B6     
   1Q 5.74 16.71 8.81 28.43 
   2Q  5.18 20.67 5.21 27.41 
   3Q 4.20 17.32 11.44 27.94 
   4Q 2.59 19.17 8.96 23.38 
Chi-Square test P NS NS NS NS 
Trend P <0.05 NS NS NS 
 
1. Data only reflect food intake only, nutrient intakes from supplements not 
included; 2. Quartile distributions of nutrient intakes; 3. Data presented as 
risk (%) 
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Table I- Continued 1 
 
 Canada Mexico 
Characteristics PE GH PE GH 
Vitamin B12      
   1Q2 5.51 16.80 9.45 26.60 
   2Q  4.13 18.35 7.25 23.84 
   3Q 4.44 19.79 8.21 27.41 
   4Q 3.64 18.96 9.60 30.20 
Chi-Square test P NS NS NS NS 
Trend P NS NS NS NS 
Folate     
   1Q 6.84 21.05 6.91 28.65 
   2Q  4.83 18.02 8.02 26.18 
   3Q 2.58 13.95 10.42 27.18 
   4Q 3.46 21.01 9.09 25.34 
Chi-Square test P <0.05 NS NS NS 
Trend P <0.05 NS NS NS 
Thiamine     
   1Q 4.97 17.49 9.69 29.50 
   2Q  6.25 21.09 5.73 26.29 
   3Q 4.42 17.92 9.14 27.59 
   4Q 2.08 17.40 9.90 23.76 
Chi-Square test P <0.05 NS NS NS 
Trend P <0.05 NS NS NS 
Riboflavin      
   1Q 5.25 17.32 7.88 30.58 
   2Q  5.48 16.97 7.14 26.37 
   3Q 2.87 18.23 8.90 24.23 
   4Q 4.11 21.34 10.66 25.76 
Chi-Square test P NS NS NS NS 
Trend P NS NS NS NS 
Niacine     
   1Q 4.68 17.66 8.42 27.32 
   2Q  4.95 18.23 7.04 28.22 
   3Q 4.38 19.02 10.84 28.50 
   4Q 3.69 19.00 8.21 22.96 
Chi-Square test P NS NS NS NS 
Trend P NS NS NS NS 
 
1. Data only reflect food intake only, nutrient intakes from supplements not 
included; 2. Quartile distributions of nutrient intakes; 3. Data presented as 
risk (%) 
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Table J: Unadjusted Odds ratios of dietary nutrients intake in association with preeclampsia (PE) and gestational 
hypertension (GH) in Canadian and Mexican pregnancy cohorts1  (FFQ administered at 12-18 weeks of gestational age) 
 Canada: OR (95%CI) Mexico: OR (95%CI) 
Characteristics PE GH PE GH 
Protein     
   1Q2 0.74(0.36-1.49)   0.63(0.44-0.91)1 1.53(0.74-3.17) 1.27(0.82-1.97) 
   2Q  1.32(0.71-2.44) 0.93(0.66-1.31) 1.04(0.47-2.27) 1.08(0.69-1.69) 
   3Q 0.51(0.23-1.11) 0.69(0.48-0.99) 1.70(0.83-3.50) 1.08(0.68-1.70) 
Lipoprotein      
   1Q 0.80(0.39-1.65) 1.06(0.74-1.52) 1.89(0.89-4.03) 1.17(0.75-1.83) 
   2Q  1.43(0.75-2.70) 1.02(0.71-1.47) 1.26(0.56-2.85) 1.27(0.81-1.99) 
   3Q 0.75(0.36-1.58) 0.81(0.56-1.18) 2.21(1.04-4.69) 1.24(0.79-1.95) 
Carbohydrate     
   1Q 1.24(0.60-2.55) 1.14(0.79-1.65) 0.60(0.28-1.29) 0.80(0.51-1.25) 
   2Q  1.23(0.60-2.53) 1.04(0.72-1.50) 1.09(0.56-2.14) 1.17(0.76-1.79) 
   3Q 1.46(0.73-2.94) 1.14(0.79-1.64) 1.04(0.53-2.03) 0.96(0.62-1.49) 
Fiber     
   1Q 2.01(0.96-4.21) 1.17(0.80-1.71) 1.18(0.62-2.25) 0.89(0.57-1.37) 
   2Q  2.04(0.98-4.28) 1.39(0.96-2.01) 0.48(0.21-1.08) 1.04(0.67-1.59) 
   3Q 1.16(0.51-2.63) 1.27(0.88-1.85) 0.97(0.50-1.89) 0.82(0.53-1.27) 
Cholesterol       
   1Q 1.00(0.49-2.03) 0.78(0.54-1.11) 1.70(0.81-3.58) 1.05(0.68-1.64) 
   2Q  1.15(0.58-2.29) 0.73(0.51-1.05) 1.91(0.91-4.00) 1.12(0.72-1.75) 
   3Q 1.15(0.58-2.29) 0.99(0.70-1.40) 1.34(0.61-2.95) 1.21(0.77-1.88) 
1. Data only reflect food intake only, intake from supplements not included. 2.  Quartile distributions of nutrient intakes.  
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Table J-Continued1  
 
 Canada: OR (95%CI) Mexico: OR (95%CI) 
Characteristics PE GH PE GH 
Saturated fatty acids     
   1Q2 1.09(0.53-2.23) 0.75(0.53-1.08) 0.84(0.44-1.62) 1.29(0.83-2.00) 
   2Q  1.00(0.48-2.07) 0.86(0.61-1.22) 0.48(0.23-1.01) 0.88(0.56-1.40) 
   3Q 1.54(0.79-3.02) 0.72(0.50-1.04) 0.72(0.36-1.43) 0.96(0.60-1.52) 
Pantotenic acid       
   1Q 1.63(0.82-3.23) 0.79(0.56-1.12) 0.76(0.40-1.45) 1.08(0.70-1.68) 
   2Q  1.58(0.79-3.15) 0.69(0.48-1.00) 0.51(0.24-1.06) 0.89(0.56-1.40) 
   3Q 0.81(0.37-1.82) 0.70(0.49-1.01) 0.61(0.31-1.21) 1.07(0.69-1.67) 
Monounsaturated fatty 
acid  
    
   1Q 1.21(0.59-2.49) 0.99(0.69-1.42) 1.80(0.87-3.75) 1.31(0.83-2.06) 
   2Q  1.75(0.89-3.44) 1.21(0.85-1.73) 1.58(0.75-3.36) 1.25(0.79-1.98) 
   3Q 0.90(0.43-2.01) 0.81(0.56-1.18) 1.22(0.56-2.69) 1.36(0.87-2.15) 
Polyunsaturated fatty acid     
   1Q 1.05(0.52-2.10) 1.56(1.08-2.24) 1.03(0.51-2.08) 0.97(0.63-1.50) 
   2Q  1.36(0.70-2.63) 1.49(1.03-2.16) 0.80(0.37-1.73) 0.98(0.63-1.54) 
   3Q 0.80(0.38-1.69) 0.91(0.61-1.36) 1.41(0.73-2.75) 1.15(0.75-1.78) 
Calcium     
   1Q 1.50(0.77-2.94) 0.84(0.59-1.20) 0.53(0.25-1.15) 1.10(0.70-1.74) 
   2Q  1.01(0.49-2.09) 0.80(0.56-1.14) 1.01(0.52-1.95) 1.26(0.80-1.96) 
   3Q 1.06(0.52-2.17) 0.76(0.53-1.10) 0.85(0.43-1.67) 1.04(0.66-1.63) 
 
1. Data only reflect food intake only, intake from supplements not included. 2. Quartile distributions of nutrient intakes 
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 Table J-Continued 1 
 
 Canada: OR (95%CI) Mexico: OR (95%CI) 
Characteristics PE GH PE GH 
Iron     
   1Q2 1.25(0.64-2.44) 1.32(0.91-1.89) 1.01(0.51-1.99) 1.33(0.84-2.09) 
   2Q  1.01(0.50-2.04) 1.18(0.81-1.71) 0.84(0.42-1.68) 1.25(0.80-1.97) 
   3Q 0.99(0.49-2.00) 1.02(0.70-1.49) 0.77(0.38-1.56) 1.37(0.88-2.14) 
Magnesium      
   1Q 2.65(1.30-5.39)3 1.04(0.73-1.49) 0.53(0.25-1.12) 0.86(0.56-1.33) 
   2Q  1.28(0.58-2.86) 0.90(0.62-1.30) 0.80(0.40-1.58) 0.97(0.63-1.49) 
   3Q 1.39(0.63-3.07) 0.92(0.64-1.33) 1.04(0.55-1.99) 0.79(0.51-1.24) 
Potassium      
   1Q 2.61(1.31-5.17)3 0.88(0.62-1.26) 0.83(0.44-1.57) 1.05(0.68-1.62) 
   2Q  1.35(0.63-2.89) 0.87(0.61-1.25) 0.55(0.27-1.12) 0.86(0.55-1.34) 
   3Q 0.82(0.35-1.92) 0.73(0.51-1.06) 0.56(0.27-1.15) 0.85(0.54-1.33) 
Sodium      
   1Q 0.65(0.34-1.24) 1.06(0.74-1.53) 1.50(0.75-3.00) 1.36(0.88-2.10) 
   2Q  0.40(0.19-0.86)3 0.99(0.69-1.43) 0.77(0.35-1.72) 0.95(0.60-1.50) 
   3Q 0.74(0.39-1.38) 0.95(0.66-1.37) 1.43(0.72-2.86) 1.08(0.69-1.68) 
Zinc      
   1Q 1.61(0.83-3.14) 0.84(0.59-1.19) 1.04(0.50-2.17) 1.09(0.70-1.70) 
   2Q  1.43(0.72-2.81) 0.72(0.50-1.03) 1.25(0.61-2.53) 1.07(0.68-1.66) 
   3Q 0.60(0.26-1.38) 0.79(0.55-1.13) 1.20(0.59-2.46) 0.98(0.63-1.54) 
1. Data only reflect food intake only, intake from supplements not included.  
2. Quartile distributions of nutrient intakes 
3. P<0.05 
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Table J-Continued 1 
 
 Canada: OR (95%CI) Mexico: OR (95%CI) 
Characteristics PE GH PE GH 
Vitamin A     
   1Q 2 2.28(1.14-4.57)3 1.05(0.74-1.51) 0.69(0.31-1.52) 0.87(0.54-1.38) 
   2Q  1.37(0.64-2.93) 0.98(0.68-1.42) 1.31(0.66-2.60) 1.34(0.86-2.07) 
   3Q 1.07(0.48-2.37) 0.99(0.69-1.43) 1.32(0.66-2.62) 1.34(0.86-2.09) 
Vitamin C      
   1Q 2.73(1.30-5.75)3 1.18(0.82-1.72) 0.86(0.44-1.67) 0.92(0.60-1.42) 
   2Q  1.53(0.68-3.46) 1.22(0.85-1.77) 0.71(0.36-1.42) 0.84(0.54-1.30) 
   3Q 1.71(0.77-3.78) 1.22(0.84-1.76) 0.64(0.32-1.30) 0.82(0.53-1.27) 
Vitamin E      
   1Q 2.49(1.13-5.49)3 1.05(0.73-1.51) 1.21(0.63-2.35) 1.10(0.72-1.69) 
   2Q  2.56(1.17-5.60)3 1.00(0.70-1.45) 0.75(0.36-1.58) 0.85(0.54-1.33) 
   3Q 1.51(0.65-3.53) 0.97(0.67-1.40) 0.99(0.49-2.00) 1.00(0.64-1.55) 
Vitamin D      
   1Q 0.96(0.49-1.89) 0.79(0.56-1.13) 1.42(0.72-2.80) 1.02(0.65-1.60) 
   2Q  0.83(0.41-1.67) 0.66(0.46-0.95) 1.20(0.59-2.44) 1.12(0.72-1.76) 
   3Q 1.01(0.52-1.97) 0.74(0.52-1.06) 0.89(0.42-1.86) 1.36(0.88-2.09) 
Vitamin B6      
   1Q 2.29(1.07-4.91)3 0.85(0.59-1.22) 0.98(0.49-1.97) 1.30(0.83-2.04) 
   2Q  2.06(0.95-4.45) 1.10(0.77-1.56) 0.56(0.25-1.24) 1.24(0.79-1.95) 
   3Q 1.65(0.74-3.68) 0.88(0.61-1.28) 1.31(0.69-2.52) 1.27(0.81-1.99) 
1. Data only reflect food intake only, intake from supplements not included.  
2. Quartile distributions of nutrient intakes 
3. P<0.05 
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 Table J-Continued 1 
 
 Canada: OR (95%CI) Mexico: OR (95%CI) 
Characteristics PE GH PE GH 
Vitamin B12     
   1Q2 1.55(0.77-3.09) 0.86(0.60-1.25) 0.98(0.50-1.92) 0.84(0.54-1.29) 
   2Q  1.14(0.55-2.38) 0.96(0.67-1.38) 0.74(0.36-1.52) 0.68(0.44-1.07) 
   3Q 1.23(0.60-2.53) 1.06(0.74-1.51) 0.84(0.42-1.69) 0.87(0.57-1.35) 
Folate      
   1Q 2.05(1.04-4.06)3 1.00(0.71-1.42) 0.74(0.36-1.54) 1.18(0.77-1.83) 
   2Q  1.42(0.69-2.92) 0.83(0.58-1.18) 0.87(0.43-1.76) 1.05(0.67-1.63) 
   3Q 0.74(0.32-1.71) 0.61(0.42-0.89) 1.16(0.61-2.23) 1.10(0.71-1.70) 
Thiamine      
   1Q 2.47(1.07-5.70)3 1.01(0.69-1.46) 0.98(0.50-1.89) 1.34(0.86-2.09) 
   2Q  3.14(1.39-7.08)3 1.27(0.89-1.82) 0.55(0.26-1.19) 1.14(0.73-1.80) 
   3Q 2.18(0.92-5.11) 1.04(0.72-1.50) 0.92 (0.47-1.79) 1.22(0.78-1.91) 
Riboflavin      
   1Q 1.29(0.66-2.53) 0.77(0.54-1.11) 0.72(0.36-1.42) 1.27(0.82-1.96) 
   2Q  1.35(0.70-2.63) 0.75(0.53-1.08) 0.65(0.32-1.31) 1.03(0.66-1.61) 
   3Q 0.69(0.32-1.51) 0.82(0.58-1.17) 0.82(0.42-1.60) 0.92(0.58-1.46) 
Niacine      
   1Q 1.28 (0.63-2.61) 0.92(0.63-1.32) 1.03(0.50-2.12) 1.26(0.80-2.00) 
   2Q  1.36 (0.67-2.75) 0.95(0.66-1.37) 0.85(0.40-1.79) 1.32(0.84-2.07) 
   3Q 1.20(0.58-2.46) 1.00(0.70-1.44) 1.36(0.69-2.68) 1.34(0.85-2.10) 
1. Data only reflect food intake only, intake from supplements not included.  
2. Quartile distributions of nutrient intakes 
3. P<0.05
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Table K: The risk (cumulative incidence, %) of GH or PE according to 
quartile distributions of nutrient intakes estimated from FFQ administered 
at 32-34 weeks of gestational age1,3 
 Canada Mexico 
Characteristics  PE GH PE GH 
Protein     
   1Q2 5.32 20.60 7.14 23.84 
   2Q  4.92 15.74 11.45 29.34 
   3Q 3.28 12.13 10.32 32.08 
   4Q 4.26 23.53 6.47 23.26 
Chi-Square test P NS <0.05 NS NS 
Trend P NS NS NS NS 
Lipoprotein      
   1Q 4.97 18.21 8.67 26.44 
   2Q  7.28 18.48 11.11 31.29 
   3Q 2.92 19.16 6.79 23.81 
   4Q 2.63 16.12 8.64 26.67 
Chi-Square test P <0.05 NS NS NS 
Trend P <0.05 NS NS NS 
Carbohydrate     
   1Q 2.93 19.22 9.09 26.79 
   2Q  3.29 17.05 5.59 22.42 
   3Q 6.23 18.36 11.73 31.52 
   4Q 5.33 17.33 8.77 27.33 
Chi-Square test P NS NS NS NS 
Trend P NS NS NS NS 
Fiber     
   1Q 4.89 17.92 7.59 27.50 
   2Q  5.88 21.90 8.02 23.49 
   3Q 3.68 16.33 11.24 26.16 
   4Q 3.29 15.79 8.24 30.81 
Chi-Square test P NS NS NS NS 
Trend P NS NS NS NS 
Total cholesterol       
   1Q 3.96 16.83 7.74 25.00 
   2Q  5.67 16.67 10.78 24.85 
   3Q 4.89 17.86 10.24 30.00 
   4Q 3.27 20.59 6.33 28.22 
Chi-Square test P NS NS NS NS 
Trend P NS NS NS NS 
1. Data only reflect food intake only, intake from supplements not 
included;  2. Quartile distributions of nutrient intakes; 3. Data 
presented as risk (%) 
 l
Table K-Continued 1,3 
 
 Canada Mexico 
Characteristics  PE GH PE GH 
Saturated fatty acids     
   1Q2 5.90 17.70 8.29 27.47 
   2Q  3.31 16.17 11.25 27.16 
   3Q 3.97 18.21 7.55 29.27 
   4Q 4.56 19.87 8.18 24.07 
Chi-Square test P NS NS NS NS 
Trend P NS NS NS NS 
Pantotenic acid       
   1Q 3.28 15.74 4.71 23.56 
   2Q  5.26 16.45 8.75 23.46 
   3Q 5.26 18.75 14.65 34.16 
   4Q 3.96 21.05 7.56 27.17 
Chi-Square test P NS NS <0.05 NS 
Trend P NS NS NS NS 
Monounsaturated fatty acid      
   1Q 5.96 18.54 10.00 22.81 
   2Q  6.27 18.75 8.93 31.18 
   3Q 2.61 18.57 9.26 26.19 
   4Q 2.96 16.12 6.92 27.95 
Chi-Square test P <0.05 NS <0.05 NS 
Trend P <0.05 NS <0.05 NS 
Polyunsaturated fatty acid      
   1Q 3.63 17.16 7.74 24.85 
   2Q  5.63 19.21 8.28 27.95 
   3Q 4.92 16.99 9.43 27.61 
   4Q 3.59 18.63 9.71 27.68 
Chi-Square test P NS NS NS NS 
Trend P NS NS NS NS 
Calcium     
   1Q 4.28 13.16 6.55 26.32 
   2Q  6.91 20.72 10.00 29.70 
   3Q 3.29 20.00 10.37 28.14 
   4Q 3.29 18.09 8.38 23.95 
Chi-Square test P NS NS NS NS 
Trend P NS NS NS NS 
 
1. Data only reflect food intake only, intake from supplements not 
included; 2.Quartile distributions of nutrient intakes; 3. Data 
presented as risk (%) 
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Table K-Continued 1,3  
 
 Canada Mexico 
Characteristics  PE GH PE GH 
Iron     
   1Q2 3.27 18.63 8.28 26.74 
   2Q  5.57 19.67 9.20 27.88 
   3Q 4.67 13.62 10.98 29.17 
   4Q 4.26 20.00 6.75 24.24 
Chi-Square test P NS NS NS NS 
Trend P NS NS NS NS 
Magnesium      
   1Q 5.84 19.28 6.75 25.75 
   2Q  5.21 17.76 8.92 26.09 
   3Q 3.59 17.76 10.30 28.31 
   4Q 2.95 17.16 9.20 27.84 
Chi-Square test P NS NS NS NS 
Trend P NS NS NS NS 
Potassium      
   1Q 5.57 19.67 7.23 26.74 
   2Q  3.92 16.34 6.79 23.93 
   3Q 4.95 19.41 12.12 29.76 
   4Q 3.31 16.56 9.04 27.54 
Chi-Square test P NS NS NS NS 
Trend P NS NS NS NS 
Sodium      
   1Q 3.92 17.97 10.00 28.65 
   2Q  3.31 16.17 12.42 29.94 
   3Q 3.96 16.83 5.36 25.58 
   4Q 6.56 20.98 7.74 24.12 
Chi-Square test P NS NS NS NS 
Trend P NS NS NS NS 
Zinc      
   1Q 4.61 16.45 8.75 28.66 
   2Q  6.93 20.13 9.58 25.88 
   3Q 3.62 15.13 10.84 28.57 
   4Q 2.62 20.26 6.02 25.00 
Chi-Square test P NS NS NS NS 
Trend P NS NS NS NS 
 
1. Data only reflect food intake only, intake from supplements not 
included; 2. Quartile distributions of nutrient intakes; 3. Data 
presented as risk (%) 
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Table K-Continued 1,3 
 
 
 Canada Mexico 
Characteristics PE GH PE GH 
Vitamin A     
   1Q2 5.59 17.43 6.83 23.64 
   2Q  5.26 17.76 10.90 28.48 
   3Q 5.54 20.52 8.09 27.01 
   4Q 1.33 16.23 9.47 28.90 
Chi-Square test P <0.05 NS NS NS 
Trend P <0.05 NS NS NS 
Vitamin C      
   1Q 4.93 19.74 8.43 25.88 
   2Q  3.96 16.50 7.41 28.31 
   3Q 5.56 19.54 9.64 27.38 
   4Q 3.30 16.17 9.70 26.51 
Chi-Square test P NS NS NS NS 
Trend P NS NS NS NS 
Vitamin E     
   1Q 4.59 19.02 6.17 27.27 
   2Q  4.92 16.07 11.66 28.05 
   3Q 4.95 17.76 7.50 26.06 
   4Q 3.30 19.14 9.77 26.70 
Chi-Square test P NS NS NS NS 
Trend P NS NS NS NS 
Vitamin D      
   1Q 2.60 12.99 9.41 26.74 
   2Q  6.62 18.54 11.80 29.70 
   3Q 4.97 20.20 9.38 23.31 
   4Q 3.62 20.33 4.76 28.24 
Chi-Square test P NS NS NS NS 
Trend P NS <0.05 NS NS 
Vitamin B6     
   1Q 4.59 20.66 5.56 23.03 
   2Q  4.58 18.63 15.00 36.59 
   3Q 5.02 19.00 7.69 25.58 
   4Q 3.59 13.75 7.14 23.08 
Chi-Square test P NS NS <0.05 NS 
Trend P NS NS <0.05 NS 
 
1. Data only reflect food intake only, intake from supplements not 
included.; 2. Quartile distributions of nutrient intakes; 3. Data 
presented as risk (%) 
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Table K-Continued 1,3 
 
 Canada Mexico 
Characteristics PE GH PE GH 
Vitamin B12      
   1Q2 3.97 15.56 6.43 24.71 
   2Q  6.56 20.66 10.97 27.67 
   3Q 2.95 14.10 7.78 23.81 
   4Q 4.28 21.64 10.24 31.95 
Chi-Square test P NS NS NS NS 
Trend P NS NS NS NS 
Folate     
   1Q 4.28 18.42 7.05 28.40 
   2Q  6.21 18.63 8.54 27.71 
   3Q 4.30 19.14 10.43 26.83 
   4Q 2.96 15.79 9.09 25.28 
Chi-Square test P NS NS NS NS 
Trend P NS NS NS NS 
Thiamine     
   1Q 4.26 16.72 5.39 22.81 
   2Q  5.26 19.02 14.91 34.76 
   3Q 4.92 20.98 9.82 27.88 
   4Q 3.31 15.23 5.36 22.94 
Chi-Square test P NS NS <0.05 <0.05 
Trend P NS NS NS NS 
Riboflavin      
   1Q 4.25 15.03 8.82 27.75 
   2Q  5.94 17.49 10.83 31.48 
   3Q 3.96 21.38 8.43 23.35 
   4Q 3.62 18.09 7.23 25.60 
Chi-Square test P NS NS NS NS 
Trend P NS NS NS NS 
Niacine     
   1Q 2.95 18.36 7.27 24.40 
   2Q  6.56 17.70 10.26 25.79 
   3Q 4.29 17.82 9.77 31.46 
   4Q 3.96 18.09 7.93 26.06 
Chi-Square test P NS NS NS NS 
Trend P NS NS NS NS 
1. Data only reflect food intake only, intake from supplements not 
included.; 2. Quartile distributions of nutrient intakes; 3. Data 
presented as risk (%) 
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Table L. Unadjusted Odds ratios of changes in nutrient intakes (standardized as Z score) in association with preeclampsia (PE) 
and gestational hypertension (GH) in Canadian and Mexican cohorts 1 
 Canada: OR (95%CI) Mexico: OR (95%CI) 
Characteristics PE GH PE GH 
Z-scores      
Protein 0.91(0.66-1.25) 0.94(0.81-1.11) 0.82(0.59-1.14) 0.92(0.75-1.13) 
Total carbohydrate  0.94(0.70-1.27) 0.96(0.82-1.12) 0.80(0.57-1.12) 0.96(0.78-1.19) 
Total lipid  0.89(0.65-1.21) 0.95(0.81-1.12) 0.99(0.72-1.37) 1.02(0.83-1.26) 
Total fiber  0.99(0.72-1.35) 0.94(0.80-1.11) 1.05(0.77-1.42) 1.05(0.86-1.28) 
Total cholesterol  1.01(0.75-1.36) 1.00(0.85-1.17) 0.78(0.55-1.12) 0.95(0.78-1.17) 
Calcium  0.93(0.69-1.26) 0.96(0.82-1.12) 0.88(0.64-1.22) 0.96(0.79-1.17) 
Iron  0.97(0.70-1.32) 0.99(0.85-1.17) 0.72(0.55-0.95) 1.00(0.82-1.21) 
Magnesium  0.97(0.71-1.32) 0.92(0.78-1.08) 0.94(0.68-1.29) 0.98(0.80-1.20) 
Potassium  1.04(0.77-1.42) 0.91(0.78-1.07) 0.91(0.66-1.26) 0.97(0.80-1.18) 
Sodium  1.01(0.77-1.33) 1.04(0.88-1.21) 0.78(0.57-1.08) 0.99(0.81-1.21) 
Zinc  0.91(0.67-1.26) 0.98(0.84-1.15) 0.72(0.51-1.02) 0.94(0.77-1.15) 
Vitamin A  0.71(0.49-1.03) 1.03(0.88-1.21) 0.93(0.68-1.26) 1.11(0.91-1.36) 
 
1.  Data only reflect food intake only, intake from supplements not included.  
 
 
 
 lv
 
 
 Table L. Continued 1 
  
 Canada: OR (95%CI) Mexico: OR (95%CI) 
Characteristics PE GH PE GH 
Z-scores      
Vitamin C  1.02(0.74-1.41) 0.92(0.78-1.09) 0.94(0.69-1.29) 1.01(0.84-1.23) 
Vitamin E  0.91(0.65-1.29) 0.97(0.82-1.14) 1.13(0.84-1.52) 1.05(0.86-1.29) 
Vitamin D  0.99(0.73-1.33) 1.01(0.87-1.17) 0.84(0.63-1.13) 1.08(0.91-1.29) 
Vitamin B6  1.04(0.77-1.41) 0.92(0.78-1.08) 0.73(0.55-0.97) 0.99(0.81-1.20) 
Vitamin B12  0.98(0.71-1.37) 1.00(0.86-1.17) 1.03(0.76-1.40) 1.05(0.87-1.27) 
Folate  1.10(0.82-1.48) 0.98(0.84-1.15) 0.75(0.55-1.02) 0.98(0.80-1.20) 
Thiamine  0.99(0.72-1.35) 0.93(0.79-1.10) 0.70(0.53-0.92) 0.99(0.81-1.20) 
Riboflavin 0.97(0.72-1.33) 0.95(0.81-1.11) 0.69(0.51-0.92) 0.99(0.81-1.20) 
Niacin  1.02(0.74-1.42) 0.96(0.82-1.13) 0.72(0.54-0.95) 0.98(0.80-1.19) 
Pantotenic acid  1.07(0.78-1.44) 0.98(0.84-1.14) 0.87(0.63-1.19) 0.99(0.82-1.21) 
Saturated fatty acid  0.91(0.68-1.23) 0.93(0.80-1.09) 0.82(0.60-1.13) 0.91(0.75-1.11) 
Monounsaturated fatty acid  0.88(0.64-1.19) 0.97(0.83-1.14) 0.89(0.64-1.24) 1.02(0.83-1.26) 
Polyunsaturated fatty acid  0.96(0.71-1.31) 1.01(0.86-1.20) 1.15(0.86-1.54) 1.11(0.91-1.34) 
  
 
1.  Data only reflect food intake only, intake from supplements not included.  
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9.1 FOOD FREQUENCY QUESTIONNAIRE  
 
 Canadian FFQ (English, French) 
  
 Mexican FFQ (Spanish) 
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9.2 ROLE OF NUTRITION IN THE RISK OF 
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